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Abstract
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder o f haematopoietic 
cells that primarily affects the elderly. Previously, our laboratory identified y-catenin as 
significantly overexpressed in AML. y-Catenin shares close structural and functional 
homology with the more intensively studied /3-catenin. Both catenins have dual roles in 
cell adhesion complexes and in transcription. Their transcriptional role is regulated by 
Wnt signalling which is critical for normal development and is one o f the most 
frequently dysregulated processes in AML. In spite o f this, little is known regarding the 
specific role o f y-catenin in normal haematopoiesis or AML pathology. This study 
devised an intracellular flow cytometric staining assay to characterise the expression o f 
y-catenin in normal haematopoietic subsets. y-Catenin exhibited a similar expression 
profile to /3-catenin. Expression was relatively high in haematopoietic stem/progenitor 
cells (HSC/HPC) and showed increased expression in myeloid differentiated cells 
(granulocytes and monocytes) while expression was lower in lymphoid cells and 
undetectable in red blood cells. Studies o f  subcellular distribution by confocal imaging 
showed reciprocal localisation o f catenins in CD34+ cells, with /3-catenin predominantly 
nuclear translocated and y-catenin nuclear excluded. Conversely, in granulocytic and 
monocytic cells nuclear y-catenin levels were relatively high whilst nuclear /3-catenin 
levels were reduced. A small subset o f the CD14+ monocyte population exhibited 
heavily nuclear translocated y-catenin. Subsequent knock-down studies of y-catenin 
showed this protein to be required for normal haematopoietic development in vitro, 
evidenced by the inhibition o f macrophage differentiation and apparent reprogramming 
o f committed monocyte progenitors for granulocytic development. In AML patients, y- 
catenin mRNA expression conferred a reduced complete remission rate arising from 
resistant disease, however discordance was found between mRNA and protein level, 
implying post-translational control o f y-catenin expression in AML. In primary AML 
blasts (undifferentiated) y-catenin was aberrantly localised to the nucleus suggesting a 
transcriptional role in AML pathology. A correlation was identified between y- and (3- 
catenin protein expression in primary AML blasts and an association between nuclear 
levels o f  these proteins. To determine whether this association was causal, y-catenin was 
ectopically expressed in normal human CD34+ haematopoietic progenitor cells but had 
no significant influence on /3-catenin expression or localisation even following 
subsequent differentiation. In contrast, overexpression o f y-catenin in leukaemic cell 
lines stabilised /3-catenin protein and promoted its translocation to the nucleus 
suggesting that the influence o f y-catenin on /3-catenin is a feature o f leukaemic cells but 
not normal cells. Phenotypically, overexpression o f y-catenin had little effect on normal 
progenitor cells but was able to block agonist-induced differentiation o f AML cell lines, 
probably via stabilisation o f /3-catenin. In summary, this study indicates a role for y- 
catenin in the regulation o f  normal haematopoietic development and that its nuclear 
translocation is strictly regulated independently o f  /3-catenin in normal haematopoiesis. 
In leukaemic cells, however, this control is dysfunctional allowing y-catenin to promote 
the stabilisation and translocation o f /3-catenin. This relationship may represent a 
pathological mechanism active in AML blasts to block myeloid differentiation and 
promote a leukaemic phenotype.
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1 - Introduction
1.1 Normal haematopoiesis
1.1.1 Overview of human haematopoiesis
Haematopoiesis is the life-long co-ordinated process o f  creating and maintaining all the 
cells that constitute blood. In the human embryo, the yolk sac is the main site for 
haematopoiesis up to 6 weeks gestation, before the liver and spleen take over for the 
following 6-7 months o f  foetal life (Hoffbrand et al., 2005a). The bone marrow (BM) 
then becomes the most important site, and represents the only source o f new blood cells 
in healthy childhood and adult life. Alternative sites o f haematopoiesis such as the liver 
and spleen have been reported in adults but are generally only prevalent in times o f
haematopoietic stress or injury (Wilson and Trumpp, 2006). Otherwise, it is estimated
1 0that around 1x10 blood cells are turned over daily in the healthy human body (Ogawa, 
1993), with critical functions in host immunity (innate and adaptive), oxygen transport, 
blood coagulation and tissue repair.
Overwhelming evidence suggests the haematopoietic system is organised as a 
hierarchical structure, whereby rare pluripotent haematopoietic stem cells (HSC) with 
high potential for self-renewal, give rise to increasingly mature progeny with decreased 
self-renewal capacity but raised potential for differentiation {Figure 1.1). Although 
there remains some debate as to the intricate details o f  this organisation (reviewed by 
Rosenbauer and Tenen, 2007), the overall concept is a clear one: Increasing 
commitment to a particular lineage, leads to more restricted developmental capacity 
such that progeny eventually terminally differentiate into a single cell type with 
specialised function, structure and biochemical properties. For example, the small, 
smooth, enucleate, bi-concave morphology o f the erythrocyte, and the high expression 
o f haemoglobin, allows both maximum retention o f oxygen and augmented navigation 
o f the fine capillary networks to which it is delivered. Also, granulocytes (consisting o f 
neutrophils, basophils and eosinophils) are able to fulfil their function o f destroying 
pathogens and priming the adaptive immune system, through an extensive arsenal o f
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lysosomal granules, and a flexible, hyper-segmented nucleus that permits trans- 
endothelial migration through blood vessels into affected tissues.
Normal steady state haematopoiesis is regulated by a host o f intrinsic and environmental 
influences. A complex network o f signalling pathways, transcription factors, cytokines 
and growth factors synergise to influence the lineage fate, differentiation, proliferation 
and function o f developing haematopoietic cells (see 1.1.3). Although this process is 
tightly regulated, it must also adapt to the changing physiological demands o f  the body. 
In particular, erythropoiesis has been well studied in this context. For example, at times 
o f haematopoietic injury, tissue hypoxia stimulates the secretion o f  erythropoietin 
(EPO) from the peritubular interstitial cells o f  the kidney. The presence o f EPO in the 
BM biases developing HSCs down an erythroid path o f differentiation. However, 
influencing the lineage fate o f primitive HSC alone cannot solely replenish the 
haematopoietic system since more rapid responses are required. Rather, proliferation 
and apoptosis are are also critical regulators o f a primed reservoir o f  more committed 
haematopoietic progenitors (De Haan et al., 1996). Once again studies in erythropoiesis 
have demonstrated that a committed pool o f erythroid progenitors reside in the bone 
marrow which can either; A) be rapidly induced by EPO to proliferate and terminally 
differentiate upon haematopoietic stress, or B) readily apoptose at times o f excess 
during steady state erythropoiesis (De Maria et al., 1999). The production o f  leukocytes 
is susceptible to similar regulatory mechanisms and can also be influenced by 
physiological demand, as evidenced by the increased pool o f circulating neutrophils and 
lymphocytes prevalent during parasitic or viral invasion.
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Figure 1.1 - The hierarchical arrangement of human haematopoietic development.
The rare pluripotent HSC with increased capacity for self-renewal (curved arrow), 
gradually gives rise to mature progeny with reduced capacity for self renewal and 
increased differentiation potential (straight arrows). Eventually, cells terminally 
differentiate, where their morphology and physiology is adapted to their biological 
function. Abbreviations: HSC = haematopoietic stem cell; HPC = haematopoietic 
progenitor cell; CMP = common myeloid progenitor; CLP = common lymphoid 
progenitor; CFU-GEMM = colony forming unit -  granulocyte-erythrocyte-monocyte- 
megakaryocyte; CFU-GM = colony forming unit -  granulocyte-macrophage; NK cell = 
natural killer cell. Adapted from http://dalev.med.harvard.edu.
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1.1.2 Haematopoietic stem cells and the microenvironment
1.1.2.1 HSC properties 
HSCs represent the most intensively studied and accurately characterised stem cells in 
human biology. They are rare cells, estimated to contribute between 0.01-0.15% of adult 
human and mouse BM cellularity (Spangrude et al., 1988; Beerman et al., 2010), and 
are seldom present in normal peripheral circulation. HSCs can be broadly classified into 
long-term HSC (LT-HSC) which have long-term capacity to reconstitute all blood 
lineages (months-years), and short-term HSC (ST-HSC), which have a more finite 
potential (days-weeks) to replenish the haematopoietic system (Morrison and 
Weissman, 1994; Guenechea et al., 2001; Christensen and Weissman, 2001). 
Characterisation o f the exact immunophenotype o f HSC remains incomplete although 
the use o f human SCID-repopulating cells (SRC) with the capacity to repopulate sub- 
lethally irradiated nonobese diabetic-severe combined immunodeficient (NOD-SCID) 
mice has allowed the broad immunophenotypic classification o f human HSC 
(Larochelle et al., 1996; Bhatia et al., 1997; Guenechea et al., 2001). LT-HSC are Lin' 
CD34+CD38 , ST-HSC are Lin'CD34+CD38+, and overwhelming evidence suggests an 
even more primitive Lin'CD34'CD38' HSC exists in human BM that can generate all 
subsequent HSCs (Osawa et al., 1996; Goodell et al., 1997; Bhatia et al., 1998; Zanjani 
et al., 1998; Nakamura et al., 1999).
It is imperative that HSC are able to satisfy the enormous demand for mature blood cells 
throughout human life, without completely exhausting the comparatively small pool o f 
pluripotent HSC. One stem cell can generate around 106 mature blood cells after 20 cell 
divisions, whilst preserving an exact copy (daughter) o f itself. This considerable 
amplification is only achievable through a critical balance between self-renewal and 
differentiation. A number o f models have been proposed to explain how HSCs co­
ordinate this balance, and are summarised in Figure 1.2 (reviewed by Roeder and 
Lorenz, 2006, Wilson and Trumpp, 2006 and Schroeder, 2007). It is likely that all 
models outlined are active to some degree during normal HSC division. The 
heterogeneity within this population make it probable that differentiation is a multi-step 
process where HSCs gradually lose their ‘stem-ness’. This process is largely governed
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by the transcription factors and the supporting network of cytokines, growth factors, 
signalling cascades described further in section 1. 1.3.
Figure 1.2 - Theoretical models of HSC division.
The two main models o f stem cell division that have been proposed to explain the 
inherent ability o f HSCs to continually replenish populations o f mature cells whilst 
preserving the pool o f uncommitted cells. A) The rigid asymmetric model whereby one 
HSC always generates one stem and one differentiated daughter cell. The probability of 
generating each type is fixed and ensures a continuous reservoir o f stem cells. However, 
such a process is unlikely to represent the only type of division since a more dynamic 
expansion of the HSC pool is required at times o f haematopoietic injury or 
myeloablation B) The more dynamic symmetrical or ‘stochastic’ theory where the HSC 
is able to produce either two identical stem daughter cells or two identical differentiated 
daughter cells according to physiological demand. Abbreviations: S = stem cell; D= 
differentiated cell. Adapted from Roeder and Lorenz, 2006.
1.1.2.2 The HSC niche 
The instinctive ability o f HSCs to home to the BM allowed the finding that stem cells 
are not randomly distributed through the marrow cavity, but instead occupy specialised 
niches close to blood vessels and the endosteum o f the trabecular bone (Kopp et al., 
2005; Kiel et al., 2005). The concept of a ‘HSC niche’ was originally coined by 
Schofield in 1978 following studies o f colony forming units (CFU) in the spleen 
(Schofield, 1978). Earlier studies by Shackney had identified a development gradient in 
the BM whereby primitive cells were located along the endosteum, with developing 
cells moving towards the highly vascularised cavity (Shackney et al., 1975). The BM 
niche itself (Figure 1.3) is composed o f osteoblasts, osteoclasts, and various stromal 
cells including adipocytes, fibroblasts, reticulum cells, endothelial cells and 
macrophages, all enriched with a dense micro-vascular network. Stromal cells are able 
to generate an extracellular matrix by secreting molecules such as collagen,
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glycoproteins (fibronectin and thrombospondin) and glycosaminoglycans (hyaluronic 
acid and chondroitin derivatives).
There is increasing genetic and functional evidence indicating a complex molecular 
cross-talk between HSC and components o f the BM niche. Typically proteins involved 
with signalling, adhesion, migration or homing have been implicated, and are 
summarised in Figure 1.4. Most o f these interactions are relevant to the osteoblastic 
niche, and human osteoblasts have been shown to support haematopoietic progenitor 
cells in vitro (Taichman et al., 1996; Taichman et al., 2001). This relationship was 
formally demonstrated in vivo through the pioneering studies o f Zhang et al. (Zhang et 
al., 2003), and Calvi et al. (Calvi et al., 2003), who both increased osteoblast frequency 
through different means in mice, to the ultimate effect o f increasing HSC number. This 
concept was reaffirmed by the reverse experiment by Visnjic et al. where conditional 
ablation o f osteoblasts led to loss of normal haematopoiesis including a decline in HSC 
number (Visnjic et al., 2004).
Since this discovery, much work has been undertaken to identify the specific signalling 
proteins active in the niche and many receptor/ligand relationships have been 
characterised between osteoblasts and HSC including; stem cell factor (SCF)/c-kit, 
Jagged-1 (JAG-l)/Notch, Angiopoietin-1 (Ang-1)/ tyrosine kinase receptor 2 (Tie2) and 
Wingless-type MMTV integration site family (Wnt)//3-catenin. SCF has been found 
secreted and expressed from the osteoblast surface, and signalling through c-kit receptor 
expression in HSC is well known to promote the proliferation and survival o f  this cell 
type. Interestingly, this relationship has also been proposed to contribute an adhesive 
function (Kinashi and Springer, 1994). The apparent haematopoietic failure in mice 
caused by loss o f SCF from the supporting environment would indicate a crucial 
function o f this signalling axis in the niche (Bernstein et al., 1991). Similarly, Notch 
receptors are expressed on HSC which can be bound by JAG-1 expression from 
surrounding stromal cells to expand the HSC pool (Calvi et al., 2003). Another well 
characterised interaction is that between Ang-1 (expressed on osteoblasts) and Tie-2 
(expressed on HSC) which has been formally demonstrated to maintain LT-HSC in a 
quiescent state (Arai et al., 2004).
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A host o f adhesion molecules have been implicated in maintaining HSC interaction with 
the niche including N-cadherin(N-cad)//3-catenin, vascular cell adhesion molecule-1 
(VCAM-l)/integrin, osteopontin (OPN)/j31-integrin and Ca2+-sensing receptor (CaR) 
(reviewed by Yin and Li, 2006). O f particular interest, the adhesive interaction between 
N-cad and /Lcatenin has been previously demonstrated in a stem cell context within 
Drosophila (Song and Xie, 2002; Yamashita et al., 2003). Both proteins have also been 
found symmetrically localised at the interface between HSCs and the osteoblastic niche, 
implying a heterotypic interaction maybe active in anchoring HSCs to the local stroma 
(Zhang et al., 2003). Curiously this interaction may not be restricted to adhesion, and 
may instead negatively regulate /3-catenin-mediated transcription o f  Wnt target genes. A 
study by Reiss et al. showed that N-cad cleavage by a disintegrin and metalloproteinase- 
10 (ADAM-10) leads to /3-catenin redistribution to the cytoplasm thus increasing the 
pool o f signalling competent /3-catenin available to the nucleus (Reiss et al., 2005). A 
similar re-localisation o f /3-catenin was observed upon cleavage o f E-cadherin (E-cad) 
(Ito et al., 1999). Despite the associated role o f y-catenin with cell adhesion (see 1.3.5.1) 
no such role has ever been implicated for this molecule within the HSC BM niche.
Finally, a number o f proteins crucial to the homing o f HSCs to the niche are present 
within the BM microenvironment including stromal derived factor-1 (SDF-1), FGF-4, 
E- and P-selectins, integrins, very late antigen-4 (VLA-4) and lymphocyte function- 
associated antigen-1 (LFA-1) (Wilson and Trumpp, 2006). The most well characterised 
o f these molecules, SDF-1 (also known as CXCL12), is constitutively released from 
endothelial and osteoblastic cells o f the niche and the receptor, CXC chemokine 
receptor 4 (CXCR4) is present on the surface o f HSCs (Peled et al., 1999; Lapidot et al., 
2005; Kortesidis et al., 2005). This chemokine is involved in the mobilisation, 
migration and retention o f HSCs, and expression from stromal cells can be induced 
upon haematopoietic injury or myeloablation (Ponomaryov et al., 2000; Ara et al., 
2003). Such properties have been exploited in modem BM transplant procedures.
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Figure 1.3 - The HSC bone marrow microenvironment.
Haematopoietic stem cells are immobilised in highly specialised BM niches. Two types 
of niche are believed to exist: the osteoblastic niche located near the endosteal bone and 
the vascular niche located on the endothelium o f the sinusoidal vessels (reviewed by 
Yin and Li, 2006). Mesenchymal stem cells are located throughout the 
microenvironment and are able to continually replenish the stromal components of the 
niche (featured in right-hand legend box, reviewed by Uccelli et al., 2008). Numerous 
adhesion and growth factors are responsible for anchoring and regulating the self­
renewal/differentiation o f HSC within the niche. A gradient o f blood cell development 
is active in the BM. Primitive HSC, of which only 3.8% are estimated to be proliferating 
at any given time (Kiel et al., 2005), are located near the endosteum. These gradually 
give rise to increasingly differentiated progeny with reduced self-renewal capacity, that 
are eventually released into the vasculature network upon terminal differentiation. This 
process is believed to be augmented by a co-increasing gradient o f oxygen and growth 
factors. Abbreviations: MSCs = mesenchymal stem cells; HCSs = haematopoietic stem 
cells; ECM = extracellular matrix. Adapted from http://www.bioscience.org 
/2007/vl 2/af72440/figures.htm.
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Figure 1.4 - The multitude of adhesion, signalling and homing molecules present in 
the endosteal HSC bone marrow niche.
The complexity o f molecular cross-talk proposed to be active between HSC and niche 
components. Abbreviations: ANG1= angiopoietin-1; BMI1= polycomb repressor; 
BMP= bone morphogenetic protein; BMPR1A= BMP receptor 1A; CSL= CBF1 
suppressor of Hairless and LAG1; CXCL12= CXC chemokine ligand 12; CXCR4= 
CXC-chemokine receptor 4; FAK= focal adhesion kinase; HOXB4= homeobox B4; 
HSC= haematopoietic stem cell; ICAM1= intercellular adhesion molecule 1; LFA1 = 
lymphocyte function-associated antigen-1; LRP= low-density-lipoprotein-receptor- 
related protein; MAPK= mitogen-activated protein kinase; OPN= osteopontin; PI3K= 
phosphatidylinositol-3 kinase; PLC= phospholipase C; PKC= protein kinase C; PPR= 
PTH/PTH-related protein receptor; PTH= parathyroid hormone; SCF= stem-cell factor; 
SMADS= mothers against decapentaplegic-related homologue; SNO= spindle-shaped 
N-cadherin-expressing osteoblast; TIE-2= tyrosine kinase receptor 2; VCAM-1= 
vascular cell-adhesion molecule 1; VLA4= very late antigen 4; *?’ = molecules and/or 
interactions for which only indirect or contradictory evidence is available. Adapted from 
Wilson and Trumpp, 2006.
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1.1.3 The transcriptional control of haematopoiesis
The determination o f lineage fate and subsequent differentiation o f haematopoietic cells 
is primarily under the control o f transcription factors (TF). TFs are a group o f proteins 
that recognise and bind specific DNA sequences o f a gene with the net effect o f 
activating or suppressing gene expression. Generally, TFs are classified according to the 
type o f DNA binding domain they harbour (e.g. the zinc finger domain carried by such 
TFs as specificity protein 1; SP-1), and typically genes that share a similar pattern o f 
regulation share common regulatory elements (Latchman, 1997). TFs mediate their 
effects on gene activity through interaction with components o f the basal transcriptional 
complex (RNA polymerase II, transcription factor for polymerase II (TFII) A-H, 
chromatin remodelling complexes and histone acetylases) thus influencing the ability o f 
this complex to transcribe primary gene messenger RNA (mRNA) from DNA. TFs are 
able to govern lineage development in normal haematopoiesis by transcribing the 
specific genes necessary to develop the distinct morphological and biochemical 
phenotype o f each lineage. This is achieved by promoting gene expression associated 
with one lineage whilst suppressing genes relevant to an alternative lineage (see below). 
The importance and intricate regulation o f TFs in normal haematopoietic development 
is affirmed by the prevalence o f TF abnormalities in haematological malignancies such 
as AML (see section 1.2.2).
A plethora o f TFs have been identified for their role in directing lineage-specific 
commitment (reviewed by Shivdasani and Orkin, 1996 and Tenen et al., 1997) and 
some o f the best characterised are outlined in Table 1.1. O f particular interest for 
myeloid development, is the complex relationship between GATA-binding protein 1 
(GATA-1) and PU.l (also known as spleen focus-forming virus proviral integration 
oncogene-1; Spi-1) which govern the transcriptional ‘check-point’ between erythroid 
and myeloid commitment respectively. GATA-1 is a zinc-finger domain transcription 
factor that is able to bind and repress PU.l in order to suppress myeloid differentiation 
and promote erythropoiesis (Nerlov et al., 2000). Consistent with this GATA-1 
expression is up-regulated in erythroid cells and concomitantly suppressed in committed 
myeloid precursors (Sposi et al., 1992). Furthermore, loss o f GATA-1 expression both 
in vitro (Weiss et al., 1994; Pevny et al., 1995; Weiss and Orkin, 1995), and in vivo 
(Pevny et al., 1991; Simon et al., 1992) leads to a loss o f erythropoiesis. GATA-1 is
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able to mediate erythropoiesis through transcription o f genes indispensable for red cell 
development, such as the upregulation o f globin proteins (Orkin, 1992) and the EPO 
receptor (Zon et al., 1991). Interestingly, GATA-1 is able to maintain these 
developmental stimuli on a continuous automated feedback loop through self­
transactivation o f its own promoter (Tsai et al., 1991).
For HSCs to commit to myeloid development the converse is the case; GATA-1 
expression is suppressed whilst PU.l is upregulated (Lee et al., 1991; Sposi et al., 1992; 
Voso et al., 1994; Pevny et al., 1995). Consistent with this, enforced expression o f 
GATA-1 in multi-potent progenitor (MPP) cells leads to a block in myeloid 
development (Kulessa et al., 1995). PU.l is a member o f the Ets family o f  TFs (Klemsz 
et al., 1990) and its elevated expression is observed in various myeloid cells including 
monocytes, macrophages and granulocytes (Chen et al., 1995b). Loss o f PU.l itself 
causes haematopoietic deficiencies in vivo, and mice die shortly before birth with a lack 
o f monocytes and granulocytes (Scott et al., 1994). Like GATA-1, PU.l is able to 
positively regulate its own expression, and thus that o f other myeloid-specific genes, 
through its ability to transactivate its own promoter (Chen et al., 1995a). PU.l is in 
transcriptional control o f  a number o f  genes critical for early myeloid differentiation 
cues including the receptors for macrophage - colony stimulating factor (M-CSF) 
(Zhang et al., 1994a), granulocyte macrophage - colony stimulating factor (GM-CSF) 
(Hohaus et al., 1995), and granulocyte - colony stimulating factor (G-CSF) (Smith et 
al., 1996), as well as markers o f  mature myeloid cells such as CD14 (Zhang et al., 
1994b), C D llb  (Pahl et al., 1992) and the macrophage scavenger receptor (Horvai et 
al., 1995). Therefore, the interaction between GATA-1 and PU.l represents a well 
characterised mechanism o f how transcriptional activation and suppression are 
necessary for haematopoietic lineage-commitment and development. A summary o f this 
concept encompassing the influence o f growth factor signalling is shown in Figure 1.5.
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Table 1.1 - Characterised transcription factors involved in lineage commitment.
Erythroid
Myeloid (monocyte and macrophage) 
and lymphoid
Myeloid (granulocytes)
Myeloid
Erythroid
B-cell lymphocytes
B-cell lymphocytes
Myeloid (granulocytes)
Megakaryocytic
Lymphoid
Myeloid and lymphoid
Lymphoid
1.1.3.1 Cytokines and growth factors
Haematopoietic growth factors (GF) and cytokines are soluble or membrane-bound 
glycoproteins that direct TFs in mediating proliferative and developmental changes in 
cells. They are also vital to the continued functionality o f terminally differentiated cells. 
It was generally appreciated that GFs and cytokines played a supplementary role to TFs 
in mediating lineage selection, however, emerging evidence suggests these proteins are 
also capable o f initiating lineage fate in otherwise uncommitted cells (Rieger and 
Schroeder, 2009; Schroeder, 2010). GFs and cytokines are predominantly secreted from 
stromal cells and many types o f mature and primitive leukocyte, except for EPO and 
thrombopoietin (TPO) which are produced in the kidney and liver, respectively. These
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proteins are able to mediate their effects through specific receptors on target cells at 
very low concentrations in a para-, endo- or auto-crine fashion. For example, stem cell 
factor (SCF) and FMS-like tyrosine kinase 3 ligand (FLT-3L) act predominantly on 
pluripotent HSCs, CMP’s and CLP’s to mediate proliferation o f these subsets 
(Hoffbrand et al., 2005a). GFs and cytokines are also capable o f working synergistically 
with one another in order to generate effects on target cells. An example o f this would 
be the ability o f G-CSF and TPO to augment the effects o f  SCF, FLT-L, and GM-CSF 
on the survival and proliferation o f MPPs. GFs and cytokines mediate their effects on 
transcription via signalling cascades.
1.1.3.2 Overview o f  cell signalling pathways in haematopoiesis
Signal transduction is an evolutionary conserved mechanism allowing an immediate 
genetic response to changes from the external environment. Invariably, a common 
mechanism is shared between pathways whereby transmembrane receptor and ligand 
interactions result in the phosphorylation and conformational change o f downstream 
cytosolic proteins, with the ultimate effect o f DNA binding by TFs. In haematopoiesis, 
the pathway by which GFs and cytokines mediate their developmental effects has been 
well characterised (Robb, 2007). Typically, these proteins bind the extracellular domain 
o f class-I or class-II cytokine receptors resulting in a conformational change. The 
alteration in the intracellular domain o f the receptor causes activation o f bound tyrosine 
kinases, like the janus associated kinase family (JAK). JAK then phosphorylate 
members o f  the signal transducer and activator o f transcription (STAT) family, resulting 
in dimerisation and nuclear translocation, where they serve as TFs for lineage-specific 
genes. Alternatively, receptor tyrosine kinases such as FLT-3 and c-kit (SCF receptor) 
exist which are capable o f directly phosphorylating downstream targets such as 
phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) 
(reviewed by Doepfner et al., 2007) when bound to the relevant ligand. JAK family 
members may also induce anti-apoptotic and proliferative responses. For example, JAK- 
mediated activation o f  protein kinase B (PKB), results in an anti-apoptotic response 
through phosphorylation and inactivation o f BAD (pro-apoptotic) protein. Alternatively, 
JAKs also initiate a proliferative response by stimulation o f Rat sarcoma (RAS), RAF 
and MAPK to induce myelocytomatosis oncogene (myc) and FBJ murine osteosarcoma 
viral oncogene homo log (FOS) TFs (Hoffbrand et al., 2005a).
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Aside from JAK/STAT signalling, additional well-established pathways and their 
effector molecules have been implicated in the normal development o f haematopoietic 
cells. These include Wnt, Notch, Sonic hedgehog (SHH), mothers against 
decapentaplegic-related homologue (Smad) and epidermal growth factor (EGF) 
signalling pathways and have been reviewed by others (Rizo et al., 2006; Blank et al., 
2008; Campbell et al., 2008). Components within these cascades communicate in much 
the same manner as previously described but utilise distinct TFs to activate/suppress 
target genes. Typically, these pathways can autoregulate themselves either positively by 
transcribing promoter molecules, or negatively by transcribing inhibitory molecules. 
These signalling cascades regulate important processes in haematopoietic cells 
including survival, proliferation, self-renewal and differentiation. Specifically, the Wnt 
pathway has been shown to be important for the self-renewal o f  HSCs (Reya et al., 
2003), whilst SHH signalling appears to be vital for lymphoid differentiation (El et al., 
2006). The regulation o f haematopoietic cells by signalling pathways is complicated by 
the finding that several pathways can interact to mediate a developmental phenotype. 
Such molecular cross-talk was identified between the Wnt and notch pathways which 
could converge to maintain the HSC pool (Duncan et al., 2005). The overall importance 
o f signal transduction networks in normal haematopoietic development is underlined by 
the observation that so many, like runt-related transcription factor 1 (RUNX-1), are 
dysregulated in haematological malignancies such as AML (Majeti et al., 2009) (see 
also section 1.2.2.1).
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Figure 1.5 - The m olecular control o f haem atopoiesis.
Schematic summarising the factors involved in haematopoietic development, as 
exemplified by myeloid differentiation. Lineage fate is primarily driven by powerful 
intrinsic transcription factors such as GATA-1 or PU.l which can direct erythroid or 
myeloid commitment, respectively, by transcribing developmentally relevant genes such 
as growth factor receptors (e.g. EPO or GM-CSF). Recent evidence would suggest that 
specific growth factors (featured in red and blue writing) can also determine lineage fate 
of uncommitted downstream progenitor cells (Rieger and Schroeder, 2009). Ultimately, 
growth factors initiate cell signalling pathways, through the relevant receptor, which 
activates/suppresses additional transcription factors necessary for terminal 
differentiation. Adapted from Tenen et al., 1997.
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1.2 Acute myeloid leukaemia
1.2.1 Overview
AML is a heterogeneous clonal disorder of HSC and haematopoietic progenitor cells 
(HPC) with a UK prevalence o f 3.4 cases per 100,000 (Milligan et al., 2006). It 
represents the most common malignant myeloid disorder in adults, and the median 
presentation age o f 65 years makes it predominantly a disease o f the elderly (Dombret et 
al., 2008) (Figure 1.6A). The disease is characterised by the rapid accumulation in the 
BM and peripheral blood o f dysfunctional ‘blasts’, which are developmentally arrested 
during myeloid differentiation, and thus prevented from generating functionally mature 
myeloid cells {Figure J.6B and Q . The acute onset o f this disease means, if left 
untreated from diagnosis, death would occur in less than a year through anaemia (lack 
o f erythrocytes), infection (lack o f immune cells such as neutrophils), bleeding (lack o f 
platelets) or major organ infiltration. AML is typically diagnosed through a range of 
clinical tests including full blood counts, blood cell morphology, cytogenetic analyses 
(chromosomal arrangement), flow cytometric measurements (of surface marker 
expression) and polymerase chain reaction (PCR) assessment o f molecular 
abnormalities (such as DNA mutations). AML can be further subdivided using two 
different classification systems (see 7.23.2).
Risk factors for AML acquisition include exposure to benzene, ionising radiation and 
cytotoxic chemotherapy (Estey and Dohner, 2006). Indeed Japanese survivors o f the 
atomic bombs (Nakanishi et al., 1999), workers in the nuclear industry (Cardis et al., 
1995) and flight crews o f commercial aircraft (Gundestrup and Storm, 1999), have all 
been associated with an increased susceptibility to AML. Genetic predisposition is a 
further risk factor for AML that is beyond human control. AML can either be primary 
{de novo) or secondary, developing through existing haematological disorders (e.g. 
myelodysplastic syndrome; MDS) or through previous chemotherapeutic treatment o f 
cancer (10-15%). Current treatment strategies in AML (see 1.2.4.1) generally involve 
the infusion o f cytotoxic agents with the aim o f achieving a complete remission (CR) 
through reduction o f the blast count, and restoration o f normal circulating neutrophils 
and platelets.
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Figure 1.6 - The incidence and morphological appearance of AML.
A) The incidence o f AML in the UK according to age group, illustrating this 
malignancy is primarily a disease of the elderly. Sourced from the Leukaemia and 
Lymphoma Research (LLR) website. B) The cellular morphology o f normal BM by 
cytochemical staining shows a range o f different blood cell lineages at varying stages of 
maturation. C) The BM o f an AML patient exhibits the domination of dark staining, 
dysfunctional, developmentally perturbed blasts. Images obtained from 
http://pathology.wustl.edu/~yaseenlab/?page=180.
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1.2.2 Pathophysiology of AML
Given that more people have been exposed to AML risk factors, than have actually 
developed the disease suggests a genetic predisposition is necessary. Evidence for this 
exists with the genetic variation prevalent in the genes o f benzene detoxifying enzymes 
such as the cytochrome P450 family or NAD(P)H quinine oxidoreductase 1 (NQOl) 
(Smith, 1999; Bowen et al., 2003; Barragan et al., 2007). Indeed, the accumulation o f 
genetic lesions throughout a lifetime, combined with the reduced capacity to rectify 
them, is believed to explain the increased prevalence o f AML in the elderly.
Since Knudson’s original ‘2-hit’ hypothesis which suggests multiple genetic mutations 
are required for cancer development (Knudson, Jr., 1971), Kelly and Gilliland have 
extended this further proposing multiple types o f genetic lesion are also required for 
leukaemogenesis (Kelly and Gilliland, 2002). In AML, it is thought that an initiating 
event, often a chromosomal translocation, occurs in primitive HSC/HPC. A 
translocation such as t(8;21) (leading to the generation o f the RUNX-1/ETO fusion 
protein, see section 1.2.2.1) can perturb normal differentiation programmes but is 
insufficient to generate leukaemia in vivo (Downing, 2003). Instead, this initiating event 
confers the necessary advantages required for a pre-malignant clone to acquire the 
further genetic lesions required for transformation. Such additional genetic mutations 
include those capable o f constitutively activating intracellular signalling such as RAS, 
or receptor tyrosine kinases like FLT-3, which provide the survival or proliferative 
stimuli necessary for the malignant clone to dominate.
There is overwhelming evidence supporting the above proposed pathophysiology o f 
AML. The very existence o f MDS is a testament to the requirement o f multiple genetic 
lesions in AML. MDS is generally regarded as a ‘pre-leukaemic’ syndrome, which 
displays many o f the same haematopoietic abnormalities and symptoms, albeit with 
slower evolution. Should the patient survive long enough, this condition often develops 
into AML which is generally attributed to the acquisition o f further transforming genetic 
mutations. The requirement for an early initiating event in AML is evidenced by the 
detection o f chromosomal translocations in haematopoietic cells which remain stably 
retained no matter what the treatment outcome (remission or relapse). The RUNX-
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1/ETO fusion transcript is one such abnormality that has been frequently detected in 
haematopoietic cells o f  patients even in long-term remission (Nucifora et al., 1993; 
Miyamoto et al., 2000). Further studies o f clonal evolution in acute lymphoblastic 
leukaemia (ALL) by the Greaves lab have shown that whilst the intiating genetic lesion 
like ETS variant gene 6 (ETV-6)/RUNX-l remains stably expressed in all malignant 
clones, the prevalence o f additional gene mutations such as deletions o f paired box 
protein 5 (Pax-5) and B-cell translocation gene 1 (BTG-1) remain variable between 
subpopulations o f the malignant clone (Anderson et al., 2011). Finally, the requirement 
for co-operating mutations in leukaemogenesis is clear from the observation that many 
AMLs harbouring a core binding factor1 (CBF) abnormality also frequently co-express 
additional mutations such as c-kit (Care et al., 2003; Valk et al., 2004; Cammenga et 
al., 2005; Cairoli et al., 2006; Schnittger et al., 2006). Despite the overwhelming 
evidence described above clearly this is not the limit o f  complexity in AML 
pathophysiology given that 50% o f de novo AML patients present with an otherwise 
normal karyotype (Grimwade et al., 1998).
1.2.2.1 Frequent genetic aberrations in AML
Frequent gene mutations involving transcriptional/signal transduction components have 
been identified in AML (reviewed by Ravandi et al., 2007 and Dohner and Dohner, 
2008), with the most frequent including Nucleophosmin-1 (NPM1), FLT-3, CEBPa, c- 
kit, neuroblastoma RAS viral oncogene homolog (NRAS), Wilms tumour 1 (WT1), 
brain and acute leukaemia cytoplasmic (BAALC), mixed-lineage leukaemia (MLL) and 
ecotropic viral integration site 1 (EVI1). The mutational status o f many o f these genes 
is now routinely assessed due to the prognostic influence in normal karyotype AML 
(section 1.2.3.3) and some have even become a therapeutic target given their 
pathological role in AML.
1 CBFs are a group of heterodimeric transcription factors composed of a DNA-binding RUNX-1, RUNX-
2 or RUNX-3 subunit (CBFa), and a non-DNA-binding CBF/3 subunit. CBFs are required for both 
effective embryonic and adult haematopoiesis, and are frequently dysregulated in leukaemia (De Bruijn 
and Speck, 2004). Disruption of CBF genes as seen in the chromosomal translocations t(8;21)(q22;q22) 
or inv(16)(pl3;q22) perturbs normal haematopoietic differentiation, and can co-operate with further 
mutations to promote proliferation.
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O f particular note, NPM1 mutations represent the most frequent and well characterised 
molecular aberration in AML occurring in approximately 35% o f AML cases but not 
reported in any other cancer (Falini et al., 2005). NPM1 is a nuclear chaperone protein 
that resides in the nucleoli o f  cells and can regulate the ARF-p53 tumour suppressor 
pathway. However, a mutation in exon 12 o f the gene leads to its cytoplasmic 
mislocalisation in AML blasts (Dohner and Dohner, 2008). Also o f relevance in AML 
are the frequent internal tandem duplications (ITD) mutations (20-30%) observed in the 
FLT-3 gene (Gilliland and Griffin, 2002). Such mutations lead to constitutive activation 
of tyrosine kinase activity and subsequent activation o f downstream signalling pathways 
responsible for proliferation and survival.
Chromosomal abnormalities like inversion o f chromosome 16 (inv(16)), or reciprocal 
translocations between chromosomes 15 and 17 (t(l 5;17)), and 8 and 21 (t(8;21)), have 
also been well characterised in AML. For example the t(8;21) CBF abnormality leads to 
fusion o f the RUNX-1 gene on chromosome 21, with the eight twenty one (ETO) gene 
on chromosome 8 generating the RUNX-1/ETO fusion protein. This abnormality is 
present in 10-15% o f de novo AML and 40% o f the FAB M2 subtype. The RUNX-1 
portion o f the protein can bind DNA and heterodimerise with CBF/3 as normal, but lacks 
the transcription activation domains which are replaced with transcriptionally repressive 
sequences o f ETO (Meyers et al., 1993). This suppressive complex recruits additional 
nuclear receptor corepressors (N-CoR), paired amphipathic helix protein (Sin3A) and 
histone deacetylases (HDAC) which lead to the deacetylation o f  histones and chromatin 
remodelling (Wang et al., 1998; Amann et al., 2001). Therefore, normal transcriptional 
regulation by RUNX-1 in haematopoiesis is disturbed leading to reduced expression o f 
some developmentally significant genes such as myeloperoxidase (MPO), the receptor 
for colony-stimulating factor 1 (CSF-1R), and the subunits o f the T-cell antigen receptor 
(TCR) (Downing, 1999). Interestingly, this fusion protein has also been associated with 
transcriptional activation (Klampfer et al., 1996).
It is becoming increasingly apparent that epigenetics also plays a role in AML 
pathology. Epigenetics is the alteration o f gene expression unrelated to changes in the 
DNA sequence. One example o f epigenetic change is DNA methylation which is
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frequently dysregulated in tumourigenesis (Baylin and Herman, 2000). The addition o f 
a methyl group to a cytosine-phosphate-guanosine (CpG island) stretch o f DNA, often 
within the promoter region o f a gene, renders that gene (typically tumour suppressors) 
permanently silenced. Methylated promoters o f various Wnt signalling inhibitors (e.g. 
dickkopf-1; DKK1) have been discovered in AML no doubt contributing to the 
dysregulation o f this pathway observed in this disease (Griffiths et al., 2010).
Finally, the relatively recent and rapid emergence o f microRNAs (miR) as important 
mediators in AML pathology must also be briefly considered. miRs are short (~22 
nucleotides) regulatory non-coding RNAs that are abundantly expressed in the human 
genome and conserved across multiple species (reviewed by Zhao et al., 2010). miRs 
are able to specifically repress gene expression through their incorporation into the 
RNA-induced silencing complex (RISC) and subsequent guidance to the target mRNA, 
which is degraded through mRNA cleavage or translational repression. Such regulation 
is vital to normal haematopoietic processes such as differentiation, proliferation and 
apoptosis, but deregulation is often observed in AML. For instance, Garzon et al. has 
reported the upregulation o f miR-107 in acute promyelocytic leukaemia (APL), which 
specifically targets nuclear factor I/A (NFI-A), a gene important to normal CEBP- 
mediated granulocytic differentiation (Garzon et al., 2007).
1.2.2.2 Leukaemic stem cells
Over the past two decades much excitement and controversy has surrounded the 
proposed existence o f leukaemic stem cells (LSC) in AML. LSCs have historically been 
described as a rare subset o f leukaemic cells which, through significant genetic damage, 
have acquired the sufficiently dysregulated self-renewal capacity necessary to both 
establish and maintain a malignant clone. They are typically defined by a primitive 
HSC-like phenotype (i.e. CD34+) with the ability to initiate leukaemia when 
xenografted into immuno-suppressed mice. Despite the seemingly detailed 
characterisation o f LSCs conflicting evidence exists over the origin, function and 
therapeutic potential o f  these cells in AML.
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Evidence for the existence o f  an LSC population in AML was initially provided through 
the experiments o f Lapidot and Dick in the 1990’s which demonstrated that only 
specific subsets o f the bulk AML clone (Lin‘CD34+CD38‘ and not Lin'CD34+CD38+) 
could successfully re-establish the disease when infused into sub-lethally irradiated 
mice (Lapidot et al., 1994; Bonnet and Dick, 1997). However this work has since been 
challenged by the findings o f  Taussig and colleagues who showed that the CD38 
antibodies used to purify such populations can in fact hinder the engraftment potential 
o f these cells (Taussig et al., 2008). Indeed, when such inhibitory factors were removed, 
the CD34+CD38+ fraction o f AML samples was found to contain most, if not all, 
leukaemia intiating cells (LIC).
There are also limitations to the murine xenograft model as a system for assaying LSC 
activity. Indeed, rather than an assessment o f LIC capability, this model could merely 
assess the ability o f  certain cells to engraft mice. In support o f this it has been found that 
APL blasts, and indeed a significant proportion o f other AML samples, fail to engraft at 
all, suggesting this system cannot efficiently model all LIC subsets (Bonnet and Dick,
1997). Interestingly, the vast majority o f melanoma cells engraft this model (Quintana et 
al., 2008). Whilst this could reflect a higher number o f LSC/LIC in different tumours, 
this could also represent the variability in different cell types to engraft this model. 
Furthermore, the engraftment potential o f  certain cells can be influenced by the dose 
and site o f inoculation (Yahata et al., 2003; Wang et al., 2003; Chabner et al., 2004; Liu 
et al., 2010).
Further work from the Dick lab has proposed that LSCs are analogous to normal CD34+ 
HSCs (quiescence, high self-renewal potential, residence in the BM niche, phenotype) 
and hence are likely derived from them. Tracking o f human LSCs in NOD-SCID mice 
showed heterogenous self-renewal potential leading the author to conclude that AML, 
similar to normal haematopoiesis, is organised hierarchically with self-renewing LT- 
LSCs with high LIC capacity, giving rise to leukaemic progeny with reduced self­
renewal potential and LIC capability (Hope et al., 2004). Although stem cell 
characteristics are indispensible for leukaemogenesis, it is not necessarily CD34+ HSC 
themselves which represent the transformed LIC population. This is evidenced by the
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fact intiating mutations such as the t(8;21) translocation have been observed in non- 
leukaemic cells (Miyamoto et al., 2000; Downing, 2003). Also a substantial number o f 
AML cases (including most NPM1 mutated AML) exhibit very little or no CD34 
positivity suggesting the LSC/LIC population must contain considerably more 
heterogeneity than originally defined. Indeed much evidence now exists showing LIC 
capability at the level o f  committed myeloid progenitors (Jamieson et al., 2004; 
Goardon et al. 2011). CD34+CD38+ granulocyte-macrophage progenitors in chronic 
myeloid leukaemia (CML) demonstrate greater self-renewal capacity than their normal 
counterparts and also expand more significantly than the CD34+CD38" HSC pool during 
disease progression (Jamieson et al., 2004). Furthermore the t(15;17) abnormality 
encoding the pro myelocytic leukaemia/retinoic acid receptor alpha (PLM/RARo) fusion 
product in APL has been detected in CD34'CD38+ cell populations and not in the HSC 
enriched CD34+CD38‘ subset (Turhan et al., 1995) potentially explaining this subtype’s 
failure to engraft.
The emergence o f the LSC concept has provoked much optimism into the potential for 
therapeutic targeting in AML. Indeed the failure o f current therapeutic regimens to fully 
eradicate LSC or LIC populations still represent the best explanation as to why so many 
patients relapse following CR or BM transplantation. However, clonal evolution 
experiments by Mel Greaves (see above 1.2.2) have demonstrated that this strategy may 
be more difficult than first anticipated. These studies show that although the founding 
genetic mutation is stably retained throughout the malignant clone, differing selective 
(Darwinian) pressures within the leukaemic environment can lead to genetically and 
phenotypically distinct LIC subpopulations. Such clonal evolution means that if LSCs 
truly exist then they are likely to represent an elusive, continually moving target, rather 
than a fixed entity (Greaves, 2010).
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1.2.3 Diagnosis, classification and prognosis in AML
1.2.3.1 Diagnosis
Traditionally, a diagnosis o f  AML was made upon presentation o f BM containing 30% 
blasts in the BM or peripheral blood, using cytomorphological techniques o f  the FAB 
classification system (Estey and Dohner, 2006). The more recent World Health 
Organisation (WHO) classification lowers the threshold to 20% provided the AML blast 
population exhibits myeloid origin (CD13+CD33+) or is present with atleast one known 
cytogenetic abnormality (see 1.2.3.2 below).
1.2.3.2 Classification
Although AML is generally referenced as a single disease, it is heterogeneous and better 
resembles a collection o f myeloid malignancies. In acknowledgement o f this, two 
classification systems exist to address the distinct genetic, biochemical and 
morphological subsets o f this disease.
The first and oldest FAB classification {Figure 1.7A) uses cytochemical techniques such 
as May-Grimwald-Giemsa staining to subtype AML according to blast morphology. 
AML is then classified by the extent o f myeloid differentiation exhibited by the bulk 
blast population, with MO representing the most undifferentiated blasts, through to the 
extensive megakaryocytic differentiation exhibited by the M7 variant. This system 
remains popular with developmental haematologists attempting to model the disease in 
vitro, since it provides information on the extent o f differentiation prior to 
transformation.
This system has now been largely superseded by the recently updated 2008 WHO 
classification o f AML which now incorporates all available clinical information 
including the cytogenetic, immunophenotypic, morphological and molecular properties 
o f the disease (Vardiman et al., 2009). From this it defines four major categories o f 
AML as shown in Figure 1.7B. This allows a more accurate diagnosis o f  the subtype o f
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AML which has become increasingly vital given the emergence o f  genetically tailored 
therapeutics.
1.2.3.3 Prognosis
Major prognostic factors in AML include response to initial treatment, age, cytogenetic 
status, WBC count, secondary disease (e.g. from MDS, which results in more 
aggressive and resistant disease), and serum albumin, bilirubin and creatinine level 
(Estey and Dohner, 2006).
Performance status is a highly relevant predictor o f  therapy-related death. Using the 
Zubrod scale, the general patient health prior to induction is assessed on a 6-point scale 
from 0 (unaffected health), through to 4 (bed-bound) and 5 (death) (Estey and Dohner, 
2006). Unsurprisingly, higher performance status scores are associated with a higher 
rate o f treatment-related mortality.
Age is powerful predictor o f resistant disease in AML. Despite significant progress in 
the survival o f  young adults (<60 years old) with AML, relatively little progress has 
been made in the last 40 years for elderly patients. Data from the UK Medical Research 
Council (MRC) AML trials {Figure 1.8), shows around 50% o f young patients achieve 
a long-term ‘cure’ (>5 years), which halves for patients between 60-69 years and is less 
than 10% for patients 70 years or older. Major obstacles to CR in elderly patients 
include more aggressive and resistant disease (due to higher frequencies o f acquired 
chromosomal aberrations and DNA mutations), and poor tolerance o f intensive 
treatment regimes.
Cytogenetics provide a reliable predictor o f treatment outcome in AML, such that 
established abnormalities can be categorised as adverse, intermediate or favourable for 
prognosis {Figure 1.7C). Approximately 60% o f AML patients present with a 
karyotypic abnormality prior to treatment (Mrozek et al., 2001), and large-scale AML 
patient studies by Grimwade et al have characterised the clinical relevance o f  such
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abnormalities (Grimwade et al., 1998; Grimwade et al., 2001). For example, AML 
harbouring a CBF abnormality such as t(8;21) or inv(16) are highly responsive to 
chemotherapy and yield higher CR rates with longer overall survival. However patients 
with a complete deletion o f chromosome 5 (-5) or chromosome 7 (-7), or complex 
karyotypes o f multiple aberrations are linked with poor response to treatment, and often 
present in old age. Curiously, the largest cytogenetic group in AML is a normal 
karyotype (intermediate risk). In this instance, specific molecular mutations (such as 
those described in section 1.2.2.1) are highly predictive o f  outcome. Indeed the NPM1 
and CEPBa mutations carry such accurate prognostic power (higher CR rate, longer 
survival, and improved event-free survival; (Frohling et al., 2004; Dohner et al., 2005) 
that they have been recently included as a provisional entity in the WHO classification 
o f AML (see Figure 1.7B). The presence o f multiple molecular mutations can 
complicate the prognosis in AML. For example the otherwise favourable prognosis o f  
an NPM1 mutation is all but abrogated when present with a FLT3-ITD (Dohner et al., 
2005; Thiede et al., 2006). Furthermore, some o f these individual gene mutations are 
capable o f conferring a worse prognosis in otherwise favourable cytogenetic risk 
groups, as exemplified by the c-kit mutation in t(8;21) leukaemias (Schnittger et al., 
2006; Paschka et al., 2006).
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FAB subtype Description
M0 Undifferentiated
Ml Myeloblastic without maturation
M2 Myeloblastic with maturation
M3 Promyelocytic
M4 Myelomonocytic
M4Eo Myelomonocytic with bone
marrow eosinophilia
M5 Monocytic
M6 Erythroleukaem ic
M7 Megakaryocytic
B )
A cute m yeloid leukaem ia and related neoplasm s
A cute m yeloid leukem ia w ith recurrent genetic  
abnorm alities
AML with t(8;21Xq22;q22); RUNX1-RUNXIT1 
AML with inv(16)(pl3.1q22) or t( 16; 16 )(p l3.1 ;q22); 
C BF B -M YH ll
APL with t( 15; 17)(q22;q 12); PML-RARA
AML with t(9;l I)(p22;q23); MLLT3-MLL
AML with t(6;9)(p23;q34); DEK-NUP214
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPNJ-
EVI1
AML (megakaryoblastic) with t( 1 ;22)(pl3;q 13); RBM15- 
MKLl
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA
A cute m yeloid leukem ia with m yelodysplasia-related  
changes
T herapy-related  m yeloid neoplasm s
A cute m yeloid leukem ia, not otherw ise specified
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukemia 
Acute monoblastic/monocytic leukemia 
Acute erythroid leukemia 
Pure erythroid leukemia 
Erythroleukemia, erythroid/myeloid 
Acute megakaryoblastic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis
Risk Group Abnormality Comment
Favourable t(8;21) Alone or
t( 15; 17) with other
inv( 16) aberrations
Intermediate Normal Cytogenetic
+8 abnormlities
+21 not classified
+22 as favourable
del (7q) 
del (9q)
or adverse
Abnormal Lack of
1 lq23 additional
All other favourable or
structural and adverse
numerical cytogenetic
abnormalities changes
Adverse -5 Alone or in
-7 conjunction
del(5q) with
Abnormal 3q intermediate-
Complex risk or other 
adverse-risk
Figure 1.7 - The classification of AML subtype and prognostic cytogenetics.
A) The FAB classification of AML which defines eight subtypes o f disease based on the 
blast morphology. Adapted from Tenen, 2003. B) The updated 2008 WHO 
classification of AML which defines four main categories o f AML on the basis o f 
morphological, immunophenotypic, molecular and clinical characteristics o f the disease. 
Adapted from Vardiman et al., 2009. C) The favourable, intermediate and adverse 
cytogenetic risk groups of AML. Adapted from Grimwade et al., 1998.
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Figure 1.8 - The overall survival of different AML patient age groups.
Kaplan-Meier survival curves showing the overall survival rates of AML patients 
enrolled in the UK MRC AML trials since 1970 (courtesy of Professor Alan Burnett). 
Significant progress has been demonstrated in the A) younger patient cohort (15-59 
years), however the prognosis remains poor for older patients of B) 60-69 years or C) 
70 years plus.
28 | P a g e
Introduction C hapter I
1.2.4 Treatment for AML
1.2.4.1 Current treatment strategies
The standard treatment for AML in the UK involves the use of chemotherapeutics with 
the aim o f reducing the bulk leukaemic blast population and inducing a long-term CR 
(defined as <5% blasts in a bone marrow displaying maturation o f other lineages; (Gale 
et al., 2005)). Typically, these cytotoxic agents are non-specific in action and target 
specific cellular process (e.g. DNA replication) active in both blasts and normal cells. 
This leads to the considerable toxicity and side-effects associated with chemotherapy 
including alopecia, nausea, vomiting, immune-suppression and infertility. An example 
of such an agent includes the anthracyclines, which are a class o f  eukaryotic antibiotics 
with broad anti-tumourigenic activity. They work by intercalating DNA preventing its 
replication and subsequent transcription, thus inducing apoptosis in targeted cells (Pratt 
WB and Ruddon RW, 1994).
The induction therapy for most AML patients (except the acute promyelocytic M3 
variant) over the last two decades has been the standard ‘3+7’ regimen (Appelbaum et 
al., 2001). This involves a combination o f the anthracycline daunorubicin (45mg/m 
intravenously for 3 days) with the anti-metabolite cytarabine (AraC; lOOmg/m 
continuous infusion over 7 days). This regimen has been capable o f inducing CR rates 
o f 65-75% in adults aged 18-60 years (Tallman et al., 2005). Patients failing to achieve 
a CR, or relapsing shortly after, may be considered for an autologous (self) or allogeneic 
(matched donor) bone marrow transplant. This procedure involves sub-lethal 
obliteration o f the existing BM followed by infusion o f normal CD34+ HSCs. The 
instinctual ability o f these cells to home to the bone marrow niche should reconstitute a 
new healthy haematopoietic system. However, in reality, this procedure is met with 
frequent relapse, and the severe toxicity and potentially morbid effects o f graft versus 
host disease (GVHD), restrict this option only to the fittest patients.
The lack o f progress in survival rates from elderly patients with AML over the last 40 
years (Figure 1.8C), has led many experts to conclude that current chemotherapeutic 
regimens have reached ‘the end o f the road’ in terms o f treatment efficiency. The
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genetic and molecular heterogeneity exhibited in AML means a more targeted approach 
to specific aberrations within the patient is now required. The Wnt signalling pathway is 
one such target that has rapidly accumulated interest o f late because o f its frequent 
dysregulation in AML.
1.3 Wnt signalling
1.3.1 Overview
Wnt signalling is an evolutionary conserved pathway critical for normal developmental 
processes in both the embryo and adult, including cell growth and differentiation. The 
human genome encodes for a total o f  19 Wnt genes, which are all members o f a lipid- 
modified family o f  secreted glycoproteins (Clevers, 2006). All are capable o f  activating 
the multiple pathways which comprise Wnt signal transduction when bound to their 
cognate receptor complex, with the net result o f downstream Wnt target gene activation. 
At least three different intracellular signalling pathways are recognised to emanate from 
a Wnt stimulus. These include the well characterised canonical pathway, and the lesser
O i
understood planar cell polarity (PCP) and Wnt-Ca non-canonical pathways (Staal et 
al., 2008). Only the canonical pathway will be described further here given the central 
involvement o f catenin molecules, which have particular relevance to this study.
In the absence o f a Wnt signal, the canonical Wnt pathway is maintained in a state o f 
suppression (Figure 1.9A ) through continual degradation o f  the central mediator, /3- 
catenin. In this state, /3-catenin is bound by a catenin destruction complex (CDC) 
consisting o f casein kinase 1 (CK-1), glycogen synthase kinase 3 beta (GSK-3(3), axis 
inhibition protein 1 (Axin-1) and adenomatous polyposis coli (APC). This complex 
phosphorylates /3-catenin on Serine 45 (Ser) by CK-1 and then on Ser33, Ser37 and 
Threonine 41 (Thr) by GSK-3jS, generating recognition sites for the /Ttransducin- 
repeat-containing protein (/3-TRCP) (Aberle et al., 1997; Orford et al., 1997). This 
protein tags /3-catenin with ubiquitin molecules ultimately targeting it for proteasome- 
mediated degradation in the cytoplasm (Salomon et al., 1997; Kitagawa et al., 1999; 
Hart et al., 1999). In the nucleus, the transcription factor TCF suppresses Wnt target 
gene activation by forming a repressor complex with members o f the groucho (GRG)
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family o f  transcriptional repressors, C-terminal binding protein (CtBP) and HDACs 
(Rooseefa/., 1998).
The canonical pathway is activated {Figure 1.9B) upon binding o f a Wnt ligand, such as 
Wnt3A, to a transmembrane receptor complex consisting o f the frizzled (FZ) family o f  
G protein-coupled receptors, and the low density lipoprotein receptor-related protein 
(LRP) family o f multifunctional endocytic receptors. Activation o f this complex leads to 
the recruitment o f dishevelled (DVL) which in turn assists CK-1 and GSK-3/3 in the 
phosphorylation o f LRP5/6 (Zeng et al., 2005; Zeng et al., 2008). The phosphorylated 
residues o f LRP5/6 provide ‘docking’ points for Axin-1 which subsequently dissociates 
from the CDC, and re-locates to the plasma membrane. This ultimately causes the 
failure o f all CDC components to assemble (through a mechanism that is incompletely 
understood) and so /3-catenin is not phosphorylated or degraded. Instead the cytoplasmic 
pool o f signalling competent 0-catenin accumulates, culminating in its eventual 
translocation to the nucleus through a largely unknown mechanism. Here, jS-catenin is 
able to activate Wnt target genes by displacing groucho repressors on DNA and binding 
the high-mobility group (HMG) family o f nuclear proteins TCF and LEF in a complex 
also requiring B-cell CLL/lymphoma-9 protein (BCL-9) and pygopus (Kramps et al., 
2002; Thompson, 2004; Townsley et al., 2004a; Townsley et al., 2004b). The 
architectural TCF/LEF transcription factors serve to physically bend DNA and permit 
the association o f the DNA-protein complexes necessary for gene transcription. Well 
characterised gene targets o f TCF/LEF-mediated Wnt//3-catenin signalling include c- 
myc (He et al., 1998), cyclinDl (Shtutman et al., 1999), survivin (Zhang et al., 2001; 
Kim et al., 2003a), CD44 (Wielenga et al., 1999), and TCF-1 (Roose et al., 1999).
The canonical pathway is also negatively regulated at varying stages o f  the cascade. The 
binding o f Wnt ligand to the FZ and LRP activation receptors is antagonised by the 
presence o f soluble decoy proteins in the extracellular matrix (Kawano and Kypta, 
2003). Inhibitory proteins such as DKK1, Wnt inhibitory factor (WIF), soluble frizzled- 
related protein (sFRP), and norrin are capable o f binding, but not transducing, a Wnt 
stimulus. Within the nucleus, /5-catenin mediated transcription is inhibited by 
sequestration o f /3-catenin from TCF/LEF complexes by the /3-catenin-interacting
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protein (ICAT) (Daniels and Weis, 2002). Finally, alternative splicing o f the TCF gene, 
in particular TCF-1, can also regulate the sensitivity o f the cell to Wnt signals. Longer 
forms o f the transcription factor harbour the amino-terminal required to bind catenin, 
whilst shorter forms lack this domain and subsequently function as endogenous 
transcriptional repressors (Van de Wetering M. et al., 1996).
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Figure 1.9 - Overview of the canonical W nt signalling pathway.
A) In the absence of a Wnt ligand, /3-catenin is bound by the CDC, phosphorylated, and 
targeted for degradation in a ubiquitin/proteasome-dependent manner. Wnt signalling is 
further inhibited by soluble antagonists such as DKK-1, or binding o f nuclear /3-catenin 
by ICAT. Wnt target gene expression is suppressed by recruitment of co-repressors such 
as GRG/TLE (Groucho/transducin-like enhancer), CTbP and HDACs. B) Wnt 
signalling is activated upon binding o f a lipid-modified Wnt ligand FZ/LRP receptor 
complex. DVL initiates the sequestering of Axin-1 from the CDC by phosphorylation of 
LRP, leading to the dissolution of this complex. Failure of this complex to degrade /5- 
catenin causes its accumulation and nuclear translocation where it binds TCF/LEF 
promoters on DNA to activate Wnt target genes. Additional co-factors such as legless 
(LGS; also known as BCL-9) and Pygopus (PYGO), CBP/p300, brahma and MED 12 
are recruited to facilitate transcription. Adapted from Staal et al., 2008.
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1.3.2 Wnt signalling in normal haematopoiesis
The Wnt pathway is known to regulate the fate and function o f many different cell types 
(reviewed by Clevers, 2006 and Cadigan and Peifer, 2009), and evidence over the last 
15 years has established that this pathway is also active in normal haematopoiesis (Staal 
and Luis, 2010). A number o f studies have indicated that haematopoietic cells can both 
receive, and respond, to various Wnt stimuli under normal homeostatic conditions.
Initial studies by Austin et al found various components o f the Wnt pathway expressed 
early in murine haematopoiesis including FZ receptors and the Wnt proteins, Wnt5A 
and Wnt 10B (Austin et al., 1997). Furthermore the in vitro culture o f HSCs in W ntl, 
Wnt5A and W ntl0B conditioned medium lead to the substantial expansion o f these 
cells, suggesting the Wnt pathway conferred survival and proliferative advantages to 
this population. Subsequent investigations from Van den Berg et al characterised the 
expression o f various Wnt genes active in human haematopoiesis (Van den Berg et al.,
1998). Wnt2B, Wnt5A, and Wntl0B were found expressed in bone marrow stroma and 
variably in multiple haematopoietic lineages including lymphocytes, myeloid and 
erythroid cells. Interestingly, only Wnt5A was expressed in the Lin'CD34+ HSC/HPC 
population, which was once again significantly expanded in the presence o f Wnt- 
producing stroma. These primitive cells were also found to express atleast 6 members o f 
the FZ family o f Wnt receptors. Since these initial studies further reports have 
confirmed both the expression and influence o f various Wnt components on normal 
haematopoietic cells (Reya et al., 2000; Hackney et al., 2002; Murdoch et al., 2003; 
Willert et al., 2003; Wagner et al., 2005; Dosen et al., 2006; Congdon et al., 2008; 
Sercan et al., 2010; Gallagher et al., 2010). In particular, much interest has surrounded 
the influence o f Wnt signalling within the HSC niche.
Although not completely characterised, there is much evidence to support active Wnt 
signalling within the BM niche. Indirectly, it is likely to affect HSC regulation through 
its role in maintaining mesenchymal tissue, such as osteoblasts (Guo et al., 2004; Day et 
al., 2005). Fleming and colleagues demonstrated a direct relationship in vivo through 
targeted expression o f the Wnt pathway inhibitor dickkopf-1 (DKK1) in the niche 
(Fleming et al., 2008). Loss o f Wnt signalling arising from DKK1 overexpression
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caused increased cell cycling and reduced regenerative capacity o f HSC following 
transplant, leading the authors to conclude that Wnt signalling in the niche regulates 
HSC quiescence and reconstitution function. Kim et al. used a different approach to 
demonstrate Wnt importance in the niche (Kim et al., 2009). Enforced expression o f /?- 
catenin in the surrounding stromal cells promoted HSC self-renewal in a contact- 
dependent manner, whilst direct stabilisation in HSC led to loss o f this population. 
Indeed, both Wnt receptors and /3-catenin were expressed more highly in the BM stroma 
than haematopoietic cells, and could be further induced through stimulation with 
Wnt3A. Notch ligands were also enriched in Wnt//3-catenin activated stroma leading to 
downstream activation o f Notch signalling in HSCs suggesting cross-talk between these 
pathways within the niche.
Evidence for a direct role o f Wnt signalling in haematopoietic cells is strengthened by 
recent functional studies into various components o f the pathway (reviewed recently by 
(Staal and Luis, 2010)). For example, Wnt signalling is likely to be important for 
lymphopoiesis given thymic T-cell development is perturbed upon overexpression o f 
the Wnt inhibitors ICAT (Pongracz et al., 2006) and sFRP (Staal et al., 2001). 
Conversely, the proliferation o f  B-cells appears to be negatively regulated by the Wnt 
signalling agonist, Wnt3A (Dosen et al., 2006). Inhibition o f the Wnt CDC constituent 
GSK-3/3 has been shown to promote the self-renewal and reconstitution capacity o f 
HSCs in vivo indirectly through its influence on /3-catenin level (Trowbridge et al., 
2006; Holmes et al., 2008). The downstream transcriptional activators TCF/LEF have 
also demonstrated relevance in a normal haematopoietic setting. Repression o f the 
downstream Wnt transcriptional activator, LEF-1, was shown to inhibit proliferation 
and induce apoptosis in CD34+ progenitor cells (Skokowa et al., 2006). Mice deficient 
in TCF-1 demonstrate severe thymocyte abnormalities with a reduction in overall 
thymocyte number, and a block in differentiation between transition from immature 
CD8+ precursors to more mature CD4+CD8+ T-cell lymphocytes (Verbeek et al., 
1995). Finally, the manipulation o f differing exogenous Wnt proteins is capable o f 
altering the course o f haematopoietic development. Depletion o f  Wnt3A reduced the 
number and repopulation capacity o f HSC/HPC, whilst further reducing the frequency 
o f myeloid progenitors (Luis et al., 2009). Furthermore, loss o f  Wnt 11 caused the 
domination o f vacuolated macrophages during in vitro culture o f HPC, at the expense o f
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red cells and monocytes (Brandon et al., 2000). These lineages were rescued by re­
addition o f  Wntl 1 and Wnt5A, and can actually stimulate the reverse phenotype when 
over-concentrated, implying that a fine balance o f exogenous Wnt proteins is required 
for normal haematopoiesis.
Arguably the most disputed function o f a Wnt signalling component in normal 
haematopoiesis is that o f the central mediator (3-catenin. A host o f studies have 
demonstrated Wnt//3-catenin signalling is vital in mediating the survival and self­
renewal o f  HSC (Reya et al., 2003; Willert et al., 2003; Jamieson et al., 2004; Zhao et 
al., 2007; Holmes et al., 2008; Kim et al., 2009; Nemeth et al., 2009). However, other 
studies have contradicted these findings by demonstrating that constitutively activated 
/3-catenin in HSC impairs multi-lineage differentiation and completely exhausts the 
HSC pool (Baba et al., 2005; Baba et al., 2006; Kirstetter et al., 2006; Scheller et al.,
2006). To further complicate the picture, the constitutive deletion o f /3-catenin, and or 
the close homologue y-catenin, in HSC did not affect the ability o f  these cells to fully 
reconstitute a normal haematopoietic system when transplanted into irradiated mice 
(Cobas et al., 2004; Jeannet et al., 2008; Koch et al., 2008). Interestingly, TCF/LEF 
activation remained intact in these cells suggesting the existence o f other catenin-like 
molecules that can also bind these transcription factors and even compensate in the 
absence o f catenin. The disparate results arising from these many investigations has 
been suggested to arise from the considerable variation in the experimental approaches 
adopted to generate them (Staal and Luis, 2010). Although the precise role o f  
individual Wnt signalling components requires further elucidation, it seems undeniable 
that Wnt signalling and its strict regulation are indispensible for normal, healthy 
haematopoiesis.
1.3.3 Dysregulated Wnt signalling in AML
The importance o f Wnt signalling to normal development makes this pathway an ideal 
target during malignant transformation. Indeed, its dysregulation has been reported in 
many epithelial cancers (reviewed by others (Polakis, 2000; Giles et al., 2003)) and 
there is much evidence, although some still controversial, pointing to its dysregulation 
in AML.
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A landmark study by Majeti et al compared the gene expression profiles between 
normal BM HSCs and AML LSCs and identified the Wnt signalling pathway as 
aberrantly regulated (Majeti et al., 2009). It must be noted however that very small 
patient numbers were used (<10 per comparison), and CD34 positivity was adopted as 
the only LSC marker which remains controversial (as previously discussed 1.2.2.2). A 
recent study by Wang et al identified the Wnt//3-eaten in axis to be vital in mediating the 
self-renewal and survival o f  murine LIC (Wang et al., 2010). In particular, activation o f 
Wnt//3-catenin signalling was suggested to represent the mechanism by which certain 
oncogenes can transform even committed progenitors. However, caution must be 
exercised when comparing this to human AML-initiating cells since the oncogenes used 
in this murine model (Meis homeobox la  (M eisla) and homeobox A9 (HoxA9)) are 
rarely implicated in human AML.
Further dysregulation o f Wnt signalling components has been reported in myeloid 
leukaemias including the soluble Wnt proteins Wntsl/2B/3A (Simon et al., 2005; 
Kawaguchi-Ihara et al., 2008), FZ-4 receptor (Tickenbrock et al., 2008), GSK-3/3 (De 
Toni et al., 2006; Abrahamsson et al., 2009) LEF-1 (Li et al., 2004; Petropoulos et al., 
2008) and TCF-4 (Siti Sarah Daud et al., 2010). Using Western blotting or 
immunohistochemical techniques, many studies have demonstrated the variable 
expression o f the central mediator /3-catenin in primary AML blasts (Chung et al., 2002; 
Serinsoz et al., 2004; Simon et al., 2005; Ysebaert et al., 2006; Xu et al., 2008; Chen et 
al., 2009). The studies o f Ysebaert, Xu and Chen et al were all able to further verify (3- 
catenin expression as a prognostic indicator o f poor survival in AML patients. Despite 
these findings, many o f the above mentioned studies are hampered by relatively small 
cohort sizes (typically <  80) which are too small to be definitive in such a 
heterogeneous disease as AML. The study o f  Xu et al investigated another possible 
level o f /3-catenin dysregulation in AML; namely the inappropriate nuclear localisation. 
The detection o f non-phosphorylated nuclear /3-catenin (the only form which should 
theoretically enter the nucleus) was detected immunohistochemically in nearly half o f 
all AML samples examined, implying aberrant transcriptional activity in AML. 
However this study is once again hampered by small sample numbers and does not 
declare how nuclear localisation compares with that o f normal HSC/HPC. Given the 
associated role o f /3-catenin with self-renewal in normal HSC, it is conceivable that /3-
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catenin would be expected in the nucleus o f a HSC/HPC disorder. This concept was 
taken further by the research o f Simon et al, who proposed aberrant /3-catenin 
transcriptional activity in AML given the finding that leukaemic cells demonstrated 
higher outputs from the TOPFLASH reporter (internal measurement o f TCF/LEF 
activity). However, the authors do not show how /3-catenin correlates with TCF/LEF 
activity, which becomes important given that TOPFLASH is non-specific for catenin- 
TCF/LEF activation and other molecules are also capable o f activating these 
transcription factors. Furthermore this paper compares /3-catenin protein level in AML 
blasts with that o f  normal progenitors which have been cultured in vitro for 6  days. Such 
a comparison may be inappropriate given the lack o f exogenous Wnt factors present in 
culture medium which may influence /3-catenin level within a normal in vivo setting. 
Finally, methylation o f  Wnt negative regulators, such as WIF-1, DKK and sFRP have 
also been identified in AML which would be predicted to elicit uncontrolled Wnt 
signalling (Chim et al., 2006; Valencia et al., 2009; Griffiths et al., 2010). 
Unfortunately these studies mainly focus on the gene status o f these Wnt inhibitors in 
AML blasts and do not formally demonstrate inhibition at the protein level, or 
hyperactivity o f the Wnt pathway through /3-catenin or TCF/LEF measurement. All 
three studies are in agreement however, that methylation o f Wnt negative regulators is 
associated with an adverse prognosis in AML.
Well established gene mutations in AML such as FLT3-ITD may also mediate their 
pathogenic effects through perturbation o f Wnt signalling. Tickenbrock et al discovered 
the FLT3-ITD mutation can induce expression o f the FZ-4 receptor and /3-catenin, 
which could enhance the sensitivity o f these cells to Wnt signal transduction 
(Tickenbrock et al., 2005). The study by Simon et al, also noted high TCF/LEF output 
in FLT3-ITD+ AML but this did not reach significance given the high levels observed in 
most patient samples regardless o f FLT-3 status (Simon et al., 2005).
Finally, an additional Wnt signalling component has recently been identified as 
dysregulated in AML (Zheng et al., 2004; Muller-Tidow et al., 2004; Tonks et al.,
2007). y-Catenin, a close structural and functional homologue o f /3-catenin, was 
originally identified as dysregulated in AML by its overexpression (at mRNA and
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protein level) in the presence o f common AML translocation products such as RUNX- 
1/ETO (Zheng et al., 2004; Muller-Tidow et al., 2004). Indeed these fusion proteins 
were shown to be directly capable o f activating the y-catenin gene promoter, and y- 
catenin mRNA levels were significantly higher in fusion protein-positive primary AML 
BM blasts. More extensive AML patient microarray studies from our laboratory 
identified y-catenin mRNA expression as higher across the majority o f AML FAB 
subtypes, regardless o f  fusion protein status, in comparison to normal CD34+ progenitor 
cells (Tonks et al., 2007). The highest levels of y-catenin expression were observed in 
patients with a CBF abnormality (t(8;21) or inv(16)). Collectively, these data suggested 
that CBF abnormalities in AML mediate their pathogenic effects in part by disrupting 
Wnt signalling through y-catenin activation. Such reports were the first to implicate y- 
catenin within a haematopoietic context.
1.3.4 y-Catenin
y-Catenin (aka plakoglobin, junction plakoglobin (JUP)), is a close structural and 
functional homologue o f /3-catenin and is a member o f the armadillo protein family, an 
evolutionary conserved group o f proteins critical to normal physiological processes such 
as cell signalling, adhesion and motility. Armadillo was originally discovered as a 
segment-polarity gene vital for proper axis formation during Drosophila embryogenesis 
(Peifer and Wieschaus, 1990). The identification o f human y-catenin through immuno- 
precipitation with cadherin protein showed it shared close amino acid sequence 
homology with both Drosophila Armadillo (63%) and Xenopus /3-catenin (6 8 %) 
(McCrea and Gumbiner, 1991; Knudsen and Wheelock, 1992; Peifer et al., 1992). 
Further work has shown that y-catenin protein is highly conserved amongst mammalian 
species with mouse (Mus musculus), rat (Rattus norvegicus), cow (Bos taurus) and dog 
(Canis familiaris) all sharing >98% amino acid sequence homology with the human 
form2. Complete sequencing has shown it to span 745 amino acids, with a predicted 
molecular weight o f 82kDa (Franke et al., 1989). The y-catenin gene (CTNNG) is 
located on chromosome 17q21 (Aberle et al., 1995), and is subject to alternative 
splicing. Nine different transcripts have been identified to date (see Sanger Ensembl
2 http://www.genecards.org/cgi-bin/carddi sp.pl?gene=JUP
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website ), nearly all o f  which are protein coding. Three o f the transcripts encode the 
full-length 745 amino acid sequence, with the rest encoding short variants (<300 amino 
acids) with no known functional significance. O f note, an alternatively spliced form o f 
y-catenin has been identified harbouring a 1 2 0 bp deletion leading to loss o f the fourth 
armadillo repeat and prevents its binding with protein partners such as APC and E- 
cadherin (Ozawa et al., 1995a; Ozawa et al., 1995b). y-Catenin protein is known to be 
regulated through the same post-translational modifications as are active for /3-catenin 
protein (see below).
In addition, to the main constituents o f the armadillo protein family (a-, /3- and y- 
catenin) a further subfamily o f armadillo repeat containing proteins have been described 
including p i20 catenin and 5-catenin. However, these proteins as yet have no known 
relevance to haematopoiesis and consequently will not be discussed further (for review 
see McCrea and Park, 2007).
Armadillo proteins share a common structure including a highly conserved central 
armadillo domain flanked by amino- (NH2) and carboxy (COOH) -termini (Hatzfeld,
1999). The central domain consists o f  12 armadillo repeat regions (consisting o f 45 
amino acids each) that exhibit considerable sequence homology (-85%) between y- and 
/3-catenin molecules {Figure 1.10A). Crystallographic analysis has revealed this ‘arm’ 
repeat motif can fold into a tertiary structure composed o f densely packed a-helices that 
form a superhelix with a positively charged groove spanning the entire arm region 
(Huber et al., 1997). This groove has been proposed to mediate the binding o f many 
common protein partners including Qf-catenin, cadherin, APC, Axin and TCF/LEF 
transcription factors (Ben-Ze'ev and Geiger, 1998). The amino-termini of y- and /3- 
catenin share only modest similarity {Figure 1.10A), but both contain the crucial GSK- 
3/3 consensus site necessary for the phosphorylation and subsequent degradation o f the 
molecules (Aberle et al., 1997). Indeed, y-catenin is also known to interact with many o f 
the same degradation components also active in the maintenance o f /3-catenin protein 
stability (see 1.3.1) including APC and Axin (Rubinfeld et al., 1995; Miller and Moon,
3 http://www.enscmb1.org/Homo sapiens/Gcne/Suinmarv?db=corc;g=ENSG00000173801 ;r=l 7:39910856-39943183
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1997; Kodama et al., 1999; Sadot et al., 2000). The NH2-terminus o f /3-catenin has also 
been identified to carry functional significance by housing transcriptional activation 
domains. In particular these activation domains have been found important for binding 
and stimulating LEF-1 mediated transcription in epithelial cells, however no such 
function has yet been ascribed to the corresponding region o f y-catenin (Simcha et al., 
1998; Hsu et al., 1998; Kolligs et al., 1999). The COOH-termini o f catenins {Figure 
1.10A) share the least homology and the function o f this domain is incompletely 
resolved. They are also believed to assist transcriptional function (Orsulic and Peifer, 
1996; Simcha et al., 1998; Hsu et al., 1998; Hecht et al., 1999), but substantial evidence 
also implicates this terminal with regulating the specificity o f  catenin binding with 
various adhesion and transcriptional partners including the desmosomal and classical 
cadherins (see 1.3.5.1 below) (Wahl et al., 1996; Palka and Green, 1997; Wahl et al., 
2000), LEF-1 (Zhurinsky et al., 2000a) and TCF-4 (Solanas et al., 2004). O f particular 
note, the studies by Wahl et al confirmed the COOH-terminus o f y-catenin to be 
important for interactions with desmosomal cadherins, and furthermore, through 
chimaeric modelling, showed such COOH-terminal specificity can explain the exclusion 
o f /3-catenin from these adhesion structures. Also o f interest, Zhurinsky et al, showed 
that the COOH-, and indeed NH2-termini, o f y- and /3-catenin are not required for actual 
binding to LEF-1-DNA complexes, but are required for subsequent transcriptional 
activation. The molecular similarity between y- and /3-catenin has led many to 
hypothesise, or demonstrate, that they share considerable functional overlap.
1.3.5 Functions of y-catenin
y-Catenin shares many common protein partners with /3-catenin and, as a consequence, 
assumes many o f the same functions within the cell, however, important differences 
also exist.
1.3.5.1 Cell adhesion
The best characterised function o f y-catenin is in cell adhesion. Like /3-catenin, it is 
located within adherens junctions (AJ) between cells, where it anchors classical 
cadherins (i.e. N- or E-cadherin) in the membrane, to the actin cytoskeleton, via a-
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catenin {Figure 1.10B). The presence o f additional protein binding sites in the NH2- and 
COOH-terminal domains, enable y-catenin to function as a scaffold protein for these 
multi-protein assemblies (Aberle et al., 1994; Nagafiichi et al., 1994). Such types o f 
adhesion are critical for maintaining tissue integrity within an epithelial context such as 
the skin or gut. Unlike /3-catenin, it can also be found as a constituent o f desmosomal 
plaques {Figure 1.1 OB), where it anchors the desmosomal cadherins desmocollin and 
desmoglein, to cytosolic intermediate filaments through desmoplakin and plakophilin 
(Schmidt et al., 1994; Co win and Burke, 1996). These strong adhesion structures are 
tissue-specific and limited to organs undergoing constant physical stress such as the 
heart. The is affirmed by the finding that y-catenin-deficient murine embryos die early 
in development from severe cardiac defects resulting from improper formation o f 
desmosomes (Bierkamp et al., 1996; Ruiz et al., 1996). Understandably, much 
knowledge o f y-catenin’s adhesive function has arisen from experiments conducted 
within an epithelial context, given that adherence is not a feature o f haematopoietic cells 
which exist in single-cell suspensions. Although homotypic interactions (between same 
cell types) are rare, heterotypic interactions (between different cell types) may be 
relevant within a haematopoietic context, particularly within the BM niche. The 
interaction between N-cad and /3-catenin has been proposed to regulate the interaction 
o f HSC with the local BM stroma (see 1.1.2.2). However the questionable N-cad 
expression on HSC (see 3.5.2), and the ability o f double-catenin knockout (KO) HSC to 
fully reconstitute immunosuppressed mice (Cobas et al., 2004; Jeannet et al., 2008; 
Koch et al., 2008), would challenge this concept.
1.3.5.2 Transcription
The functional role of y-catenin as a transcription factor for the Wnt signalling pathway 
is more contentious. y-Catenin is regulated in the same manner as /3-catenin within the 
cell, being degraded by the same machinery (see above 1.3.1) in the absence o f  a Wnt 
signal, and stabilised then translocated in the presence o f Wnt ligand {Figure 1.10B) 
(Bradley et al., 1993; Papkoff et al., 1996; Kim et al., 2011). Within an epithelial 
context, y-catenin has previously been shown to effectively bind TCF/LEF transcription 
factors (Huber et al., 1996; Simcha et al., 1998; Hecht et al., 1999; Kolligs et al., 2000; 
Zhurinsky et al., 2000a; Miravet et al., 2002) and y-catenin transcriptional activity has 
also been reported in /3-catenin-null epithelial backgrounds (Conacci-Sorrell et al.,
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2002; Maeda et al., 2004; Kim et al., 2011). y-Catenin is further capable o f 
transforming R3KE epithelial cells in a TCF/LEF dependent mechanism where it 
activates c-myc expression more extensively than /3-catenin (Kolligs et al., 2000). 
However, in general, its affinity for forming ternary complexes with DNA, and resulting 
transcriptional power, has been demonstrated as inferior to that o f /3-catenin (Simcha et 
al., 1998; Zhurinsky et al., 2000a; Maeda et al., 2004). Furthermore y-catenin is unable 
to compensate for the loss o f /3-catenin in KO mice (Haegel et al., 1995; Huelsken et al.,
2000). The study by Huelsken et al shows the failure o f y-catenin to compensate the 
Wnt signal required for proper axis formation results in the death o f /3-catenin-deficient 
embryos.
There is a small quantity of evidence to suggest that y-catenin could have transcriptional 
relevance within a haematopoietic context. Experiments by Miiller-Tidow et al, have 
shown that induction of y-catenin by AML fusion proteins, such as RUNX-1/ETO, in 
U937 cells lead to the increased frequency o f y-catenin/LEF-1 complexes (Muller- 
Tidow et al., 2004). They were further able to show that y-catenin was found bound 
directly to the promoter region o f the well characterised Wnt target gene c-myc. It must 
be mentioned however that the frequency o f /3-catenin/LEF-l complexes also increased 
with fusion protein induction in these cells making it more difficult to ascribe /3-catenin 
independent TCF/LEF activation by y-catenin. Work from our laboratory has also 
involved the analysis o f  gene expression profiles between normal human CD34+ 
HSC/HPC and those overexpressing y-catenin (Liddiard, unpublished data). Although 
global differences in gene expression were fairly unremarkable, a few noteworthy 
examples were observed including the positive induction o f myc-target protein 1 {myc- 
T1). Finally, following the demonstration of y-catenin-mediated transcriptional control 
over survivin expression on a /3-catenin deficient background (in epithelial NCI-H28 
cells), Kim et al were further able to identify a correlation between y-catenin and 
survivin expression in blast crisis CML patients (Kim et al., 2011).
1.3.6 The functional relationship between y- and /3-catenin
The close structural and functional homology shared between y- and /3-catenin has 
provoked interest into the degree o f competition, compensation, and synergy exhibited
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between these two proteins. Salomon et al employed tumour cell lines (HT1080 and 
SVT2), which express /3-catenin and N-cadherin but not y-catenin, to demonstrate that 
exogenous y-catenin was capable o f displacing /3-catenin from the AJ, augmenting its 
degradation by the proteasome (Salomon et al., 1997). As well as promoting /3-catenin 
degradation, this study also demonstrated how the ubiquitin-proteasome system can 
become overwhelmed by the extra-junctional /3-catenin leading to nuclear translocation 
o f /3-catenin. Similar findings have been observed in Xenopus embryos where 
exogenous y-catenin has been proposed to increase the cytoplasmic pool o f signalling 
competent /3-catenin, by saturating the degradation and CDC components (Miller and 
Moon, 1997; Klymkowsky et al., 1999). Simcha et al also observed similar findings in 
an epithelial MDCK cell line, where /3-catenin was identified as the primary driver of 
LEF-1 mediated transactivation (Simcha et al., 1998). Despite the interdependence o f y- 
and /3-catenin on the same regulatory components, the balance o f  protein 
expression/activity is likely to be dependent on the setting. For example in primary 
CML patient samples y- and /3-catenin level were found to inversely correlate, though it 
must be noted that only mRNA was assessed (Kim et al., 2011). Lack o f correlation 
between y- and /3-catenin protein levels has also been observed in primary tumour 
samples o f brain, lung and breast (Toyoyama et al., 1999; Bukholm et al., 2000; Amitay 
et al., 2 0 0 1 ).
As well as competition for structural and regulatory constituents, y- and /3-catenin may 
also compete for the same nuclear partners with consequences for Wnt signal 
transduction. For example, Miravet et al have shown that TCF-4 contains distinct 
binding sites for both /3- and y-catenin and, although both proteins may bind 
simultaneously, interactions with the latter antagonises the transcriptional activity o f the 
complex in epithelial cells (Miravet et al., 2002). Further evidence from experiments in 
cardiac and lung cells have also highlighted y-catenin as an inhibitor o f /3-catenin- 
TCF/LEF-mediated transcription (Winn et al., 2002; Garcia-Gras et al., 2006).
Compensatory mechanisms have also been described between y-and /3-catenin. 
Upregulation of y-catenin has been found to partially compensate for the loss o f (3- 
catenin in adult cardiomyocytes (Zhou et al., 2007), although it is unable to fully
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compensate for the loss o f /3-catenin in the developing murine embryo (see 1.3.5.2 
above). Similarly, /3-catenin compensates for the loss of y-catenin in early Xenopus 
development (Kofron et al., 1997), yet cannot functionally compensate in the 
desmosomes o f y-catenin-null murine embryos (Bierkamp et al., 1999). These results 
indicate that y- and /3-catenin probably serve distinct functions, and the nature o f 
interplay between them is likely to be highly context-dependent.
The finding that both o f these proteins are dysregulated in disease, and both specifically 
in AML, warrants further investigation into how the balance o f expression can affect the 
pathology o f the disease.
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Figure 1.10 - The structural and functional homology between y- and /3-catenin.
A) y-Catenin shares close molecular homology (red numbers) with /3-catenin, with most 
identity shared between central armadillo domains and the least between the COOH- 
termini. Adapted from Solanas et al., 2004. B) y-Catenin (Pg) shares close functional 
homology with /3-catenin (/3). Both proteins are located in adherens junctions (AJ) 
where they mediate cadherin anchoring to the actin cytoskeleton via ocatenin (a), y- 
Catenin (and /3-catenin) can also translocate to the nucleus through an unknown (?) 
mechanism where it can interact with TCF/LEF complexes to activate Wnt target genes 
such as c-myc. Like /3-catenin, y-catenin is also subject to the same mechanism o f 
proteasomal degradation as /3-catenin. Additionally, a unique role for y-catenin is 
observed in desmosomes (DES) where it anchors desmosomal cadherins to intermediate 
filaments (IF) via desmoplakin (Dsp) and plakophilin (Pip). Adapted from Zhurinsky et 
al., 2000b.
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1.3.7 y-Catenin in development and disease
The role o f y-catenin in development and disease has been more extensively 
characterised within an epithelial context. This partially reflects the greater 
understanding of how y-catenin functions in these tissues, namely through its most 
characterised function o f cell-adhesion. As described previously, y-catenin is a vital 
component of multiple adhesion complexes, and thus defines tissue integrity, mediates 
specific cell-cell recognition, determines epithelial cell polarity and sequesters many 
signalling molecules to cell adhesion sites, thereby also regulating signal transduction 
(Barth et al., 1997; Behrens, 1999; Steinberg and McNutt, 1999). With this considered, 
it’s hardly surprising that most solid tumours are actually associated with a loss o f y- 
catenin, and as such are often associated with a worse prognosis presumably due to the 
increased risk o f metastasis. Loss of y-catenin expression has been described in large 
scale cohorts o f patients with cancer o f the breast (Aberle et al., 1995), prostate (Shiina 
et al., 2005), kidney (Breault et al., 2005), lung (Winn et al., 2002) and skin (Tada et 
al., 2000). Indeed these observations, and the finding that y-catenin restoration in highly 
tumourigenic cells can suppress their tumourigenicity, has led to the proposition that y- 
catenin actually serves as a tumour suppressor within this context (Simcha et al., 1996; 
Charpentier et al., 2000).
Mutations o f CTTNG have been described in human disease. Naxos disease is an 
autosomal recessive disorder characterised by arrhythmogenic right ventricular 
cardiomyopathy (ARVC) and abnormalities o f hair and skin (Protonotarios et al., 1986). 
This condition has been described to arise from a 2 base pair deletion o f CTTNG, which 
renders the y-catenin protein unstable and thus disturbs the integrity o f cardiac tissue 
(McKoy et al., 2000). A slightly different dominant mutation o f CTNNG has been 
identified in familial ARVC. This mutation inserts an extra Ser residue at position 39 in 
the NLh-terminus o f y-catenin resulting in the ubiquitination o f the protein and its 
preferential translocation from membrane to cytoplasm (Asimaki et al., 2007). This 
ultimately reduces the frequency o f desmosomes within cardiac tissue leading to its 
overall weakening. Interestingly, only one mutation of y-catenin has ever been 
identified in human cancer (Caca et al., 1999). This was a missense mutation o f Ser 28 
found in gastric cancer, depriving the molecule o f a potential phosphorylation site. Lack 
of phosphorylation can protect the molecule from degradation and this study further
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identified increased TCF transcription when this mutation was modelled in vitro. 
Similar mutations have been described for the /3-catenin gene (CTTNB) in human 
epithelial cancers, albeit with much higher frequency (reviewed by Polakis, 2000). 
Missense mutations or in-frame deletions o f the NH2-terminus deprive the molecule o f 
its GSK3-/3 consensus site and render it resistant to degradation. These types o f 
mutation have been shown to constitutively activate LEF/TCF-dependent transcription 
in cancer o f the colon (Korinek et al., 1997; Morin et al., 1997), skin (Rubinfeld et al., 
1997), uterus (Fukuchi et al., 1998), liver (Miyoshi et al., 1998), and brain (Zurawel et 
al., 1998).
No literature exists regarding the function, or even expression, of y-catenin in normal 
human haematopoietic cells. An in vivo study o f murine haematopoiesis using Western 
blotting showed y-catenin (and /3-catenin) was ubiquitously expressed across all murine 
haematopoietic tissues analysed, including bone marrow, thymocytes and splenocytes 
(Koch et al., 2008). However this study, and others, have shown that the deletion o f y- 
catenin (and/or /3-catenin) in HSC/HPC did not effect the long term reconstitution 
ability o f  these cells in vivo (Cobas et al., 2004; Jeannet et al., 2008). Although these 
studies would initially suggest a redundant role for catenins in haematopoiesis, a 
number o f issues must first be considered (discussed in more detail in 5.5.1). Briefly, 
these studies were tailored to assess a small aspect o f haematopoiesis; namely the 
repopulating capacity o f y/p-catenin KO HSC/HPC in mice only. Consequently, the 
endpoints focus on absolute numbers o f cell lineages, rather than the intricate 
morphological, functional and immunophenotypic development o f specific 
haematopoietic lineages. The lack of knowledge regarding y-catenin expression and 
function in normal human haematopoiesis will continue to hinder any understanding o f 
a pathological role in haematological malignancy.
In AML, and indeed all haematological malignancy, only a few studies exist examining 
the pathological role of y-catenin (mentioned previously in section 1.3.3). On a 
functional level Miiller-Tidow et al, showed that overexpression o f y-catenin in murine 
HPC and myeloid 32D cells promoted their growth and proliferation (Muller-Tidow et 
al., 2004). This phenotype was however relatively weak and was only demonstrated in
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murine cells. Injection o f the y-catenin-induced 32D cells into irradiated mice 
accelerated the development o f leukaemia in vivo, albeit with long latency (~60days) 
considering this was a cell line. A study by Zheng et al showed similar findings 
whereby y-catenin induction accelerated the cell cycle progression o f murine HSCs and 
preserved an immature phenotype (Zheng et al., 2004). These cells were also capable o f 
accelerating myeloid leukaemia development when transplanted into irradiated mice. 
However, these phenotypes were again relatively weak with only 2 out o f 4 mice 
developing leukaemia after very long latency periods o f 9 and 12 months. Unpublished 
data from our laboratory also indicates a very modest drive o f self-renewal in y-catenin 
transduced human CD34+ primary cells. However this phenotype was considerably 
weaker than the self-renewal driven by the RUNX-1/ETO fusion protein (Tonks, 
unpublished data). It should be noted that none o f aforementioned studies assessed the 
co-expression o f /3-catenin level. Previous evidence has shown y-catenin induction to be 
capable o f co-stabilising /3-catenin and thus the self-renewal phenotypes observed may 
simply arise from indirect stabilisation o f /3-catenin. Indeed, such a phenotype has 
commonly been associated with /3-catenin in these cell types (see 1.3.2). Finally y- 
catenin expression has been found elevated in blast crisis CML patients, which further 
correlated with survivin expression implying a transcriptional role in CML (Kim et al., 
2011). However, this correlation was only identified at the mRNA level and cannot be 
assumed to reflect the protein level given the post-translational modifications active in 
y-catenin regulation (see 4.5.1).
Collectively, these findings justify further investigation into the potential pathological 
roles and relationship, o f y- and /3-catenin, in AML.
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1.4 Aims of the study
The main objective o f this study is to gain an understanding o f the role o f y-catenin in 
normal haematopoiesis and in AML. This will be achieved through the following aims:-
1) To determine the expression and cellular localisation of y-and P- catenin 
during normal human haematopoiesis.
Any pathological role for y-catenin in AML cannot be established without first 
understanding its role in normal haematopoiesis. Analysis o f y-catenin expression 
level in different human haematopoietic developmental subsets will allow 
identification o f stages o f normal haematopoiesis where y-catenin potentially has a 
role. These studies will be supported by subcellular localisation assays which will 
provide correlative evidence o f function within these cell lineages. A comparison 
with the close homologue /3-catenin will be necessary to identify whether there is the 
possibility for interaction/interdependence o f function between these catenins
2) To determine if y-catenin expression is dysregulated in AML.
Analysis o f y-catenin protein level and localisation in primary AML patient blasts 
will allow the identification o f any aberrant expression, when compared to normal 
primary haematopoietic cells. As for aim 1, comparison with /3-catenin will be made 
to assess whether interplay between these catenins is altered in the malignant 
context compared with that established in normal haematopoietic cells.
3) To determine the functional significance of y-catenin dysregulation on 
haematopoeitic development.
The role o f y-catenin in normal haematopoiesis and AML will be investigated 
through genetic manipulation (overexpression and silencing) o f y-catenin using 
primary human progenitor cells and myeloid leukaemia cell lines to respectively 
model the consequences o f change in y-catenin expression level in normal and 
malignant haematopoiesis.
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2 - General Materials and 
__________ Methods_________
2.1 General chemicals and reagents
Unless otherwise stated all chemicals and reagents were obtained from Sigma-Aldrich 
(Dorset, UK). Isopropanol, ethanol (EtOH), methanol (MeOH), 
tris(hydroxymethyl)aminomethane (Tris), sodium chloride (NaCl), sucrose, potassium 
hydroxide (KOH), magnesium acetate, ethylenediaminetetraacetic acid (EDTA), 
ethyleneglycoltetraacetic acid (EGTA), sodium ortho vanadate (NaV), triton detergent 
(TX-100) and sodium azide (NaAz) were obtained from Fisher Scientific 
(Loughborough, UK). Hanks balanced salt solution (HBSS), sodium bicarbonate 
(NaHCCb) and phosphate buffered saline (PBS) were purchased from Invitrogen 
(Paisley, UK). Foetal bovine serum (FBS) and horse serum were obtained from Biosera 
(Sussex, UK). Human Transferrin was supplied by Roche Diagnostics (Burgess Hill, 
UK).
Gentamicin (Amdipharm, Essex, UK), heparin (Wockhardt, Wrexham, UK) and sterile 
water (Fresenius Kabi Ltd, Cheshire, UK) were supplied from pharmacy, University 
Hospital o f  Wales, Cardiff, UK.
2.2 Tissue and cell culture
2.2.1 General cell culture conditions
All tissue culture work was performed in a Micro flow Class II biological safety cabinet 
(Bioquell, Andover, UK), where all surfaces had been pre-sterilised with 70% (v/v) 
EtOH. Cultures were incubated in a Hera Cell humidified incubator (DJB Labcare) at 
37° Celsius (C) supplied with 5% carbon dioxide (CO2) in air.
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Dulbecco’s Modified Eagle’s Medium (DMEM), Iscove’s Modified Dulbecco’s
Medium (IMDM), Roswell Park Memorial Institute - 1640 (RPMI-1640) were obtained 
from Sigma-Aldrich. L-Glutamine, human interleukin-3 (IL-3), human interleukin- 6  
(IL-6 ), granulocyte macrophage-colony stimulating factor (GM-CSF) and FMS-like 
tyrosine kinase 3 (FLT-3) were supplied by Invitrogen. Granulocyte-colony stimulating 
factor (G-CSF) and stem cell factor (SCF) were supplied by Amgen (Cambridge, UK).
All plasticware including tips, serological pipettes (Greiner Bio-One, Stonehouse, UK), 
culture flasks (Nunc, Rochester, USA), multi-well culture dishes, Falcon tubes
(Scientific Laboratory Supplies, Nottingham, UK) and universal containers (UC),
Sterilin, Caerphilly, UK) were purchased in a pre-sterilised condition. All contaminated 
waste was soaked in Precept Mini Haz-Tabs (Guest Medical, Kent, UK) for 24 hours 
prior to disposal, or disregarded into sharps bins or autoclavable waste bins if 
appropriate. If the culture work involved contact with retrovirus, then the strength o f  the 
Precept was doubled accordingly.
2.2.2 Culture of transformed cell lines
The commonly used cell lines and their culture requirements are summarised in Table
2.1 (Drexler, 2001). Unless otherwise stated, all cell lines were maintained at a density 
o f 1 x 1 0 5- 2  x l06/ml by serial passage every 48 hours.
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Table 2.1 - Commonly used cell lines and their specific growth requirements.
Human Chronic 
Myeloid 
Leukaemia
European 
Collection of 
Cell Cultures 
(ECACC)
(Ref. 89121407)
RPMI-1640, 10% (v/v) 
FBS, 2mM (v/v) L- 
Glutamine, 20/ig/ml 
(v/v) Gentamicin
24-30
Human
Monocytic
Leukaemia
ECACC 
(Ref. 88081201)
RPMI-1640, 10% (v/v) 
FBS, 2mM (v/v) L- 
Glutamine, 20/ig/ml 
(v/v) Gentamicin
34-40
Human
Erythroleukaemia
ECACC 
(Ref. 92111706)
RPMI-1640, 10% (v/v) 
FBS, 2mM (v/v) L- 
Glutamine, 20/ig/ml 
(v/v) Gentamicin
24-36
Human
histiocytic
lymphoma
American Type 
Culture 
Collection 
(ATCC)
(Ref. CRL- 
1593.2)
RPMI-1640, 10% (v/v) 
FBS, 2mM (v/v) L- 
Glutamine, 20jiig/ml 
(v/v) Gentamicin
24-30
Murine 
haematopoietic 
progenitor cell 
line
Prof. Tony 
Whetton, 
University of 
Manchester, UK.
IMDM, 20% (v/v) 
horse serum, 10% (v/v) 
WEHI conditioned 
medium (IL-3 source), 
4mM (v/v) L- 
Glutamine, 20/xg/ml 
(v/v) Gentamicin.
24-30
Murine 
Retrovirus 
producing cell 
line
Prof. Gary 
Nolan, Stanford 
University, 
California, USA.
DMEM, 10% FBS 
(v/v), 4mM (v/v) L- 
Glutamine, 20/ig/ml 
(v/v) Gentamicin.
24-36
2.2.3 Primary material
Neonatal cord blood (CB) was obtained from healthy full-term pregnancies at the 
Maternity Unit of University Hospital o f Wales (Cardiff) following informed consent. 
Samples were taken into a 50ml falcon tube containing 500 international units (IU) (v/v) 
of bacteriocide-free heparin to prevent blood clot formation. Normal bone marrow (BM) 
was obtained from the Welsh Bone Marrow Donor Registry, Spire Private Hospital
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(Cardiff) following informed consent. Bone Marrow was sampled into EDTA coated 
Vacutainer* tubes (Becton Dickinson, Oxford, UK).
2.2.4 Estimation of cell number
Cell enumeration was performed using an improved Neubauer haemocytometer 
counting chamber (Hawksley, Sussex, UK), and an Eclipse TS100 light transmission 
microscope (Nikon, Surrey, UK). An 8/d aliquot of cells to be counted were removed 
from culture aseptically and pipetted directly under the cover slip on the counting 
chamber. For enumeration of primary cell material, (CB or BM cells), ZAP- 
OGLOBIN™ Lytic Reagent (Beckman Coulter, Buckinghamshire, UK) was added to 
the cell aliquot (2//1 per 200/d) to lyse contaminating erythrocytes. Cellularity per ml 
was ascertained by counting the cells residing in each o f the four comers o f the counting 
square (which has a known volume of 0.9/d) and multiplying the average by 1 xlO4.
2.2.5 Cryopreservation and thawing of cell lines and primary cells
6 8For freezing, 1x10 -10 cells were collected by centrifugation at 200 x g  for 5 minutes 
and resuspended in the relevant growth medium (see section 2.2.2) before being added 
drop-wise to an equal volume o f freezing medium (50% IMDM, 30% FBS (v/v), 20% 
(v/v) dimethylsulphoxide (DMSO)). Cells were aliquoted into 1.8ml cryopreservation 
vials (Nunc) and immediately placed in a controlled refrigeration container (using 100% 
isopropanol as the thermal interface). After 24 hours at -80°C the tubes were transferred 
to cryovats in liquid nitrogen (LN2) for long-term storage.
Cryopreserved cells were recovered from LN2 by rapidly thawing in a 37°C water bath 
in the presence o f 900/d 0.45//m-filtered FBS and 200/xg sterile DNase I. Freezing 
medium was slowly diluted and osmotic balance restored by the drop-wise addition o f 
an equal volume o f magnetic-activated cell sorting (MACS) buffer (1 x PBS, 0.5% (v/v) 
bovine serum albumin (BSA), 5mM (v/v) MgCb) over 3 minutes. This dilution by 
dropwise doubling o f volume was repeated twice more followed by centrifugation at 
200 x g  for 10 minutes. Cells were resuspended in the relevant growth medium (see
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section 2.2.2) and seeded in tissue culture flasks for 24 hour recovery at 37°C gassed 
with 5% (v/v) CO2 in air.
2.3 Subcloning of Plasmid DNA
2.3.1 General subcloning
All restriction endonucleases, reaction buffers, BSA and DNA ladders were supplied by 
New England Biolabs (Massachusetts, USA). Molecular grade water was obtained from 
Roche. QIAquick™ Gel Extraction, QIAprep® Mini and Maxi-prep kits were obtained 
from Qiagen (Sussex, UK) and used according to manufacturer’s instructions (see 
Appendices). All DNA was quantified using a Nano Drop® ND-1000 spectrophotometer 
(NanoDrop Technologies, Delaware, USA) as per manufacturer’s guidelines and stored 
at -20°C.
2.3.2 Assessment of restriction digested DNA by agarose gel 
electrophoresis
To analyse DNA fragments generated from restriction digests, a 0.8% agarose gel was 
prepared in Tris-Borate-EDTA (TBE) buffer with 0.5/ig/ml (w/v) Ethidium Bromide 
(EtBr, Promega, Hampshire, UK). DNA was prepared for electrophoresis by 
resuspending up to 250ng o f restriction digested DNA in 10/d o f deionised water 
(dH2 0 ), and making up to a 12/d volume using loading buffer (0.25% Bromophenol 
Blue, 0.25% Xylene Cyanol, 30% Glycerol). A 1 kilobase (kb) DNA ladder was 
prepared in a similar fashion by ensuring a 1:10 dilution. The prepared samples were 
loaded onto the wells o f the gel (submerged in TBE buffer containing 0.5/ig/ml EtBr) 
and electrophoresed at 80V for 45-60 minutes followed by digital image acquisition 
using the LAS-3000 digital scanner. A raw FujiFilm data file was acquired after the gel 
was exposed to the digital sensor for 0.03-0.5 seconds.
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2.3.3 Composition of medium for growing E.coli cells
Luria Bertani (LB) medium, required for the culture o f competent E.coli cells, was 
made up to 1 litre from 950ml deionised water, lOg bacto-yeast extract, 5g tryptone 
peptone (BD) and lOg sodium chloride. To ensure sterility, the medium was autoclaved 
immediately using standard laboratory procedure. LB agar was made with the addition 
o f 15g Bacto-agar (BD) for every litre o f LB medium. The LB agar was heated to 100°C 
before adding ampicillin (University Hospital o f  Wales Pharmacy) to the concentration 
o f 50/jg/ml. To pour a plate, 30ml o f ampicillin supplemented agar medium was used 
per 90mm Petri dish plate. The plates were cooled (avoiding condensation and dust to 
ensure sterility) and used immediately.
2.3.4 Transformation of competent E.coli cells with plasmid DNA
In order to identify, isolate and amplify plasmid DNA o f interest transformation o f 
bacteria was necessary. As well as containing essential coding elements for gene 
expression in mammalian cells, retroviral plasmids also contain the necessary 
components for plasmid replication in prokaryotic (bacterial) cells. One such vital 
component is that which encodes ampicillin resistance, allowing the identification of 
bacteria transformed with, and expressing, the vector o f interest. Ampicillin resistance is 
encoded by the bla gene, which enables the bacterium to translate a protein (/3- 
lactamase) capable o f hydrolysing the /3-lactam ring structure (critical for ampicillin 
stability) rendering the antibiotic ineffective and the bacteria resistant.
Each DNA to be amplified by transformation was thawed on ice alongside one 50fi\ vial 
o f One Shot® TOP 10 Chemically Competent E.coli (Invitrogen). For each DNA sample 
6 /d was aseptically transferred directly into the respective vial o f competent cells and 
tapped gently to mix, followed by 30 minutes incubation on ice. Following this, the 
cells were placed at 42°C for 30 seconds, without agitation, before replacing on ice and 
adding 250/d o f pre-warmed S.O.C medium (Invitrogen) to each vial to maximise 
transformation efficiency (Hanahan, 1983). All vials were secured in a shaking 
incubator at 37°C for exactly 1 hour at 225 revolutions per minute (rpm). Once the 
incubation had elapsed, potentially transformed bacteria were spread onto pre-warmed
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ampicillin-containing LB agar plates using plastic spreaders to generate a film o f 
bacterial growth, and left at 37°C overnight. The process o f identifying bacterial 
colonies harbouring the DNA plasmid o f interest, and the expansion o f these relevant 
colones, is described in sections 3.3.1.6-3.3.1.9.
2.4 Purification of human CD34+ cells
2.4.1 Isolation of mononuclear cells from whole human cord blood or 
bone marrow
Whole human CB/BM was diluted 1:1 with HBSS containing 25mM 4-(2- 
hydroxyethyl)-l-piperazine-ethanesulfonic acid (HEPES), 20/zg/ml gentamicin and 
lOIU/ml bacteriocide-free heparin. This preparation was then layered over Ficoll- 
Paque™ (GE Healthcare, Hemel Hempstead, UK) in 50ml falcon tubes at a ratio o f 8:5 
(Blood:Ficoll) before centrifuging at 400 x g  for 40 minutes with slow acceleration and 
the brake disengaged. Following centrifugation the mononuclear cells formed a visible 
interface between plasma and Ficoll, and were subsequently aspirated into a UC 
containing 15ml o f wash medium (RPMI-1640, 5% FBS, 20fig/ml Gentamicin,
1 OlU/ml). The cells were centrifuged at 200 x g  for 10 minutes and further washed in 
the same way until the supernatant was free o f platelet contamination as determined by 
visual inspection o f the supernatant clarity. Mononuclear cell number was estimated as 
described in section 2.2.4 before resuspending in RPMI-1640 with 10% FBS (v/v), 
aliquoting at 5x107 mononuclear cells/vial and cryopreserving in LN2 (section 2.2.5).
2.4.2 Isolation of human CD34+ haematopoeitic progenitor cells from 
isolated mononuclear cells
CD34+ haematopoietic progenitor cells were purified (from previously isolated 
mononuclear cells, see section 2.4.1) using a magnetic-activated cell separation 
(miniMACS™) kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Briefly, following 
recovery from LN2 (section 2.2.5), 1x10s mononuclear cells were resuspended in 150/xl 
MACS buffer before incubation at 4°C for 15 minutes with 50fi\ hapten-conjugated 
monoclonal CD34 antibody (clone QBEND/10) per 108 cells, in the presence o f  FcR
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blocking agent. Next, 5ml o f MACS buffer was added to stop the reaction and the cells 
pelleted by centrifugation at 200 x g  for 5 minutes. Washed cells were resuspended in 
MACS buffer and incubated at 4°C with the addition o f 50/d o f anti-hapten microbeads 
(per 108 cells) for a further 15 minutes. After repeating the previously described wash 
step, mononuclear cells were resuspended in MACS buffer and applied to a magnetised 
(MS) column. Once the flow through had ceased, the column was removed from the 
magnet and the magnetically-labelled CD34+ cells were eluted with 1 ml MACS buffer. 
This fraction was next passed through a second column to maximise purity. Once flow 
through had stopped, CD34+ cells were eluted as before and cell number estimated 
(section 2.2.4). For larger or smaller starting densities o f  mononuclear cells the relative 
volumes o f the protocol were adjusted accordingly.
To assess the CD34+ purity o f the eluent, lxlO4 cells were resuspended in staining 
buffer (SB) (1 x PBS, 0.5% (v/v) BSA, 0.02% (v/v) NaAz) and combined with 2.5jUg/ml 
R-PE-conjugated anti-human CD34 monoclonal antibody (Clone 8G12, BD). After 30 
minutes at 4°C, cells were washed in 1ml o f staining buffer and pelleted by 
centrifugation at 200 x g  for 5 minutes. Cells were then analysed by flow cytometry as 
described in section 2.7.
2.5 Retroviral transduction
2.5.1 Principles of retroviral transduction
Retroviral transduction represents a highly efficient system for transferring genes o f 
interest into haematopoietic cells. This may be for the purpose o f overexpressing or 
silencing (through shRNA mechanisms described further in section 5.3.1.3) a particular 
protein within cells. Most transforming retroviruses used to transduce haematopoietic 
cells are derived from the Moloney Murine Leukaemia Virus (MMLV), except they are 
replication deficient; that is the coding regions o f their gag, pol and env genes have been 
replaced with genes o f interest (Morgenstem and Land, 1991). The absence o f such 
critical genes means a packaging cell line such as Phoenix (see proceeding section 
2.5.2) is necessary to provide the full spectrum o f retroviral proteins required for proper
virus formation. Retroviral vectors are typically designed to express two exogenous
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genes, one being the gene o f interest and the other being a selectable marker such as 
drug resistance or green fluorescent protein (GFP). Once the infected cells have been 
‘selected’ using the appropriate marker, one can be sure any resulting phenotype is 
almost exclusively due to the introduced gene. Genetically engineered retroviruses 
exploit many o f the features that allow the wild type (wt) virus to efficiently infect host 
cells. The viral envelope recognises and interacts with the specific host cell surface 
receptors permitting cellular entry o f the virion. The viral core, including the reverse 
transcriptase protein, is then essential for the conversion o f single-stranded viral RNA 
(including the engineered gene o f interest) into double-stranded DNA, which is 
randomly integrated into the host genome with the assistance o f viral integrase (see 
Stanford university website4). This unique property allows stable, long-term expression 
(from powerful retroviral promoters) o f desired genes within target cells and all their 
subsequent progeny.
2.5.2 Generation of Amphotropic retrovirus
Phoenix amphotropic packaging cell lines are adapted to yield high titre retroviral 
virions by providing the full complement o f viral polypeptides necessary for RNA 
packaging including the gag (viral core), pol (enzymes required for integration o f RNA
into host genome) and env proteins (protein capsid). Phoenix cells were seeded at 6 . 8  x
6 210 cells per 80cm tissue culture flask using the conditions specified in Table 2.1. The 
following day, the medium was aspirated and replaced with 15ml o f fresh medium, after 
which calcium-phosphate mediated transfection of plasmid DNA was performed. 
Firstly, 45fig o f  the relevant plasmid DNA was combined with 125mM (v/v) Calcium 
Chloride (CaCh) and made up to a total volume o f 450/xl in sterile water. This mixture 
was then added drop-wise to 450/d HEPES-buffered saline, under gentle ‘bubbling’ 
using a 1ml serological pipette. The mixture was then briefly vortexed and allowed to 
incubate undisturbed at room temperature (RT) for 20 minutes. When CaCb, DNA and 
a phosphate-containing buffer are combined at a neutral pH, a visible precipitate is 
generated consisting o f calcium-phosphate-DNA complexes (Okayama H and Chen C, 
1991). This sediment can then be actively incorporated from the surface o f the cell by 
endocytosis. Approximately 5 minutes before completion o f the incubation, 25/dVI
4 http://www.stanford.edu/group/nolan/tutorials/tutorials.htm 1
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chloroquine was applied to all phoenix cultures to be transformed. Chloroquine 
promotes the uptake o f the foreign DNA by neutralizing the pH within lysosomal 
vesicles which prevents DNases destroying plasmid DNA. Once the incubation had 
elapsed, the lull 900/d o f calcium-phosphate-DNA precipitate was pipetted gently onto 
the cells, gassed with CO2 , and returned to 37°C. The following morning, the medium 
was aspirated from every culture and discarded (to minimize the toxic side effects o f 
chloroquine exposure) before replacing with 8 ml o f fresh medium, gassing with CO2, 
and incubating at 33°C for optimal retrovirus production. On the final day, the 
retrovirus-containing medium was harvested by pipetting and centrifuged at 2 0 0  x g  for 
10 minutes. The retroviral-containing supernatant was then distributed into 1ml 
cryovials aliquots, snap frozen in LN2 , and stored at -80°C until further use. DNA 
transfections with the PINCO retroviral vector permitted a second retroviral harvest the 
following day given the presence o f the Epstein Barr Virus (EBV) origin o f replication 
and EBV nuclear antigen 1 (EBNA-1) gene. These components allow the construct to 
be episomally replicated within mammalian cells which maintains retroviral titre 
(Grignani et al., 1998).
2.5.3 Retroviral transduction procedure
The required number o f wells o f  a sterile, untreated 24 multi-well plate were coated 
with 25//g o f retronectin (Takara-Bio, Shiga, Japan) and incubated at RT for 2 hours. 
The retronectin was then aspirated and replaced with 250/d o f PBS containing 1% BSA 
(w/v) for 30 minutes at RT. Meanwhile, the relevant viruses were prepared by rapidly 
thawing at 37°C, adding 320/zg o f polybrene, and incubating at 37°C for 20 minutes. 
Polybrene is a positively charged molecule that increases the efficiency o f retroviral 
transduction by neutralising the negative charge o f cell surfaces. This allows the viral 
glycoproteins to more efficiently bind their receptors on the target cell surface, by 
reducing the repulsion between sialic acid-containing molecules (Davis et al., 2002). 
Once the incubation with 1% BSA (w/v) had elapsed it was removed from each well in 
turn and immediately replaced with 1 ml o f the relevant retrovirus, before centrifugation 
o f the multi-well plate for 90 minutes at 3,200 x g  in a double sealed carrier. High speed 
centrifugation is required to rapidly purify and concentrate the retroviral particles to the 
plate surface thus allowing the increased frequency o f retrovirus-target cell interactions.
General Materials and Methods Chapter 2
Incidentally, the use o f polybrene also assists this process by providing a vehicle with 
which retroviral particles may sediment (Landazuri et al., 2006).
During the centrifugation, cell lines or primary haematopoietic progenitor cells (isolated 
as described in section 2.4) were prepared by counting (section 2.2.4) and resuspending 
at a density o f  1 x 1 0 5/ml in the relevant continuation cell culture medium (refer to 
section 2.2.2). Upon completion o f retroviral sedimentation, the supernatant was 
removed from all wells and replaced with 1 ml o f non-specific, serum-containing 
medium to wash off any residual polybrene. This medium was aspirated after 5 minutes 
and substituted with 1 ml (i.e. 1 x 1 0 5) o f the relevant cells, followed by an overnight 
incubation at 37°C in 5% (v/v) CO2 in air. The following day, a second round of 
infection was carried out. The cells o f each well were carefully harvested to a separate 
UC and maintained at 37°C in the same conditions, whilst the plate was centrifugally 
loaded with a second round o f virus (as above). At the end o f retroviral sedimentation, 
the cells were returned to the appropriate well for the second round o f retroviral 
transduction overnight.
2.6 Determination of protein expression by Western blot
2.6.1 Generation of protein homogenate from whole cells
For extraction o f protein from whole cells, approximately lxlO6 cells were collected 
and washed twice in Tris-buffered Saline (TBS) (H2O, 20mM Tris, 135mM NaCl) by 
centrifugation for 10 minutes at 200 x g. Following the removal o f supernatant, cell 
pellets were snap-frozen by placing directly into LN2 and stored at -80°C until required. 
Cell pellets were recovered from storage by thawing on ice, in the presence o f 1 mg/ml 
DNase I. Once thawed, 50/d o f homogenisation buffer (0.25M sucrose, lOmM HEPES- 
KOH pH7.2, ImM Magnesium acetate, 0.5mM EDTA, 0.5mM EGTA, lOmM beta- 
mercaptoethanol (BME)) containing one complete mini EDTA-free protease inhibitor 
tablet (Roche), ImM activated sodium ortho vanadate (pH 10) and 1% TX-100 (v/v), was 
added per lxlO6 cells and incubated on ice for 30 minutes with occasional vortexing to 
promote cell lysis. Following incubation, the cell homogenate was transferred to a pre­
chilled eppendorf tube, before centrifuging at 16,000 x g  for 5 minutes in a Biofuge 
(Heraeus) pre-cooled to 4°C to pellet insoluble cellular components. The supernatant,
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containing the isolated cellular proteins, was transferred to a fresh eppendorf tube and 
immediately assessed for protein concentration.
2.6.2 Generation of fractionated cytosolic and nuclear homogenate
f\ 7Either 2x10 transformed cells or 1x10 primary cells were fractionated using a 
nuclear/cytosol fractionation kit (Biovision, California, USA). Briefly, cells were first 
washed twice with 20ml washes o f TBS followed by centrifugation at 200 x g  for 10 
minutes. Following washing, cells were fully resuspended in 200/d CEB-A (Cytosol 
extraction buffer) containing ImM dithiothreitol (DTT) and 1 X protease inhibitor 
cocktail (PIC). This suspension was then transferred to a clean, pre-chilled eppendorf, 
vortexed for 15 seconds and returned to ice for 10 minutes. Once the incubation had 
elapsed, l l / d  o f CEB-B was added to the cells followed by a brief 5 second vortex 
before resuming incubation on ice for 1 further minute. Cells were again vortexed for 5 
seconds before undergoing centrifugation at 16,000 x g  for 8  minutes in a pre-chilled 
(4°C) micro centrifuge. The supernatant, representing the cytoplasmic extract, was 
carefully removed to a fresh mini-eppendorf tube and held on ice for the remainder o f 
the protocol. The residual pellet (now containing mostly nuclei) was washed free o f 
cytosolic contamination by carefully applying 500/d o f pellet wash (1 x PBS, 5mM 
MgCE) and centrifuging as above for 3 minutes. After removal o f supernatant, nuclear 
cell pellets were submerged in LN2 to begin the process o f nuclear destruction. Semi- 
lysed nuclear pellets were then rapidly thawed on ice in the presence o f 1 mg/ml DNase, 
before being resuspended in 100/d o f NEB (Nuclear Extraction Buffer) also containing 
ImM DTT and 1 X PIC. This suspension was then vortexed maximally for 15 seconds 
before being returned to ice, a process repeated every 10 minutes during a 40 minute 
incubation. After the final vortex, eppendorfs were centrifuged for 15 minutes at 16,000 
x g  to pellet insoluble material, before finally isolating the supernatant (nuclear extract) 
to a separate tube. The cytosolic and nuclear homogenate was then either immediately 
measured for protein concentration (see section 2.6.3 below) or stored at -80°C.
2.6.3 Quantification of protein in cell homogenate
Protein concentration o f  cell lysates was determined using the Bradford protein assay 
(Bradford, 1976). Firstly, protein calibration standards ranging from 0, 10, 40, 70 and
lOOpg/ml BSA were diluted in lysis buffer. 10/d o f each protein standard, and 10/d o f
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each cell lysate was placed into the well o f a 96-well microtitre plate (all samples were 
run in duplicate) and 190/d o f Bradfords working solution (Bradford’s stock 1:1 with 
ultra pure water) applied to the samples. The absorbances o f the samples were read at 
590nm using an ASYS Hitech Expert plus spectrophotometer (Biochrom, Cambridge, 
UK). For estimation o f protein concentration see Equation 2.1 below:
Protein ( p g / m l )  =  A s q o -  c  
m
Where;
A590 = the absorbance o f the sample at 590nm 
c = the value at which the standard curve intersects the y-axis 
m = the gradient o f the standard curve
Equation 2.1 - Linear equation for a straight line used to calculate the protein 
concentration within cell homogenate
2.6.4 Resolution of proteins by SDS-PAGE electrophoresis
Western blotting was completed using the NuPAGE® Pre-Cast Gel System 
(Invitrogen). Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
involves the separation o f proteins within a gel matrix under the influence o f an electric 
field. Denaturisation and reduction o f sample proteins is necessary to linearise proteins 
and dissociate polypeptides from each other. Protein lysates were removed from -80°C, 
thawed on ice, and then a sufficient volume o f lysate was used so that all samples were 
normalised in terms o f cell equivalents. In general, 50pl of cell homogenate was 
prepared with 50nM NuPAGE® sample reducing agent (DTT), 1 X NuPAGE® lithium 
dodecyl sulphate (LDS) sample buffer and made to volume with dEEO. Once well 
mixed, these samples were denatured by incubation at 70° C for 10 minutes, and then 
returned to ice.
Pre-cast NuPAGE Novex 4-12% bis-Tris gels were rinsed with water, and the wells 
washed with 1 x NuPAGE® MOPS-sodium dodecyl sulphate (MOPS-SDS) running 
buffer, before being secured into an XCell SureLock™ Mini Cell electrophoresis tank. 
The inner chamber o f the tank was filled with 200ml o f running buffer containing 500/xl
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NuPAGE® anti-oxidant, and the reduced samples loaded onto lanes o f the gel alongside 
a MagicMark™ XP Western Standard protein ladder (Invitrogen). The outer chamber of 
the tank was filled with running buffer, and electrophoresis was performed at 200V 
(400mA) over 50 minutes. Resolved proteins within the gel were next transferred onto a 
nitrocellulose membrane.
2.6.5 Transfer of separated proteins onto a nitrocellulose membrane
Following electrophoresis the gel was removed from the tank and released from its 
plastic holding. One surface o f the gel was moistened with transfer buffer (dt^O, 10% 
MeOH, 1 X NuPAGE® Transfer Buffer, 1ml antioxidant) before layering a piece of 
pre-soaked Whatman 3M filter paper on the gel. Any air bubbles were removed by 
rolling out trapped air. The other gel side was also wetted with transfer buffer, before 
layering a pre-soaked nitrocellulose membrane (0.45 pm pore size) complete with an 
additional piece o f filter paper on top o f the gel surface ensuring all trapped air bubbles 
were removed. The gel/membrane was sandwiched between pre-soaked blotting pads as 
shown in
Figure 2.1 and inserted into an XCell II™ Blot Module. The blot module was filled to 
the top o f the pads with transfer buffer and the outside o f the tank filled with distilled 
water, before completing the transfer over 1 hour at 30V (400mA).
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Figure 2.1 - Assembly of components during Western blot transfer.
The pre-soaked nitrocellulose membrane was placed immediately against the gel, and 
this arrangement sandwiched between two soaked pieces of filter paper with all trapped 
air bubbles removed. This assembly was then laid on top of 2 saturated blotting pads 
located closest to the cathode core within the blot module. A further 2 saturated blotting 
pads were aligned on top of the membrane sandwich, or enough so that adequate tension 
was placed on the assembly when then module was sealed together.
Upon completion of electroblotting the membrane sandwich was removed from the blot 
module and the nitrocellulose membrane rinsed twice with ultra-pure water, followed by 
two further water washes of 5 minutes on a rotary shaker. To check for efficient transfer 
of proteins, 30ml o f Ponceau S solution was incubated with the membrane for 30 
seconds with gentle agitation. Inaccurate loading and transfer errors could be noted at 
this point. A further two washes with water of 5 minutes were necessary to remove 
excess Ponceau S stain. The membrane was then ready blocking and detection stages.
2.6.6 Detection of transferred proteins by chemiluminescence
The visualization of transferred proteins present on the membrane was assisted using the 
Amersham ECL™ Advance Western Blotting Detection Kit (GE Healthcare). The
+
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membrane was placed in 10ml o f blocking solution (5% ECL advance blocking reagent 
in TBS supplemented with 1% (v/v) Tween20 (Invitrogen) (TBS-T)) on the shaker for 1 
hour at RT. Following blocking, a fixed wash method o f 15 minutes in TBS-T followed 
by three short washes o f 5 minutes, was performed. Primary antibodies to the relevant 
antigen (see individual relevant chapters) were prepared to the appropriate concentration 
in 10ml o f 5% (w/v) blocking solution. This primary antibody diluent was added to the 
membrane overnight at 4°C under gentle rotation, and the following day the wash steps 
were performed as above. During washing, a horseradish-peroxide conjugated anti­
mouse or -rabbit secondary antibody (GE Healthcare) was prepared in 10ml o f 2% (w/v) 
blocking solution at a dilution o f 50,000-fold, and then added to the membrane for 1 
hour at RT under gentle shaking. Following incubation, the wash steps were again 
performed.
Chemiluminescent detection was performed according to the manufacturer’s instruction. 
Briefly, ‘solution A’ and ‘solution B’ were combined at RT in a 1:1 working solution 
(10ml per full size membrane 1 0x 1 0  cm) and protected from the light. The membrane 
surface was blotted dry using filter paper and flooded with 4ml o f the combined 
chemiluminescent substrate. The reaction developed over 5 minutes, after which the 
excess substrate was blotted away, and a piece of clean acetate placed over the 
membrane with all trapped air pockets smoothened out. A digital image of the 
chemiluminescent reaction was captured over a 1-30 minute exposure using a LAS- 
3000 digital scanner (FUJIFILM UK Ltd, Bedfordshire, UK).
2.6.7 Analysis of protein using densitometry
Captured images were analysed semi-quantitatively using post-acquisition software 
(Advanced Image Data Analyzer (AIDA) software version 4.26.038, Raytek Scientific, 
Sheffield, U.K)) and protein intensity measured using pixel-based densitometric 
analysis. This software utilises the intensity o f pixels to quantitate the amount o f protein 
present on the blot. Using the raw data files, a region of interest (ROI) was constructed 
around the desired band(s) with which a histogram of peak intensity was produced. 
From this histogram, a baseline of background (noise) pixel intensity was set which was
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established from the surrounding area o f the protein band within the ROI. Following the 
establishment o f the background baseline, the area under the curve was calculated to 
give an arbitrary intensity value, from which estimates o f fold-overexpression and 
under-expression o f protein were calculated.
2.7 Flow cytometry
2.7.1 Principles of flow cytometry
Flow cytometry is capable o f analysing multiple characteristics o f  a single cell through 
light scattering or fluorescence emission. This makes flow cytometry particularly useful 
for analysing heterogenous mixtures o f cells such as blood within a short time-frame. 
The general configuration o f a standard flow cytometer is illustrated in Figure 2.2A. 
Hydrodynamic focusing is pivotal to the technology, since this generates a laminar flow 
o f single-cells in sheath fluid that passes through a flow cell allowing multi-parameter 
analysis o f  individual cells. Cells are typically exposed to a light source (usually a laser) 
at an interrogation point within the flow cell. The ability o f a cell to scatter light when 
hit directly with a laser allows the measuring o f physical properties such as size or 
internal complexity (see Figure 2.2B below). The ability o f fluorescent dyes or 
compounds (section 2.7.2) to emit light when excited by varying wavelengths o f laser 
light provides a further parameter for measuring distinct biochemical features such as 
DNA content or antigen expression (Brown and Wittwer, 2000). Scattered or emitted 
light from analysed cells is collected by optical detectors and directed through a series 
o f filters and dichroic mirrors, to isolate light o f a particular wavelength. 
Photomultiplier tubes (PMT) are then responsible for converting the collected light from 
an analogue to a digital signal that is usually displayed as 2D plots or histograms on 
computer software.
2.7.2 Concept of fluorescence
A fluorescent molecule (or fluorophore) is any which becomes excited to a higher 
energy state upon light absorption and subsequently emits a higher wavelength o f light 
upon returning to resting (ground) state (.Figure 2.3A). The fluorophore only emits light 
o f a given wavelength (or colour) when absorbing light o f a particular optimal
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wavelength for its initial excitation. This property has resulted in a large range o f 
fluorophores (or fluorochromes) being utilised in flow cytometry (and other 
fluorescence technologies such as confocal microscopy) to provide additional 
parameters for detecting biochemical features o f cells. Commonly, these fluorochromes 
are conjugated to an antibody targeted to a particular antigen o f interest allowing its 
specific detection upon exposure to the correct light wavelength. Some frequently used 
fluorochromes include synthetic compounds such as fluorescein isothiocyanate (FITC), 
or naturally occurring fluorogenic molecules such as R-Phycoerythrin (R-PE) or 
allophycocyanin (APC). Alternatively, fluorescent dyes exist which only emit when 
bound in a particular confirmation such as TO-PRO-3 which only fluoresces when 
bound to nucleic acid. All such fluorochromes have distinct excitation and emission 
spectra (Figure 2.3B), which can be satisfied by the many configurations o f lasers and 
filters present in the cytometer. A precise knowledge o f the excitation/emission spectra 
o f experimental fluorochromes is necessary so that; A) the correct laser line is employed 
for excitation, B) the correct filters are applied for collection o f a specific wavelength o f 
emitted light, and C) additional fluorochromes present in the sample sharing spectral 
overlap may be appropriately ‘compensated’ for.
The heterogeneity o f flow cytometry experiments undertaken in this project means no- 
one single protocol is appropriate to cover all, so please consult individual chapters for 
detailed outlines o f the flow cytometric methods and analyses performed.
2.8 Statistics
Significance o f difference was tested using the Student’s t-test. For additional specific 
statistical tests performed see individual chapters. GraphPad Prism version 5.01 
(GraphPad Software, California, USA) was used for all analyses.
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Figure 2.2 - The principles of flow cytometry.
A) The configuration of a standard benchtop flow cytometer. Cells are 
hydrodynamically focussed in sheath fluid to a single-cell suspension which are 
analysed individually at an interrogation point within the flow cell. Resulting scattered 
or emitted light is directed by optics and dichroic mirrors, through specific filters, onto 
PMTs (1-4). The collected analogue signal is digitised and displayed on a connected 
computer. Adapted from Brown and Wittwer, 2000. B) The measuring of physical 
properties o f cells through the ability of individual cells to scatter direct laser light. The 
amount of forward scatter generated is proportional to the cell size, whilst the amount of 
side scatter is relative to the internal complexity of the cell (e.g. granularity). Adapted 
from http://probes.invitrogen.com/resources/education/tutorials/4Intro Flow/player.html.
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Figure 2.3 - The concept of fluorescence.
A) Schematic showing the definition of fluorescence. A fluorescent molecule becomes 
excited to a higher energy state upon absorption o f a particular light wavelength and can 
consequently emit light of a higher wavelength when it returns to ground state. Adapted 
from http://probes.invitrogen.com/resources/education/tutorials/4Intro Flow/plaver.html. B) 
Example o f the excitation/emission spectra of a fluorophore. This particular molecule 
absorbs optimally at ~450nm and emits maximally at ~550nm. Stokes shift represents 
the difference in wavelength (nm) between the peak excitation and emission 
wavelengths. Adapted from http://www.advancedaquarist.eom/2006/9/aafeature.
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3 - Characterisation of y-Catenin 
and /3-Catenin Expression in 
Normal Haematopoiesis
3.1 Introduction
Wnt signalling is an evolutionary conserved signalling pathway critical to normal 
development, and its dysregulation has been frequently identified in disease (Clevers, 
2006; Klaus and Birchmeier, 2008). Previously, expression of the Wnt signalling 
protein y-catenin has been identified as abnormal in AML (Zheng et al., 2004; Muller- 
Tidow et al., 2004; Tonks et al., 2007), however the role it plays in the disease 
pathology remains unclear. The understanding o f any pathological function will remain 
elusive given the lack o f knowledge of y-catenin’s role in normal haematopoietic 
development. The full characterisation o f a protein’s normal role often aids in the 
identification o f any aberrant function in disease. For example the delineation o f FLT- 
3’s (Fms-like tyrosine kinase 3) role within normal haematopoiesis, allowed it’s 
identification as a potent mediator o f survival and proliferation in AML blasts, and has 
allowed potential targeted therapies such as CEP701 to be developed (Gilliland and 
Griffin, 2002).
The role o f y-catenin expression in normal haematopoiesis is currently not well 
understood, and although /3-catenin expression has been demonstrated in HSC and 
progenitor cells (Reya et al., 2003; Jamieson et al., 2004; Simon et al., 2005; Holmes et 
al., 2008), it’s involvement in latter stages of haematopoiesis remains largely unknown. 
Studies have been published attempting to decipher the roles o f y- and /2-catenin in 
normal haematopoiesis; however, the variety o f experimental models and techniques 
used has produced contrasting and contradictory results, as summarised recently (Staal 
and Luis, 2010). The fact that these catenins have dual roles in cell adhesion and 
transduction o f Wnt signalling (see section 1.3.5) suggests a multitude of potential 
functions within haematopoietic cells. This chapter sought to fully characterise y- and /?-
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catenin expression in haematopoietic development. To this end, assays were developed 
that could accurately detect intra-cellular y- and /3-catenin expression in discrete 
developmental subsets o f haematopoiesis at a single-cell level using flow cytometric 
and confocal microscopy. Such methods for y-catenin measurement have not been 
previously reported and therefore required optimisation.
3.2 Aims
In order to establish a better understanding of the role of y- and /3-catenin in normal 
haematopoiesis the aims o f this chapter were:
1) To optimise and validate a flow cytometric protocol capable o f  accurate and 
specific detection of intracellular y- and /3-catenin protein.
2) To use the above assay to determine the y- and 0-catenin expression level in 
discrete developmental subsets o f human cord blood (CB) and bone marrow 
(BM).
3) To optimise and validate a confocal immunofluorescence protocol that could 
accurately and specifically identify the sub-cellular localisation of y- and (3- 
catenin protein in haematopoietic cells.
4) To use the above assay (point 3) to identify the sub-cellular localisation of y- and 
/3-catenin protein within specific haematopoietic lineages o f human CB and BM.
C haracterisation  o f  y-C aten in  and /3-Catenin Expression in N orm al A .
. . ' C h a p te r s
H aem atopoiesis
3.3 Materials and Methods
3.3.1 Establishment of y-catenin overexpression system
In order to establish the expression level and subcellular localisation o f both y- and p- 
catenin in developmental subsets o f normal human haematopoiesis, a specific flow 
cytometric assay was optimised using K562 cells overexpressing both these catenins 
(3.3.4). A K562 cell line overexpressing /3-catenin was already available (see 3.3.4.2). 
For y-catenin it was necessary to create an expression vector based on the retroviral 
vector pBabe-Puro (Morgenstem and Land, 1990) which gave stable expression o f y- 
catenin and conferred resistance to the antibiotic puromycin (the mechanism o f which is 
described in detail in section 3.3.2). The following section describes the creation o f this 
vector.
3.3.1.1 Excision o f  human y-catenin cDNA from PINCO plasmid
The PINCO retroviral vector (illustrated in Figure 3.1) was used as a source o f human 
y-catenin cDNA and was excised using a BamWMEcoKX double restriction digest 
(Figure 3. IB). PINCO-y-catenin DNA (10/xg) was mixed with IX EcoRl buffer 
(recommended buffer for optimal enzymatic activity o f both restriction endonucleases), 
100U each o f BamHl and EcoRl, lOO/jg/ml BSA, and the reaction volume made up to 
100/zl with molecular grade water. A control tube was also set up containing the above 
mixture minus the restriction endonucleases to ensure the PINCO-y-catenin vector was 
free o f contaminating nucleases. The reaction mixture was incubated at 37°C for 60 
minutes.
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Figure 3.1 - An endonuclease enzyme restriction map of the PINCO vector from 
which y-catenin was excised.
A) Key restriction enzyme recognition sites of the PINCO retroviral expression vector 
(adapted from Grignani et al., 1998). B) Human y-catenin cDNA was originally 
subcloned into the multiple cloning site (MCS) of the PINCO expression vector (Zheng 
et a l 2004). The strategy used to excise y-catenin cDNA from PINCO plasmid is 
illustrated. Indicated are the restriction enzymes used and the distance of the recognition 
sites from the start of the 5’LTR sequence expressed in kb. Amp: Ampicillin resistance 
gene; OriP: origin of replication; EBNAI = EBV nuclear antigen 1 gene which promotes 
episomal replication o f DNA; PURO= Puromycin resistance gene driven by PGK1 
promoter; pUC= prokaryotic control sequence; LTR= Moloney Murine Leukaemia 
Virus (MMLV) Long Terminal Repeats; ¥ =  Retroviral RNA packaging signal 
sequence; CMV= Cytomegalovirus promoter; GFP= Enhanced Green Fluorescent 
Protein gene.
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3.3 A .2 Preparation o f  pBabe-Puro vector for ligation o f  excised human y- 
catenin cDNA
The pBabe-Puro vector (see Figure 3.2A) was prepared for ligation o f human y-catenin 
cDNA by also performing a BamWMEcoBA double restriction digest {Figure 3.2B) 
generating heterologous ‘sticky ends’ (5’ or 3’ overhangs o f DNA generated following 
digestion by restriction endonucleases). pBabe-Puro DNA (5/zg), including control, was 
prepared for digest as described above for PINCO-y-catenin (section 3.3.7.7), except 
that the total reaction volume was 50/d. Undigested control pBabe-Puro DNA was also 
processed, using the same digestion conditions. The efficiency o f the aforementioned 
restriction digests were assessed by agarose gel electrophoresis as described in section
2.3.2.
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Figure 3.2 - An endonuclease enzyme restriction map of the pBabe-Puro retroviral 
vector into which y-catenin was subcloned.
A) The enzyme restriction map shows key restriction enzyme recognition sites and 
essential coding sequences. Adapted from www.addgene.org. B) Illustration of the 
BamW\ and EcoRAdouble restriction digest used to linearise the pBabe-Puro vector. The 
restriction enzyme recognition sites, within the MCS, are shown as a distance in base 
pairs (bp), from the start of the 5’LTR. Like PINCO, the LTR are based on that of 
MMLV. The retroviral RNA packaging signal sequence (XP) is flanked by a mutant 
splice donor (MSD) and a truncated gag (A gag) sequence to boost the retroviral titre. 
Transduced cells are selected by drug resistance encoded by the puromycin gene 
(PURO) driven by the Simian Virus 40 (SV40) promoter.
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3.3.1.3 Purification o f  y-catenin andpBabe-Puro DNA
Once established that the restriction digests had successfully excised human y-catenin 
cDNA from the PINCO expression construct, and that the pBabe-Puro vector had been 
linearised, it was necessary to purify these fragments from contaminating DNA. A IX 
Tris-acetate gel with 1% SeaKem GTG (Lonza, Basel, Switzerland) was prepared and 
cast in a gel tank in the absence o f EtBr. A well comb was applied which could generate 
one continuous well across the width o f the gel and this was submerged in Tris-acetate- 
EDTA (TAE) buffer. Into this one well all the restriction digested PINCO-y-catenin 
DNA and opened pBabe-Puro plasmid were combined (each 100/xl with 25[i\ loading 
buffer) and electrophoresed as above. Following electrophoresis, gels were stained (20 
minutes) for migrated DNA fragments using fresh TAE buffer containing 0.5jLtg/ml 
EtBr. Following de-staining in molecular grade water for 20 minutes, the gel was then 
exposed to an ultra violet (UV) lamp on a long wavelength setting for no longer than 
one minute (to prevent damage o f DNA) to view the migrated DNA bands on the gel. 
This provided enough time for the 2.4kb migrated band (corresponding to human y- 
catenin cDNA) and the 5.2kb band (corresponding to the linearised pBabe-Puro DNA) 
to be accurately sliced from the gel in the thinnest pieces possible using a fresh scalpel 
for each gel. The DNA contained within the gel was then extracted and purified using a 
QIAquick™ gel extraction kit according to the manufacturer’s instructions (see 
Appendix 7).
3.3.1.4 Ligation o f excised human y-catenin cDNA into pBabe-Puro
To maximize the efficiency of human y-catenin cDNA (insert) ligation into the pBabe- 
Puro vector, an insert to vector molecular ratio o f 10:1 was used. Given that the 
molecular weights o f the y-catenin and pBabe-Puro DNA were 2.35kb and 5.17kb 
respectively, a molecular ratio of 10:1 actually corresponds to a weight ratio o f 4.5:1. 
Thus, for a 10/xl ligation reaction, 113ng o f y-catenin DNA was combined with 25ng o f 
pBabe-Puro DNA, 200 cohesive end units//ri T4 DNA ligase and IX T4 DNA ligase 
reaction buffer (New England Biolabs). To estimate the level o f  background ligation 
(mainly due to self-ligation of the linearised pBabe-Puro plasmid) a ‘background’ 
reaction tube was also set up as above, but lacking y-catenin DNA. A ‘transformation
control’ was also used containing 25ng of undigested pBabe-Puro DNA. All reaction
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volumes were incubated over 1 hour at 16°C then stored at -20°C until transformation o f 
competent E.coli.
3.3.1.5 Transformation o f  competent E.coli with ligated DNA
Each vial o f  ligation reaction (3 in total as outlined in section 3.3.1.4) was thawed on ice 
and used for bacterial transformation as described in 2.3.4 .Following transformation 
75-225/d o f competent cells were spread onto pre-warmed LB agar plates using plastic 
spreaders to generate a film o f bacteria. Plates were incubated at 37°C overnight.
3.3.1. 6  Amplification o f E.coli colony DNA
Following an overnight incubation, 12 ampicillin-resistant colonies were randomly 
picked from the plate containing pBabe-Puro-y-catenin transformants. Single, isolated 
bacterial colonies were isolated from the agar surface using a sterile loop, and each 
transferred into a UC containing 5ml o f pre-warmed ampicillin-containing LB medium. 
These UCs were incubated at 37°C under vigorous agitation (approximately 300rpm) 
for 16 hours. At this point, an aliquot from each bacterial culture was taken for long­
term freezer storage by preparing 800/d o f confluent, transformed, ampicillin-resistant, 
bacterial culture into 200/d sterile glycerol and storing at -80°C in cryovials. From the 
remaining culture, bacterial cells were collected by centrifugation at 6,800 x g  for 3 
minutes in a microcentrifuge (Biofuge), and the DNA extracted using a QIAprep® 
Miniprep kit and the manufacturer’s protocol (see Appendix 2).
3.3.1.7 Identification o f  E.coli colony harbouring pBabe-Puro-y-catenin DNA
To identify colonies transformed with pBabe-Puro-y-catenin, BamHl/EcoRl double 
restriction digests were performed, as described previously (section 3.3.7.7), on all 
DNA isolated from colonies transformed in 3.3.1.5. Figure 3.3 shows the expected 
restriction sites and resulting fragment sizes generated should the colony contain pBabe- 
Puro-y-catenin DNA. Restriction digested DNA was visualised as described in section
2.3.2.
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Figure 3.3 - Strategy for identification of colonies containing pBabe-Puro-y-catenin 
vector.
A) Cartoon of BamHl and EcoRX restriction sites of newly formed pBabe-Puro-y- 
catenin vector with the location of restriction enzyme recognition sequences. Values 
represent the distance from the 5’LTR in bp. B) The predicted fragment sizes obtained 
from pBabe-Puro-y-catenin following a BamHl/EcoRl double restriction digest.
3.3.1.8 Confirmation o f correct orientation o f human y-catenin cDNA within the 
pBabe-Puro vector
The correct orientation of insert within the pBabe-Puro vector was confirmed using a 
Sma\ endonuclease digest which should generate the fragments illustrated in Figure 
3.4. The fragments obtained from a potentially incorrect insertion are also shown in this 
diagram. A lOpl reaction included 350ng of colony DNA, 100U Sma 1, NEB buffer 4 
and the remainder molecular grade water. Digested fragments were assessed as 
described previously (section 2.3.2).
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Figure 3.4 - Strategy to confirm correct orientation of y-catenin cDNA within 
pBabe-Puro vector.
A) Plasmid map of pBabe-Puro-y-catenin with the newly formed Sma\ recognition sites 
and B) the 2.8, 2.1 and 2.6kb fragment sizes expected upon correct y-catenin orientation 
within pBabe-Puro. C) The predicted Sma\ recognition sites with an incorrectly 
orientated y-catenin within pBabe-Puro and D) the 1.6, 3.3 and 2.6kb fragments 
expected following a single Smal restriction digest.
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3.3.1.9 Plasmid preparation ofpBabe-Puro-y-catenin
Upon identification o f a correctly orientated pBabe-Puro-y-catenin positive colony it 
was necessary to generate suitable amounts o f DNA (at least 45/xg) for retrovirus 
production. A glycerol stock, derived from the positive colony (as prepared in 3.3.1.6), 
was streaked onto an LB agar plate. The next day, a single colony was inoculated in 5ml 
LB medium, which was incubated for 8  hours at 37°C under vigorous agitation 
(approximately 300rpm). Next, 150/d o f this culture was transferred to 150ml fresh LB 
medium and incubated as before for a further for 12 hours. Bacteria were then pelleted 
by centrifugation at 6000 x g  for 15 min at 4°C. DNA was isolated from the pelleted 
bacteria using a QIAprep® Maxiprep kit and the manufacturer’s guidelines (see 
Appendix 3).
3.3.2 Generation of y-catenin overexpressing leukaemic cell lines
Amphotropic pBabe-Puro control (empty vector) and pBabe-Puro-y-catenin retroviruses 
were generated as described in section 2.5.2. K562, U937, HEL, THP-1 and FDCP mix 
cell lines were retrovirally transduced with each virus as described in section 2.5.3. 
Following transduction, puromycin was used to select for y-catenin expressing cells.
The pBabe-Puro retroviral construct contains a puromycin selection cassette. Puromycin 
is an aminonucleoside antibiotic produced by Streptomyces alboniger which inhibits the 
growth o f both prokaryotic and eukaryotic cells by specifically inhibiting peptidyl 
transfer on ribosomes (Vara et aL, 1985). Transfection with the pBabe-Puro vector leads 
to expression o f the pac gene which in turn encodes the enzyme Puromycin N-acetyl- 
tranferase (PAC) which inactivates puromycin by N-acetylation (Lacalle et al., 1989; de 
la Luna S. and Ortin, 1992).
The day immediately following round two o f retroviral transduction, puromycin 
(2/xg/ml) was added to the medium o f cells lines transfected with pBabe-Puro, and 
pBabe-Puro-y-catenin. A ‘mock transduced’ (i.e. cultured in the presence o f conditioned 
medium o f phoenix cells and thus no contact with any retrovirus) control was included.
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Selection was adjudged to be finished when over 99% o f this culture was dead, as 
approximated by light microscopy. Viable cells were then washed free o f puromycin by 
centrifugation at 200 x g  for 5 minutes and resuspended in fresh medium. Finally, cells 
were assessed for y-catenin expression (below in section 3.3.3).
3.3.3 Analysis of y- and /5-catenin protein expression in transfected cell 
lines
In order to assess the level of endogenous and ectopic y- and /5-catenin expression 
driven by the respective retroviral vectors, protein levels were assessed from control and 
catenin transfected cells by Western blotting. Whole cell protein lysates o f control and 
y- or /5-catenin transfected cells from each cell line were prepared and immuno-blotted 
as described in section 2.6. The normalisation o f protein lysates from each cell line to 
equal weight allowed any differences in catenin expression to be identified. A mouse 
monoclonal antibody was used for the detection of y-catenin (Clone 15, BD) at 
250ng/ml, whilst a rabbit monoclonal (Clone 6B3, Cell Signalling, Massachusetts, 
USA) was deployed for /5-catenin detection at lng/ml. The detection o f /5-actin (Clone 
mAbcam 8226, Abeam, Cambridge, UK), was achieved using a mouse monoclonal at 
2 0 ng/ml, to provide an assessment for equal protein loading.
3.3.4 Optimisation of intracellular catenin staining
3.3.4.1 Optimisation o f  y-catenin staining
For the optimisation o f intracellular y-catenin detection by flow cytometry, the K562 
pBabe-Puro control and y-catenin overexpressing cell lines created in section 3.3.2 were 
utilised since these showed both high endogenous and exogenous y-catenin expression.
Detection o f intracellular expression o f y-catenin was optimised using 1 x 106 each o f 
the K562 pBabe-Puro control and y-catenin cells. These cells were washed in 20ml o f 
serum-free (SF) RPMI-1640 and centrifuged at 200 x g  for 10 minutes. Cells were 
resuspended in 200pi SF RPMI-1640 and fixed in an equal volume o f 4%
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paraformaldehyde for 20 minutes under gentle agitation from a rotary shaker. Cells 
were subsequently washed with 1ml SF RPMI-1640 and centrifuged at 200 x g  for 5 
minutes. Cell membranes were permeabilised by resuspending the cells in 1ml 0.1% 
TX-100 detergent for 5 minutes with occasional agitation. The TX-100 was completely 
removed from the cells by 2 consecutive washes o f 5ml staining buffer (SB, see section
2.4.2 for composition) each followed by centrifugation at 200 x g  for 5 minutes. Cells 
were subsequently resuspended in 200/d SB and half were incubated with the primary 
anti-y-catenin antibody at concentrations o f 1, 3, 10, 30 or 60/xg/ml, whilst the other half 
was incubated with the corresponding isotype-matched (IgG2a or IgG2b) antibody at the 
same concentrations. Three different clones of y-catenin primary mouse monoclonal 
antibody were tested; Clone 15 (IgG2a, BD), PG 5.1 (IgG2b, AbD Serotec, Kidlington, 
UK) and M i l l  (IgG2a, AbCam). Primary antibody incubations o f 30, 45 and 60 
minutes at RT were tested, after which, the cells were washed in 1ml SB by 
centrifugation as above. Stained cells were resuspended in SB, and detected using 
secondary labelling step, where 1.5/ig/ml R-PE conjugated rat-anti-mouse (RAM) 
IgG2a+b antibody (Clone X57, BD) as incubated for 30 minutes in the dark at RT. The 
cells were washed as above and resuspended in 100/d FACSFlow™ (BD) prior to flow 
cytometric acquisition (see 3.3.6).
3.3.4.2 Optimisation o f  /3-catenin staining 
Detection o f intracellular expression o f P-catenin was optimised using the K562 cell 
line expressing a mutant form o f  p-catenin. This amino (NH2)-terminally truncated form 
o f /3-catenin, encoded within the pPOLYPOZ retroviral plasmid (/3-catAN89, kind gift 
by Prof. Dale, originally constructed by Polakis et al. (Munemitsu et al., 1996)), has a 
89 amino acid sequence missing from the NH2-terminus, thus depriving the molecule o f 
its Casein Kinase a  (CKa) and Glycogen Synthase Kinase 3/3 (GSK3/3) phosphorylation 
sites (serine 45, and threonine 41, serines 33 and 37, respectively (Liu et al., 2002)). 
The absence o f phosphorylation means the protein is not ubiquitinated and targeted for 
degradation by the proteasome leading to constitutive accumulation o f /3-catenin in the 
cytosol. The K562 pBabe-Puro transduced cells were used again as the control line.
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Cells were processed as described above (section 3.3.4.1) using a primary mouse 
monoclonal /3-catenin antibody (Clone 14, IgGl, BD) conjugated directly to FITC. The 
immuno-reactivity o f this antibody was also raised to an epitope in the COOH-terminus 
o f /3-catenin so was not affected by the Nth-terminal truncation. Primary antibody 
concentrations were optimised by incubation o f 1, 3, 10 and 30jiig/ml as above for 30 
minutes in the dark. Detection o f the primary labelling stage was achieved by flow 
cytometry (see 3.3.6).
3.3.4.3 Cross reactivity o f  y- and (3-catenin antibodies
Given the high degree o f molecular homology shared between these armadillo proteins 
(Hatzfeld, 1999), it was necessary to ensure that the respective antibodies did not cross- 
react under assay conditions. Therefore, K562-AN89-/3-catenin cells were stained for y- 
catenin (using optimised staining conditions), whilst the K562 pBabe-Puro-y-catenin 
cell line was immuno-stained with the optimal conditions for the /3-catenin primary 
antibody in each case employing K562 pBabe-Puro cells as controls. Assessment of 
cross-reactivity was measured using flow cytometry (3.3.6). It was also necessary to 
determine whether there was cross-reaction as determined by Western blotting (see 
below section 3.3.3).
3.3.5 Detection of intracellular catenin expression in normal human 
haematopoietic cells
3.3.5.1 Isolation o f  normal human haematopoietic cells from  cord blood/bone 
marrow
In order to assess the expression o f y- and /3-catenin in haematopoietic lineages 
(including developmental subsets) human CB or BM was obtained as described in 
section 2.2.3. A buffy coat containing total leukocytes, as shown in Figure 3.5, was 
isolated by centrifuging 15ml o f whole CB or BM under high speed centrifugation at 
2,500 x g  for 15 minutes. Under these conditions a pale film o f white blood cells forms 
between the red cell and serum layers, which was carefully removed using a Pasteur 
pipette. A degree o f red cell contamination was inevitable with this aspiration, but also
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desirable (provided it was not excessive) given these cells were also relevant for the 
analysis. Leukocytes were washed in 15ml of SF RPMI-1640 and centrifuged at 200 x g  
for 10 minutes, after which total leukocyte number was estimated as described in 
section 2.2.4.
Plasm a
(55% of total blood)
Buffy Coat
leukocytes & platelets 
(<1% of total blood)
Erythrocytes 
(45% of total blood)
Figure 3.5 - The fractionation of leukocytes by centrifugation of whole cord blood 
or bone marrow.
The percentages stated for each fraction represent those obtained from centrifugation of 
peripheral blood. The method was the same for human CB or BM although the relative 
percentage of leukocytes was higher in BM.
3.3.5.2 Preparation and pre-labelling o f haematopoietic cells prior to staining
Prior to intracellular staining of catenin, pre-labelling of cells with cell-surface markers 
was required in order to allow haematopoietic cell subset analysis by flow cytometry. A 
panel of antibodies specific for myeloid, lymphoid, erythroid or haematopoietic stem 
cell/progenitor populations were applied.
Total leukocytes (lxlO7) were resuspended in 100/d of staining buffer (SB) and 
subjected to the relevant panel o f cell surface anti-human antibodies (each at 10/zg/ml) 
for 30 minutes at 4°C. The threshold for cell surface staining was ascertained by also 
incubating cells with the isotype- and manufacturer-matched irrelevant control
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antibodies conjugated to the same fluorochromes. The panel of mouse monoclonal 
antibodies (including clone and manufacturer) used in conjunction with y-catenin and (3- 
catenin immune-stained cells are shown in Table 3.1 and Table 3.2, respectively. These 
differed primarily because of the different fluorochromes used to label y- and /?- 
catenins. Following the incubation, 1ml o f SB was added to all tubes which were 
subsequently centrifuged as above for 5 minutes. Cells were next resuspended in 200/d 
of SF-RPMI-1640 and assayed for intracellular catenin staining as below.
Table 3.1 - The panels of specific cell surface antibodies used in the identification 
of haematopoietic subpopulations (y-catenin analysis).
CD34-PerCP/Cy5.5 4H11 Bio legend 
(California, 
USA)
CD38-APC HIT2 Bio legend
CD45-FITC HI30 Bio legend
CD15-FITC W6D3 Bio legend
CD14-APC HCD14 Bio legend
CD45-PerCP MEM-28 AbCam
CD3-FITC UCHT1 Bio legend
CD19-APC HIB19 Bio legend
CD45-PerCP MEM-28 AbCam
GlyA-FITC YTH89.1 AbD Serotec
CD45-PerCP MEM-28 AbCam
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Table 3.2 - The panels of specific cell surface antibodies used in the identification 
of haematopoietic subpopulations (/3-catenin analysis).
Clone ManufacturerLineage Panel Antibodies and 
conjugated 
fluorochrome
Haematopoietic
Stem/Progenitor
Cell
CD34-PE 8G12
Bio legendCD38-APC HIT2
CD45-PerCP AbCamMEM-28
Bio legendMyeloid lineages CD15-PE W6D3
CD14-APC HCD14 Bio legend
CD45-PerCP MEM-28 AbC am
CD3-PELymphoid
lineages
Bio legendCD19-APC HIB 9
CD45-PerCP MEM-28 AbCam
GlyA-PE JC159Erythroid
lineages
DAKO 
(Cambridgeshire, 
UK)
CD45-PerCP MEM-28 AbCam
3.3.5.3 Intracellular staining o f y- and (3-catenin
Pre-labelled haematopoietic cells already suspended in SF-RPMI-1640 were stained for 
intracellular y- and /3-catenin using the protocol optimised in section 3.3.4.1. These 
optimised conditions involved using the primary catenin, and appropriate isotype, 
antibodies at a concentration of 10/zg/ml for 30 minutes.
3.3.5.4 Intracellular staining o f y- and (3-catenin in erythrocytes
Owing to the fragile structure of mature erythrocytes, the staining method outlined 
above was modified to ensure enough red cells survived the lysis stage and were present 
in the final analysis. Cells pre-stained with the erythroid panel of antibodies received a 
longer (30 minute) fixation to increase cross-linking of proteins. For permeabilisation,
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timings and washings remained the same, however erythroid labelled cells were 
permeabilised with 100% methanol, a gentler permeabilising agent than the triton TX- 
100 used in the above section. Finally, upon resuspension in 100/d FACSFlow™ just 
prior to flow cytometric analysis (below 3.3.6), erythroid cells were stained with 165nM 
TO-PRO®-3 iodide (Invitrogen). This nuclear stain was an important parameter in 
discriminating mature anucleate red cells from nucleated cells.
3.3.6 Analysis of total y- and /3-catenin expression by flow cytometry
Six-parameter flow cytometric analyses o f total catenin expression in haematopoeitic 
cells were performed using a FACSCalibur™ cytometer (BD) with CellQuest™ 
software version 3.3 (BD). Cells to be analysed were resuspended in 100/d 
FACSFlow™ in mini-flow tubes (Greiner Bio-one) and kept on ice in the dark until 
flow cytometric analysis. Given the presence of low-frequency developmental sub­
populations within CB/BM, such as CD34+ cells (0.05-3%), a minimum o f 5x105 events 
were collected for each panel o f cells stained. The homogenous nature o f cell lines 
meant acquisition o f only 1 x 104 events was necessary. Debris was excluded from the 
analyses on the basis o f forward- and side-scatter characteristics, whilst specific 
individual sub-populations were identified using the gating strategies outlined in results 
section 3.4.2.1. Flow cytometric data were analysed using WinMDI version 2.8 (Joe 
Trotter, Pharmingen, California, USA) and the mean fluorescence intensity (MFI) of y- 
and /3-catenin within discrete developmental subsets and cell lines were calculated using 
Equation 3.1 below:
Mean fluorescence intensity (logged arbitrary units) = CFI -  BFI
Where;
CFI = Intensity o f catenin fluorescence (given by y- or /3-catenin antibody)
BFI = Intensity o f background staining (given by iso type matched control antibody on 
same population)
Equation 3.1 - Calculation used to generate the mean fluorescence intensity of 
catenin within subpopulations of cord blood.
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3.3.7 Analysis of subcellular localisation of y- and jS-catenin by CLSM
3.3.7.1 Principles o f  CLSM
The ability o f Confocal Laser Scanning Microscopy (CLSM) to accurately resolve 
different compartments o f a single cell make it ideal for analysing the subcellular 
distribution o f intracellular proteins such as catenin. CLSM is able to deliver such high 
resolution images, unlike conventional wide-field fluorescence microscopes, through its 
unique configuration (see Figure 3.6). A laser light source is passed through a narrow 
aperture and focussed, by an objective lens, onto a small focal volume within a tissue 
specimen. Fluorophores (see 2.7.2) targeted to specific proteins and DNA within the 
pre-treated sample become excited and emit fluorescence o f  a higher wavelength that is 
re-collected by the objective lens and directed towards a beam splitter. This beam 
splitter is capable o f separating the re-collected light by allowing reflected laser light to 
pass through whilst directing collected fluorescent light wavelength o f interest through a 
small pinhole onto a PMT detector. The PMT converts light signals into an electrical 
one as described previously for flow cytometry (2.7.1) allowing a digital read-out 
(imaging) on a computer. The pinhole aperture thus excludes all out-of-focus light not 
originating from the focal point allowing a very sharp, resolved, thin area o f focussed 
tissue to be examined as the laser scans over the plane o f interest (Z-plane). 
Furthermore, the specimen stage can be adjusted vertically allowing fluorescence data 
to be collected from multiple focal planes (Z-stacks). These Z-stacks can eventually be 
compiled by intricate CLSM software into 3D information on protein expression 
throughout a single cell.
Characterisation of y-Catenin and /3-Catenin Expression in Normal . ~. . I C h ap te r 3Flacmatopoiesis
D e te c to r  
P in h o le  
A p e rtu re  —
F lu o r e s c e n c e -  
B arrie r 
F itte r
In -F o cu s  
L igh t R ay s
D ich ro m atic
M irror
O b jec tiv e -
■ P hotom ultip lier
D e te c to r L a s e r  S c a n n i n g
Confocal Microscope 
Optical
O u t-o f-F o cu s  C o n f i g u r a t i o n  
L ight R ay s
E xcita tio n
F itter
E x c ita tio n  
L ight 
R ays
L a se r  
E x c ita tio n  
S o u rc e  
I
L ight S o u rc e  
Pinhole 
A p e rtu re
F o ca l
■Planes
Specim en*
Figure 3.6 - The standard configuration of CLSM.
Schematic of a CLSM optical set-up showing the light laser source which is directed 
through pinhole apertures and the objective lens onto a focal plane within the specimen. 
Emitted fluorescence from within the sample is subsequently redirected back through 
the lens, and reflected by a dichromatic mirror through a pinhole aperture onto a PMT. 
Adapted from www.olvmpusfluoview.com/theorv/confocalintro.html.
3.3.7.2 Validation o f CLSM as a technique for subcellular localisation analysis
Before this technique could be routinely used for the analysis of primary haematopoietic 
cells, it was first validated by Western blotting. It was necessary to establish whether the 
intracellular staining protocol previously described could be used in conjunction with 
CLSM to detect shifts in the localisation of catenin between the cytosol and nucleus of 
individual cells.
To this end, the K562 pBabe-Puro control and y-catenin overexpressing lines previously 
established (see section 3.3.2) were intracellularly stained as outlined in section 3.3.4.1 
but for the exceptions listed in points 4) and 5) of section 3.3.7.3. CLSM image 
acquisition and post-acquisition analysis were completed as described in sections
3.3.7.4 and 3.3.7.5, respectively. To validate the distribution of y-catenin obtained from 
CLSM, cells from the respective K562 cultures were fractionated into cytosolic and 
nuclear homogenate using the method in section 2.6.2, and Western blotted as in
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sections 2.6. 3-2.6. 7. The primary catenin antibodies used in section 3.3.3 were again 
deployed at the same concentration. To assess both the purity o f each fraction and the 
amount relative amount o f protein loaded, /3-actin (for cytosolic protein) was used, 
again as described in 3.3.3, whilst a histone HI (for nuclear protein) mouse monoclonal 
(Clone AE-4, AbD serotec) was used at 0.5/zg/ml.
3.3.7.3 Preparation and intracellular staining o f  haematopoietic cells
The lineages o f CB/BM exhibiting the highest levels of y- and /5-catenin expression 
were further analysed by CLSM to ascertain the subcellular location o f catenin 
expression. Cells to be analysed were prepared and immuno-stained similarly to that 
described for the flow cytometric analysis (section 3.3.5), but for a number of 
fundamental differences;
1) The starting number o f cells to be analysed was never more than 2x106 since 
fewer cells were required for confocal analysis.
2) Due to the relative infrequency o f CD34+ HSC/progenitor cells within CM/BM, 
their prior purification before intracellular staining was required using the 
MACS technique outlined in section 2.4.2.
3) The limited fluorescence channels for CLSM analysis meant that just one 
fluorochrome (R-PE) was available for the pre-labelling o f target subsets 
described in section 3.3.5.2. Thus, for HSC/progenitor cells and granulocytes, 
the CD34 and CD 15 antibodies, respectively, described in Table 3.2 were used. 
An R-PE conjugated CD14 monoclonal antibody (Clone HCD14, Bio legend) 
was used for the detection o f monocytes.
4) Given the relative lack o f efficiency o f R-PE as a confocal fluorochrome, both y- 
and /3-catenin were labelled with FITC for optimal detection. The immuno - 
staining o f /3-catenin (section 3.3.4.2) was thus unaffected (due to direct FITC 
conjugation), whilst y-catenin immuno-detection required a different RAM 
secondary antibody (Clone LO-MG2a-9, AbD Serotec) used exactly as above 
(section 3.3.4.1).
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5) All cells to be analysed by confocal microscopy were stained just prior to 
analysis with 165nM TO-PRO®-3 iodide upon final re-suspension in 100/xl 
FACSFlow™. This allowed the nuclei o f  cells to be confidently discriminated.
3.3.7.4 CLSM data acquisition
Cells to be analysed by CLSM were resuspended in 100/d FACSFlow™ containing 
165nM TO-PRO®-3 iodide and kept in the dark on ice until analysis (<1 hour). At the 
time o f analysis, a 30/d aliquot o f the cells o f interest was slowly and evenly pipetted 
onto a clean 22 x 22mm coverslip (Fisher) which was secured onto the adjustable Z- 
stage o f the DMIRBE2 upright light microscope (Leica, Buckinghamshire, UK) and 
allowed to settle for approximately 5 minutes prior to focussing.
Confocal immunofluorescence was achieved using the resonant scanning head o f  a 
Leica TCS SP2 confocal laser microscope with a 63x objective NA 1.32 (HCX-PL- 
APO) assisted by Leica™ Confocal Software (LCS) version 2.61 (Leica Microsystems, 
Heidelberg, Germany). For each lineage a minimum o f 50 cells were imaged using the 
strategy outlined in Figure 3 .7. The threshold for catenin fluorescence was ascertained 
by imaging approximately 2 0  cells per lineage immuno-stained with the isotype- 
matched irrelevant control antibodies. Throughout image acquisition only whole 
nucleated cells were captured as determined by TO-PRO®-3 iodide staining. A fixed 
path o f field navigation was adopted (Figure 3.7A ), whilst a concerted effort was made 
to include as many cells o f interest per field as possible. All cells scanned with a single 
Z-plane were imaged with the focal plane dissecting as close to the centre o f the cells as 
possible (shown in Figure 3 .7B), ensuring representative areas of membrane, cytosol 
and nucleus were observed for each cell. For each field, a light transmission image was 
captured, along with membrane fluorescence, nuclear fluorescence (TO-PRO®-3), and 
catenin fluorescence (y or P) in the order exemplified in Figure 3 .7C. This ensured that 
the necessary post-acquisition analysis could be conducted as described in the 
immediately proceeding section. For each lineage, representative Z-stacks (image 
series) were constructed o f single cells which demonstrated exemplary catenin 
localisation, the principle o f  which is illustrated in Figure 3 .7D.
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Figure 3.7 - Strategy used to acquire images by CLSM.
A) The fixed direction of movement adopted to navigate through the multiple fields of 
immunofluorescence to avoid selection bias. B) 3D cross section through a cell 
demonstrating the correct (green) and incorrect (red) focal planes used for imaging. 
Targeting the correct focal plane ensures a single image is captured which fairly 
represents the actual nuclear to cytoplasmic ratio of the target cell. C) Demonstration of 
sequential fluorescence images captured for each cell and D) visual illustration of how a 
confocal image series (Z-stack) is compiled by the CLSM.
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3.3.7.5 CLSM post-acquisition analysis
Raw fluorescent images with no post-acquisition contrast enhancement or manipulation 
were used for quantitation using LCS Lite™ analysis software version 2.61 (Leica 
Microsystems). The strategy adopted for analysing cells o f interest is demonstrated 
sequentially in Figure 3.8. Firstly, for each cell within a given field, immunophenotype 
was ascertained by observation of membrane fluorescence (e.g. CD34-PE identifies 
haematopoietic progenitor cells) as seen in Figure 3.8A. Cells expressing the relevant 
cluster o f differentiation (CD) marker were viewed using the corresponding light 
transmission image to construct a region o f interest (ROI) around the entire 
circumference o f the cell (.Figure 3.8B), before using the TO-PRO®-3 fluorescence to 
compose a nuclear ROI (Figure 3.8C). The number and intensity o f catenin 
fluorescence pixels (on a linear scale from 0-255) contained within each ROI Figure 
3.8D) was visualised by histograms in Leica Lite™ {Figure 3.8E) and raw values were 
exported into a Microsoft Excel spreadsheet. From here, total cell catenin fluorescence 
and total nuclear catenin fluorescence for each cell captured could be calculated using 
Equation 3.2.
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Figure 3.8 - Analytical technique used to quantify fluorescence emitted from whole 
cell and nuclear regions of individual haematopoietic cells.
A) Lineages o f interest were first identified by immunophenotyping given by membrane 
fluorescence (red) before using the light transmission image (B) to draw an ROI around 
the entire cell circumference. C) TO-PRO-3 staining (blue) assisted in composing a 
nuclear ROI. D) Catenin fluorescence (green) was quantified within each ROI and used 
to generate histograms (E) of fluorescence intensity.
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Total cell/nuclear fluorescence = X (PFI x FPI)
Where;
PFI = Fluorescence Intensity o f Pixel (0-255)
FPI = Frequency o f Pixels at given Intensity
Equation 3.2 > Equation used to generate total cell or nuclear fluorescence for each 
cell of given lineage.
Once catenin fluorescence values were obtained for the total cell and nuclear ROIs (and 
the background subtracted from each using the ROI values obtained from the isotype- 
stained cells), the relative proportion o f fluorescence emitted from the cytosol and/or 
membrane could be calculated using Equation 3.3 below:
%  Cytosol/Membrane fluorescence of cell = 100 -  ([NF/TCF] x 100)
Where;
NF = Nuclear fluorescence 
TCF = Total cell fluorescence
Equation 3.3 - Equation used to deduce the fluorescence emitted from cytosol and 
membrane regions of cell.
Use o f the above equation meant that a Nuclear:Cytosolic/Membrane (N:C/M) ratio o f 
catenin fluorescence could be compiled for each cell within a lineage data set (minimum 
o f 50 cells). It should be noted that this ratio represents the distribution o f catenin across 
a single central Z-plane o f a cell and is not representative o f the entire cell. Each lineage 
was assayed 3 times each for y- and /3-catenin localisation, after which, an average 
N:C/M ratio, (with standard deviation (SD)), o f y- or /3-catenin per cell was calculated.
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3.4 Results
3.4.1 Optimisation of intracellular y-catenin detection assay
3.4.1.1 The generation o f a y-catenin retroviral expression vector
To overexpress human y-catenin, cDNA was subcloned from the PINCO construct into 
the pBabe-Puro retroviral vector. Using a double restriction digest (see 3.3.1.1) the 
expected fragments sizes o f 2.4kb (corresponding to y-catenin sequence) and 12.7kb 
(corresponding to PINCO sequence) were generated (Figure 3.9B).
The recipient pBabe-Puro vector was linearised using the same restriction digest as 
mentioned above and Figure 3.9C confirms the efficiency o f digestion by the generation 
o f a 5.2Kb DNA fragment that corresponds to the full length pBabe-Puro sequence. 
After transformation o f E. coli cells with the newly ligated pBabe-Puro-y-catenin it was 
necessary to identify potential colonies expressing the plasmid (Figure 3.9D). Of 12 
ampicillin-resistant colonies (c) isolated, 3 were identified (c2, c5 and c8 ) as potentially 
expressing the relevant DNA. This is shown in Figure 3.9D whereby c2 and c5 exhibit 
the DNA fragment sizes predicted in Figure 3.3.
Correct insert orientation was confirmed using a Smal restriction digest which produced 
the predicted fragment sizes (Figure 3.4) that corresponded to a correct orientation as 
illustrated in Figure 3.9E.
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Figure 3.9 - Subcloning of human y-catenin cDNA from PINCO into pBabe-Puro.
A) Range o f molecular weights indicated by the lkb DNA ladder used on all agarose 
gels (adapted from NEB website). B) Successful excision of y-catenin from PINCO 
using BamHX/EcoRX double digest as shown by generation o f 12.7kb and 2.4kb DNA 
fragments. C) Successful linearization o f pBabe-Puro using the same double digest as 
given by 5.lkb and otherwise undetectable 24bp DNA fragment. D) Representative 
agarose gel showing the range of ampicillin-resistant colonies (c) BamHMEcoRX 
restriction digested to test for the presence o f pBabe-Puro-y-catenin DNA. Presence of 
5.2kb and 2.4kb DNA fragments in c2 and c5 (c8  not shown) identified them as 
potential colonies harbouring the plasmid o f interest. E) Correct orientation of y-catenin 
cDNA within pBabe-Puro as shown in c2, 5 and 8  by generation o f 2.1, 2.6 and 2.8kb 
DNA fragments from a single SmaX restriction digest.
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3.4.1.2 The overexpression o f  y-catenin protein in transformed cell lines
Five haematopoietic cell lines were retrovirally transduced with pBabe-Puro-y-catenin 
(and the pBabe-Puro control), purified by puromycin selection, and cultured for up to 10 
days before immuno-blotting for y-catenin.
Figure 3.10 demonstrates how all cell lines overexpressed y-catenin protein albeit to 
varying degrees. Interestingly, the y-catenin detected in most o f the cell lines exhibited a 
multiple banding pattern, the significance o f which was further investigated in Chapter 
5. Given that the multiple banding was a feature of both the endogenous and ectopically 
expressed y-catenin made it unlikely that this phenomenon was due to non-specific 
binding. It should be noted that no discernible differences in growth or morphology 
were observed between control and y-catenin transgenics o f each cell line, with the 
exception o f FDCP mix (see Appendix 4).
These data confirmed that the pBabe-Puro-y-catenin vector was capable of ectopic 
expression of y-catenin in all cell lines tested. The transgenic K562 line was 
subsequently employed for optimisation o f y-catenin staining because o f a high 
induction of y-catenin relative to endogenous levels.
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Figure 3.10 - Overexpression of y-catenin protein in transformed cell lines.
Western blotting reveals the pBabe-Puro-y-catenin retroviral vector (‘y-Cat’) is capable 
of stable ectopic expression of y-catenin in comparison to pBabe-Puro controls (‘Cont’). 
Green numerals indicate the fold overexpression of y-catenin versus controls that was 
achieved in each cell line as determined by densitometric analysis. Immunoblotting for 
/3-act in indicates relative protein loading.
3.4.1.3 The optimisation o f a primary y-catenin antibody
As can be observed in Figure 3.11A, B and C, all monoclonals tested in a flow 
cytometric assay were able to detect the overexpression of y-catenin in K562 cells to 
varying degrees. Optimal working concentration for all clones examined appeared to be 
10/zg/ml. However, clone Ml 11 {Figure 3.11C) demonstrated the greatest efficiency of 
staining detecting a 9.7 fold overexpression of intracellular y-catenin from control level. 
The specificity o f this detection is validated by the fact it closely matched the 10.3 fold 
overexpression of y-catenin present in the K562 cells as shown by Western blotting in 
Figure 3.1 ID. Furthermore, the broad range of fluorescence detected by the M i l l  clone 
(as demonstrated in the histograms) most accurately reflects the heterogeneity of protein 
overexpression often generated by the random process of retroviral-mediated gene 
integration. To ensure that incubation time was not a limiting factor in y-catenin 
detection a range of primary antibody incubation times were attempted (30, 45 and 60 
minutes all at RT) with the Mi l l  clone. Figure 3.1 IE  illustrates that the 30 minute 
incubation was optimal.
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Figure 3.11 - Optimisation of y-catenin intracellular staining in K562 cells.
Histograms of fluorescence obtained from cells stained with y-catenin primary 
antibodies. The primary clones A) 15, B) PG5.1 C) Mi l l ,  at the concentrations 
indicated, were used to stain: K562 pBabe-Puro (open black histograms); K562 pBabe- 
Puro-y-catenin (red fdled); or isotype-control cells (green). Numerals (red) represent the 
fold overexpression of y-catenin detected in overexpressing versus control K562 cells as 
given by cytometric analysis. D) The fold overexpression of y-catenin protein (in green) 
present in the K526 pBabe-Puro-y-catenin cell line at the time of intracellular staining 
optimisation as deduced by western blotting. E) Optimisation of antibody incubation 
time using the optimal primary y-catenin antibody clone (Ml 11) at times of 30, 45 and 
60 minutes.
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3.4.1.4 The optimisation o f a primary (3-catenin antibody
y-Catenin has close fimctional parallels with 0-catenin suggesting these molecules may 
act in tandem, therefore the expression profile for /3-catenin in normal haematopoiesis 
was also determined. The intracellular staining protocol for /3-catenin detection also 
required optimisation and validation. This process was quicker for /3-catenin given:
1) K562 cells overexpressing /3-catenin were already available (section 3.3.4.2).
2) The optimal mouse monoclonal primary antibody for /3-catenin detection was 
already established within the field (Clone 14).
As the optimal incubation time was deduced from y-catenin staining it was only 
necessary to ascertain the optimal working concentration. As observed in Figure 3.12A. 
a working concentration o f 10/*g/ml was optimal. This detection most closely resembled 
the overexpression o f /3-catenin that was present in these cells as deduced from Western 
blotting {Figure 3.12B).
The results o f sections 3.4.1.3 and 3.4.1.4 demonstrated that the intracellular staining 
assay could accurately detect levels o f both y- and /3-catenin which were reflective o f 
levels present in K562 cells as determined by Western blotting.
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Figure 3.12 - The optimisation of p-catenin intracellular staining in K562 cells.
A) Histograms of fluorescence obtained from staining with primary P-catenin antibody 
(clone 14) on: K562 pBabe-Puro cells (open black histograms); K562 P~CatAN89 cells 
(red filled); and isotype-control stained cells (green) at the indicated concentrations. 
Numerals (red) represent the fold overexpression of p-catenin detected in 
overexpressing versus control K562 cells as given by cytometric analysis. B) Western 
blot shows the fold overexpression of mutant P-catenin protein present in pPOLYPOZ 
p-CatAN89, versus wt protein in control cells, at the time of intracellular staining 
optimisation. Note the mutant form migrates at a molecular weight of 75kDa whilst the 
wt migrates to around 90kDa.
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3.4.1.5 Lack o f  cross-reactivity between primary y- and (3-catenin antibodies
Given the degree of homology between y- and /3-catenin molecules (see Figure 1.1 OA) it 
was necessary to check cross-reactivity o f the selected antibodies using the K562 cell 
lines used in the previous two sections {3.4.1.3 and 3.4.1.4).
To fully assess cross-reactivity, the y-catenin antibody (clone M i l l )  was tested on the 
K562 /3-CatAN89 cells (i.e. where there was an abundance o f /3-catenin protein), whilst 
the /3-catenin antibody was tested on the K562 pBabe-Puro-y-catenin cells (i.e. where 
there was abundance of y-catenin protein). As can be observed in Figure 3.13, clone 
Ml 11 was able to detect the overexpression of y-catenin within the K562 pBabe-Puro-y- 
catenin cells, with no discemable shift in fluorescence (over background) when K562 /3- 
CatAN89 cells were stained. Western blots reveal the true level o f respective proteins 
being expressed at the point of the assay {Figure 3.13C and D). Similarly for Clone 14, 
Figure 3.13B shows the detection of exogenous mutant /3-catenin in K562 /3-CatAN89 
cells, whilst no significant increase in fluorescence was observed when K562 pBabe- 
Puro-y-catenin cells were stained.
These data suggested that no detectable cross reactivity was occurring between the 
optimal y- and /3-catenin antibody clones.
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Figure 3.13 - The degree of cross-reactivity between y- and |3-catenin antibodies.
A) y-catenin primary antibody (Clone Mi l l )  staining of: K562 pBabe-Puro-y-catenin 
cells (red filled histogram); pBabe-Puro controls (black); K562 /3-CatAN89/3 cells 
(green); isotype-control stained cells (open red histogram). B) Reciprocal reactivity of 
the /3-catenin primary antibody (Clone 14): K562 /3-CatAN89 cells (red filled 
histogram); K562 pBabe-Puro cells (black) K562 pBabe-Puro-y-catenin cells (green); 
isotype-control stained cells (open red histogram). Red and green numerals represent the 
fold overexpression o f the respective proteins in each K562 cell lines as given by 
cytometric analysis. C) The degree of y-catenin and D) /3-catenin overexpression present 
in respective K562 cell lines at the time of flow cytometric assessment as determined by 
Western blotting. Green numerals represent the fold overexpression o f catenin relative 
to the pBabe-Puro control line.
Clone 14
Characterisation of y-Catenin and /3-Catcnin Expression in Normal
Haematopoiesis
3.4.1.6 CLSM can detect nuclear translocation o f catenin
The total expression level of y- and /3-catenin would only provide limited scope for 
understanding the function o f these proteins in haematopoietic cells. Knowing the sub- 
cellular localisation potentially indicates function. It is not uncommon for proteins to 
shuttle between membrane, cytosol and nucleus during development, and catenins in 
particular have been frequently documented to change localisation given their dual 
structural and transcriptional roles (see 1.3.5). It was important to establish whether the 
intracellular staining protocol optimised above was capable o f detecting shifts in the 
intracellular distribution of catenin by CLSM.
To investigate this, the K562 pBabe-Puro and pBabe-Puro-y-catenin lines established 
previously (sections 3.3.2) were again utilised. Both cell lines were fixed, permeabilised 
and immuno-stained as described in methods section 3.3.7.3 before being analysed by 
CLSM as described in section 3.3.7.4.
As can be observed from Figure 3.14 the y-catenin expression in control K562 cells 
appeared to be almost entirely cytosolic (although some membrane associated y-catenin 
cannot be ruled out). This figure and further examples of y-catenin localisation in K562 
pBabe-Puro controls can be viewed within the Chapter 3 section on the supplementary 
disc within Folder 7, Fields 1.1-1.3. Also present in this folder (Field 1.4) is a 
representative image o f the level of background fluorescence obtained from K562 cells 
as determined by the isotype matched control antibody. This image demonstrates that 
non-specific fluorescence was virtually undetectable.
The analysis of K562 pBabe-Puro-y-catenin cells, exemplified in Figure 3.15, 
demonstrated a clear increase in fluorescence intensity indicating the expected higher 
expression of y-catenin. As observed for control cells, y-catenin expression was 
primarily cytoplasmic, however, a greatly increased nuclear signal was frequently 
observed, an observation not made in control K562 cells. This nuclear fluorescence was 
confirmed by the fact that TO-PRO-3 (nucleic acid stain) signal was also present in the
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same region. This figure and further examples of y-catenin localisation in K562 pBabe- 
Puro-y-catenin cells can be observed on the supplementary disc within Fields 2.1-2.5 
located in Folder 2.
These data indicate that CLSM was capable of detecting changes in the level of y- 
catenin in distinct subcellular locations.
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Figure 3.14 - Subcellular localisation of y-catenin in K562 control cells by CLSM.
Representative confocal Z-sections of K562 pBabe-Puro control cells showing y-catenin 
subcellular localisation with A) phase contrast, B) y-catenin (green), C) nuclear TO- 
PRO-3 (blue) and D) merged images.
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Figure 3.15 - Subcellular localisation of y-catenin in overexpressing K562 control 
cells by CLSM.
Representative confocal Z-sections of K562 pBabe-Puro-y-catenin cells showing y- 
catenin subcellular localisation with A) phase contrast, B) y-catenin (green), C) nuclear 
TO-PRO-3 (blue) and D) merged images.
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To provide more objective evidence as to whether the assay was capable o f detecting 
shifts in catenin subcellular localisation, the average N:C/M ratio per cell was calculated 
following the analysis o f individual cells from each K562 line. As viewed in Figure 
3.16A, K562 pBabe-Puro cells exhibited an average nuclear localisation o f  12±8% 
(1SD; n=50) giving a N:C/M ratio of 12%:88%. K562 pBabe-Puro-y-catenin cells 
exhibited a significantly higher average nuclear localisation o f 29±9% (1SD; n=50), 
PO.OOl, giving a N:C/M ratio o f 29%:71%. These figures suggested that the 
intracellular staining protocol in combination with CLSM was capable o f detecting at 
least 2.4-fold shifts in nuclear catenin translocation.
To validate the above findings, both K562 cell lines were fractionated into nuclear and 
cytosolic homogenate and Western blotted using methods described in section 2.6. 
Figure 3.16B illustrates how Western blotting confirmed an approximate 2.2-fold 
nuclear shift in y-catenin localisation within K562 pBabe-Puro-y-catenin cells relative to 
pBabe-Puro controls. The apparent N:C/M ratios obtained from this method were very 
different to that obtained from CLSM, with 1.6%:98.4% for control K562s versus 
3.5%:96.5% for y-catenin overexpressing K562 cells. This arose because Western 
blotting gave rise to a ratio based on total amounts o f y-catenin in each compartment, 
whereas CLSM compared area-intensity measurements in each compartment. To 
convert these CLSM measurements to total protein in each compartment it was 
necessary to take into account the relative volumes o f each compartment. Therefore, by 
modelling individual K562 cells as two concentric (or eccentric) spheres, total protein in 
each compartment could be estimated by adapting the volume o f a sphere (see Appendix 
5). The resulting CLSM N:C/M ratios (6.5%:93.5% for controls versus 15.0%:85.0% 
for y-catenin overexpressing) remained different to Western blot values (although the 
variation had approximately halved), but still validated the approximate 2 .2 -fold nuclear 
shift in y-catenin observed between the two K562 cell lines.
Taken together, these data confirm that the intracellular catenin detection assay could be 
used in conjunction with CLSM to detect shifts in catenin subcellular localisation within 
haematopoietic cells.
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Figure 3.16 - Direct comparison of CLSM and Western blotting techniques in the 
detection of subcellular y-catenin.
A) The average localisation of y-catenin protein per K562 cell summarised from the 
analysis o f cells (n=50) from control and y-catenin overexpressing K562 cells, 
*JP<0.001. Black numerals give the percentage localisation of y-catenin within that 
fraction relative to the total y-catenin present. Error bars represent SD from each data 
set. B) Western blot demonstrates y-catenin protein present in nuclear and cytosolic 
lysates from control and y-catenin overexpressing K562 cells. White numerals represent 
the percentage of y-catenin contained within each fraction relative to the total amount of 
y-catenin detected. Probing for actin and histone HI confirmed the purity of each 
fraction.
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3.4.2 The expression of y- and 0-catenin in normal haematopoiesis
3.4.2.1 y-Catenin expression level is highest in CD34+ and myeloid cells
In order to identify the haematopoietic cell types expressing y-catenin, it was necessary 
to analyse the expression, at a single-cell level, throughout haematopoietic 
development. To assess this accurately, normal human CB and BM was examined 
which contains all haematopoietic lineages and also cells at different stages of 
maturation. To resolve the different cell lineages multi-parameter flow cytometry was 
used. Haematopoietic lineages at differing states o f differentiation can be identified on 
the basis o f  cluster o f differentiation (CD) markers (see 5.3.1.1).
Figure 3.17 through to Figure 3.20 illustrate the hierarchical gating strategy used to 
resolve populations o f HSC, haematopoietic progenitor cells, granulocytes, monocytes, 
lymphocytes and erythrocytes, and show representative histograms of the y-catenin 
expression detected from each lineage.
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Figure 3.17 - Strategy used to measure catenin expression in haematopoietic stem cells 
and progenitor cells.
Representative flow cytometric plots showing the sequential strategy used to gate and 
measure catenin in haematopoietic stem cells and progenitor cells. A) Firstly, red cells, 
debris and cell aggregates were excluded using FSC versus SSC parameters. B) High SSC 
and CD45bngh* cells were excluded from analysis followed by C) gating on CD34+CD45low 
events. These events were further re-gated on FSC and SSC parameters to exclude 
remaining debris and doublets (not shown). D) CD34+ events were divided into CD38 ' 
using a threshold obtained from isotype staining for CD38 on the CD34+ population. 
Representative histograms showing y-catenin (red filled) and isotype (open black) staining 
obtained from E) CD34+CD38' HSCs and F) CD34 CD38+ progenitor cells. Red numerals 
indicate the representative MFI of y-catenin staining obtained for the indicated subset.
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Figure 3.18 - Strategy used to measure catenin expression in granulocytes and 
monocytes.
Representative flow cytometric plots showing the sequential strategy used to measure 
catenin in granulocytic and monocytic cells. A) Firstly, red cells, debris and cell 
aggregates were excluded using FSC versus SSC parameters. B) Gating o f CD45+ cells 
with high side scatter allowed identification of granular myeloid cells, which were re­
gated on a C) CD 14 versus CD15 plot to allow the resolution o f granulocytes 
(CD14lowCD15+) and monocytes (CD14+CD15low). Representative histograms showing 
y-catenin and isotype staining obtained from D) granulocytes and E) monocytes. Red 
numerals indicate the representative MFI of y-catenin staining obtained for each subset.
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Figure 3.19 - Strategy used to measure catenin expression in lymphocytes.
Representative flow cytometric plots showing the sequential strategy used to measure 
catenin in lymphoid cells. A) Firstly, red cells, debris and cell aggregates were excluded 
using FSC versus SSC parameters. B) Gating on low side scatter CD45bright cells allowed 
identification of the total lymphocyte pool. C) CD3 versus CD 19 plot allowed the 
separation o f T-cells (CD3+CD19) and B-cells (CD3'CD19+). Representative 
histograms showing y-catenin and isotype staining obtained from D) T-cells and E) B- 
cells. Red numerals indicate the representative MFI of y-catenin staining obtained for 
each subset.
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Figure 3.20 - Strategy used to measure catenin expression in erythrocytes.
Representative flow cytometric plots showing the sequential strategy used to measure 
catenin in erythroid cells. A) Erythroid cells were identified, and debris excluded, by 
gating on GlyA+ events. B) Erythroid cells were further resolved into nucleated red cells 
(GlyA+TO-PRO-3+) and enuclueated red cells (GlyA+TO-PRO-3 ). Representative 
histograms showing y-catenin and isotype staining obtained from C) enucleated 
erythrocytes and D) nucleated erythrocytes. Red numerals indicate the representative 
MFI of y-catenin staining obtained for each subset.
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The relative expression level o f y-catenin detected in haematopoietic cells o f  normal 
human CB and BM is summarised in Figure 3.21. y-Catenin expression was high in the 
most primitive cell type analysed; the CD34+CD38' HSC. A mean MFI o f 52±13 was 
detected in HSC from CB (n=4), whilst a mean MFI o f 84±27 was ascertained from BM 
samples (n=3). A very slight increase (1.2 fold) in y-catenin expression was detected in 
CD34+CD38+ committed haematopoietic progenitor cells (MFI 60±32) but this failed to 
reach statistical significance in CB samples. The same modest 1.2 fold increase in y- 
catenin expression was detected in BM-derived progenitor cells (MFI 100±31) which 
did reach statistical significance in these samples (P<0.05).
To address whether y-catenin expression remained constant or was more dynamic in 
haematopoietic development expression was assessed in more differentiated 
haematopoietic populations, beginning with those of myeloid origin. A significant 
increase in y-catenin expression (2.2 fold from HSC level, P<0.05) was observed in 
CD14,owCD15+ CB granulocytes (MFI 115±45), a trend also observed in granulocytes 
from BM (1.5 fold from HSC level, MFI 125±22). An increase in y-catenin expression 
was also found in CD14+CD15low monocytes from CB (1.8 fold from HSC level, MFI 
90±51) and BM (1.4 fold from HSC level, MFI 115±12) although these were more 
modest compared to the increases seen in granulocytes. Interestingly, it was observed in 
the fluorescence histograms from monocytes (of which Figure 3.18E is an example) 
that a distinct ‘shoulder’ of higher y-catenin expression was frequently present, the 
significance o f which is raised later in this chapter.
Cells of lymphoid origin were also included in the analysis and generally demonstrated 
a low expression of y-catenin. CD3+CD19" T-cell lymphocytes exhibited a significant 
down-regulation of y-catenin from HSCs both in CB (0.5 fold, MFI 27±18, P<0.05) and 
BM samples (0.4 fold, MFI 38±14, P<0.05). CD3*CD19+ B-cell lymphocytes also 
demonstrated lower levels of y-catenin expression compared to HSCs, with a 0.8 fold 
reduction in CB B-cells (MFI 44±21) and significantly lower 0.5 fold reduction in BM 
B-cells (MFI 43±14, P<0.05). Interestingly also, B-cells had consistently higher levels 
of y-catenin expression than T-cells in both CB (PO .O l) and BM (P<0.05).
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Finally, erythroid cells were also analysed using a modified permeabilisation method as 
described in section 3.3.5.4. Using this technique, mature erythrocytes (GlyA+TO-PRO- 
3 ) demonstrated virtually no y-catenin expression from CB (MFI 1±0.6, P<0.01) or BM 
(MFI 1±0.6, P<0.05). Unfortunately, even this adapted protocol was unable to 
consistently preserve the immature red cell population (GlyA+TO-PRO-3+) as illustrated 
in Figure 3.20A and B. From a few examples where analyses were possible, it appeared 
that y-catenin expression was present within this immature subset albeit at low levels 
(MFI=30±8, n=2 for CB, MFI=28±6, n=2 for BM).
Taken together, these data present a clear expression profile for y-catenin throughout 
haematopoietic development. Expression starts relatively high in primitive HSC and 
committed progenitor cells, before increasing for subsequent granulocytic and 
monocytic differentiation. Expression is lower in both types o f lymphocytes, with B- 
cells harbouring slightly higher levels than T-cells, and expression is altogether lost in 
mature red cells.
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Figure 3.21 - The relative expression level of y-catenin throughout normal 
haematopoiesis.
The expression level of y-catenin within discrete developmental subsets of normal 
haematopoietic development as determined by the average MFI obtained from normal 
cord blood (blue bars, n=4) and bone marrow (green bars, n=3) samples. Data 
represents mean ± 1SD obtained from each data set.
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3.4.2.2 /3-Catenin expression level is similar to that o f  y-catenin in normal 
haematopoiesis
To establish whether y-catenin has distinct or similar expression in haematopoiesis to its 
close homologue /3-catenin, a direct comparison was performed. Using the same 
protocol as for y-catenin analysis, (but incorporating a slightly different pre-labelling 
strategy; 3.3.5.2\ an expression profile was established for /3-catenin as illustrated in 
Figure 3.22.
Like y-catenin, /3-catenin was also expressed highly within CD34+CD38' primitive HSC 
of CB (MFI 212±124, n=6 ) and BM (MFI 873±460, n=3). The committed progenitor 
population (CD34+CD38+) demonstrated a small (1.3 fold) but significant (P<0.05) 
increase in /3-catenin expression from HSC level within cord blood samples with an 
MFI o f 279±174. This increase was not, however significant within BM samples (MFI 
912±327).
In the CD14,owCD15+ granulocytic population /3-catenin exhibited an increase in 
expression from HSC level that was more pronounced than that observed for y-catenin. 
In CB granulocytes a 4.2 fold increase in expression was observed relative to HSC level 
(MFI 1182±568, .P<0.05), whilst BM derived granulocytes exhibited a 3.3 fold up- 
regulation o f /3-catenin (MFI 3042±635, ^<0.05). Unlike y-catenin, /3-catenin did not 
demonstrate a significantly increased expression level within the CD14+CD15low 
monocyte population compared with CD34+ progenitor cells.
A significant down-regulation of /3-catenin from HSC level was present in CD3+CD19‘ 
T-cell lymphocytes from both CB (0.3 fold, MFI 56±34, ,P<0.05) and BM (0.3 fold MFI 
297±74, P<0.05). B-cells also consistently harboured a significantly higher level o f /3- 
catenin expression than T-cells in both CB (P<0.05) and BM (P<0.05), an observation 
also previously made for y-catenin.
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Finally, analysis o f  mature erythrocytes (GlyA+TO-PRO-3') confirmed that, like y- 
catenin, /3-catenin expression was completely absent in this terminally differentiated 
subset (MFI 9±5, P<0.05 in CB and MFI 25±19, P<0.05 for BM). As mentioned 
previously, analysis o f immature (GlyA+TO-PRO-3+) red cell populations was 
problematic, however a few analyses suggested that /3-catenin expression was present 
within this subset, although at low levels (MFI 47±15, n=3 for CB).
In summary, these data imply that /3-catenin assumes a very similar expression profile to 
that of y-catenin throughout haematopoietic development. The only differences being a 
more marked increase in expression within the granulocytic population and the lack o f 
any increased in expression associated with monocyte maturation.
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Figure 3.22 - The relative expression level of /3-catenin throughout normal 
haematopoiesis.
The expression level o f /3-catenin in discrete developmental subsets of normal 
haematopoietic development as determined by the average MFI obtained from normal 
CB (blue bars, n=6) and bone marrow (green bars, n=3) samples. Data represents mean 
± 1SD obtained from each data set.
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3.4.3 The subcellular localisation of y- and /3-catenin in haematopoietic 
cells
The expression profile of y- and /3-catenin in haematopoietic development has shown 
expression of both proteins to be highest in HSC/progenitor, granulocyte and monocyte 
populations. Therefore these subsets were analysed for the subcellular localisation of 
expression using CLSM.
3.4.3.1 y-Catenin is nuclear excluded in CD34+ haematopoietic progenitor cells
CD34+ cells were purified before staining for intracellular y-catenin as previously 
described (see section 3.3.7.3). Figure 3.23 clearly shows that y-catenin was almost 
entirely nuclear-excluded within this sub-population of cells. The merged images (D) 
demonstrate how the y-catenin signal (green) fails to overlap with the nuclear TO-PRO- 
3 signal (blue) suggesting nuclear exclusion. Although the y-catenin fluorescence does 
appear to be cytosolic, membrane forms cannot be ruled out. These images, plus further 
examples of y-catenin nuclear exclusion in CD34+ HSC/progenitor cells can be found 
on the supplementary disc Chapter 3 section within Folder 3, Fields 3.2-3.7. Field 3.1 
gives a representative example of the low level of background fluorescence obtained 
from these cells as determined by the matched isotype staining.
Figure 3.24 consists o f a Z-stack series whereby multiple Z-planes of a CD34+ cell 
captured by CLSM are compiled to provide a cross-section through a single cell. This 
figure can be found in movie form on the supplementary disc as Z-Stack 3.1 within 
Folder 3. It illustrates clearly how y-catenin is nuclear excluded throughout the entirety 
of a CD34+ cell and not just on a given single plane.
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Figure 3.23 - The subcellular localisation of y-catenin expression in CD34+ 
progenitor cells.
Pair of representative CLSM images of y-catenin localisation in CD34+ haematopoietic 
progenitor cells with A) phase contrast, B) nuclear (blue), C) y-catenin (green), and D) 
merged images.
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Figure 3.24 - The subcellular localisation of y-catenin throughout a CD34+ 
progenitor cell (overleaf).
Representative CLSM Z-stack series showing A) y-catenin localisation throughout an 
entire CD34+ progenitor cell, and the B) identified nuclear region as given by TO-PRO- 
3 staining.
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3.4.3.2 (3-Catenin is nuclear localised in CD34+ haematopoietic progenitor cells
In contrast to y-catenin, Figure 3.25 illustrates how /3-catenin expression was 
predominantly nuclear localised within CD34+ cells. This is particularly emphasised 
when viewing the merged images (D) where there is a considerable degree of overlap 
between the (yellow) /3-catenin signal and (blue) nuclear region. Interestingly, mid-field 
in Figure 3.25, there appeared to be a CD34+ cell in the final stages of cell division (two 
nuclei sharing a single cytoplasm) where the /3-catenin remained mostly nuclear. 
Another interesting observation seen also in Figure 3.25 was the presence of multiple 
foci o f intense /3-catenin staining. These images, plus further examples o f /3-catenin 
localisation in CD34+ cells can be browsed in Fields 4.2-4.5 o f Folder 4 on the 
supplementary disc within the Chapter 3 section.
As before for y-catenin, Figure 3.26 provides a CLSM Z-Stack series though a single 
CD34+ HSC/progenitor, which clearly demonstrates that /3-catenin distribution is 
ubiquitous through the nucleus of the cell and not just localised on a single Z-plane. A 
movie form of this Z-Stack series and others can be viewed in Z-Stacks 4.1-4.3 o f 
Folder 4 on the supplementary disc.
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Figure 3.25 - The subcellular localisation of /3-catenin expression in CD34+ 
progenitor cells.
Pairs of representative CLSM images of /3-catenin localisation in CD34+ haematopoietic 
progenitor cells with A) phase contrast, B) nuclear (blue), C) /3-catenin (yellow), and D) 
merged images.
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Figure 3.26 - The subcellular localisation of /3-catenin throughout a CD34+ 
progenitor cell.
Representative CLSM z-stack series showing A) /3-catenin localisation throughout an 
entire CD34+ progenitor cell, and the B) identified nuclear region as given by TO-PRO- 
3 staining.
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3.4.3.3 y-Catenin translocates to the nucleus o f CD15+ granulocytes
Granulocytes exhibited the highest levels of y-catenin observed in haematopoietic 
development and interestingly, although y-catenin remained for the most part cytosolic, 
increased levels of nuclear y-catenin were observed. It should be noted that there are 3 
types o f granulocyte, and CD 15 surface expression mainly identifies neutrophils and 
eosinophils, but not basophils. Also, of the total granulocyte pool present in normal 
peripheral blood, neutrophils make up over 90% (Hoffbrand et al., 2005b), making it 
likely that the wide range of maturity and morphology observed using this stain 
belonged to the neutrophil pool. However to be technically correct the term granulocyte 
will still be used for the remainder of this chapter. Figure 3.27 provides a representative 
picture of the varying states of granulocytic maturation encountered in the analysis. The 
immature form represented in Figure 3.27A, demonstrated a strong cytosolic expression 
of y-catenin but also showed an increased level of nuclear y-catenin compared to that 
observed in CD34+ cells. The part-differentiated (bi-lobed nucleus) granulocytic form in 
Figure 3.27B also harboured higher levels of nuclear y-catenin that are exemplified in 
the merged image (IV). Even in the terminally differentiated, hyper-segmented 
granulocytes seen in Figure 3.27C there remained a nuclear presence of y-catenin, as 
seen by the ‘grainy’ y-catenin signal observed in the TO-PRO-3+ nuclear regions.
Further examples of y-catenin localisation in granulocytic cells can be viewed in Fields 
5.2-5.7 o f disc Folder 5 in the Chapter 3 section. Also within this folder a number o f Z- 
Stack series (5.7-5.5) can be viewed in movie form, which demonstrate that y-catenin is 
ubiquitous throughout the granulocyte nuclei and not just localised on a single Z-plane.
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Figure 3.27 - The subcellular localisation of y-catenin expression in CD15+ 
granulocytic cells.
Representative CLSM images of y-catenin localisation in granulocytes with I) phase 
contrast, II) nuclear (blue), III) y-catenin (green), and IV) merged images. A) Example 
of undifferentiated, B) partially differentiated with bi-lobed nucleus and C) terminally 
differentiated granulocytes.
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3.4.3.4 (3-Catenin is localised similarly to y-catenin in CD 15+granulocytes
The levels o f /3-catenin were at their highest in granulocytic cells with enhanced 
intensity of /3-catenin staining in this subset of cells which correlated well with the high 
fluorescence levels detected from flow cytometry {Figure 3.22). As illustrated 
previously for y-catenin, a wide range of granulocyte morphology was examined 
{Figure 3.28A and B). Despite the increase in overall expression, the intracellular 
distribution mirrored that of y-catenin, that is; the expression was predominantly 
cytoplasmic but with some nuclear localisation, particularly in the undifferentiated 
granulocytes. As with y-catenin however, nuclear /3-catenin was still present in the 
terminally differentiated granulocytes. Interestingly, the foci o f /3-catenin staining seen 
in CD34+ cells were no longer frequently observed in these mature cells. For further 
images and Z-Stack series of /3-catenin localisation in granulocytes consult Folder 6 of 
the supplementary disc.
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Figure 3.28 - The subcellular localisation of /3-catenin expression in CD15+ 
granulocytic cells.
A) and B) Representative CLSM images o f /3-catenin localisation in granulocytes with
I) phase contrast, II) nuclear (blue), III) /3-catenin (yellow), and IV) merged images. 
Mixed fields containing examples of undifferentiated, partially differentiated and 
terminally differentiated granulocytes are shown.
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3.4.3.5 y-Catenin localisation is heterogenous in CD14+ monocytes
Although not as pronounced as the rise in expression observed from granulocytes, an 
increase in overall y-catenin expression was also observed in the monocyte population. 
The CD14+ immuno-stain identified a morphologically diverse subset and the y-catenin 
localisation was also heterogeneous. Figure 3.29A shows an example of low y-catenin 
expression (frequently observed in monocytes). Image Figure 3.29B shows monocytes 
where y-catenin was almost entirely nuclear excluded, whilst image Figure 3.29C 
exhibits a partial nuclear localisation (similar to the distribution observed in mature 
granulocytes). Interestingly, hyper-lobulated monocytes frequently displayed the 
distribution observed in images B and C.
Figure 3.29D, E and F  represent the most striking examples of y-catenin localisation in 
CD14+ monocytes (and indeed of any haematopoeitic cell observed in this study). 
Figure 3.29D represents an example whereby y-catenin expression appeared to be 
completely ubiquitous through the cell with no discrimination between cytosolic or 
nuclear regions. Figure 3.29E  and F  were representative of a small subset of monocytes 
(<10%) whereby the y-catenin was intensively nuclear localised. Curiously, it was 
nearly always the undifferentiated monocytes or those with a semi-differentiated 
‘kidney bean’ shaped nucleus that demonstrated this degree of nuclear translocation. 
This subset of cells is likely to represent the ‘shoulder’ o f high fluorescence referred to 
in section 3.4.2.1 and consistently observed in the monocyte histograms (see Figure 
3.18E). Further examples of the heterogeneous y-catenin localisation within monocytes 
are given in Folder 7 o f the supplementary disc within the Chapter 3 section.
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Figure 3.29 - The subcellular localisation of y-catenin expression in CD14+ 
monocytic cells.
Representative CLSM images of y-catenin localisation in monocytes with I) phase 
contrast, II) nuclear (blue), III) y-catenin (green), and IV) merged images. A range of 
monocyte morphology and y-catenin expression is indicated. Examples of A) low 
expression, B) nuclear exclusion, C) partial nuclear localisation, D overleaf) diffuse 
distribution and E + F) strong nuclear localisation of y-catenin are shown.
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3.4.3.6 (3-Catenin localisation is also heterogenous in CD 14^ monocytes
Figure 3.30A-F illustrate how the /3-catenin distribution was also heterogeneous in this 
morphologically variable subset. As for y-catenin, representative images of low 
expression, nuclear exclusion, partial nuclear localisation, diffuse distribution and 
nuclear localisation of /3-catenin are shown from Figure 3 .3 0 A -F respectively. 
Although the pattern of distribution corresponds to that of y-catenin there are subtle 
differences seen in Figure 3.30E and F  where the nuclear localisation is not to the same 
intensity as observed for y-catenin within cells of this morphology. This may explain 
why the ‘shoulder’ of high fluorescence observed in monocyte histograms {Figure 
3.18E) was only present for y-catenin staining and not for /3-catenin (data not shown). 
Further images and Z-Stack series of /3-catenin intracellular distribution in monocytes 
are present in Folder 8 of the supplementary disc.
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Figure 3.30 - The subcellular localisation of /3-catenin expression in CD14+ 
monocytic cells (overleaf).
Representative CLSM images of /3-catenin localisation in monocytes with I) phase 
contrast, II) nuclear (blue), III) /3-catenin (yellow), and IV) merged images. A range of 
monocyte morphology and /3-catenin expression is indicated. Examples of A) low 
expression, B) nuclear exclusion, C) partial nuclear localisation, D overleaf) diffuse 
distribution and E + F) strong nuclear localisation of /3-catenin are shown.
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3.4.3.7 y-Catenin is both similarly and differentially localised compared to (3- 
catenin in haematopoietic cells
A summary of the N:C/M ratios of y- and /3-catenin subcellular expression obtained 
from haematopoietic progenitor cells, granulocytes and monocytes are summarised in 
Figure 3.31 A and B. This shows that the degree of nuclear localisation of y-catenin in 
CD34+ cells was significantly lower than observed for /3-catenin in this cell type 
(10%±4 vs 58%±12, P<0.01, n=3). No significant difference in localisation was 
observed between y- and /3-catenin in CD15+ granulocytes (23%±8 vs 27%±9, n=3), this 
conformity apparently arose through opposing translocations of these catenins. 
Compared with CD34+ cells y-catenin demonstrated an increase in nuclear translocation 
in CD15+ cells (10%±4 in CD34+ cells vs 23%±8, .P<0.05) whilst /3-catenin exhibited a 
marked exit from the nucleus in granulocytes (58%±12 in CD34+ cells vs 27%±9 in 
CD15+ cells, i><0.01).
An average nuclear localisation o f 44%±16 (n=3) was observed for y-catenin in CD14+ 
monocytes was not significantly different from the localisation o f /3-catenin, 38%±12, in 
this cell type. As observed for granulocytic development, this apparently arose from a 
marked translocation of y-catenin to the nucleus (10%±4 in CD34+ cells vs 44%±16 in 
CD14+ cells, P<0.001) whilst /3-catenin shifted distribution to the cytosol/membrane in 
monocytes (58%±12 in CD34+ cells vs 38%±12 in CD14+ cells, P<0.05). The 
observation that y-catenin nuclear localisation was more heterogeneous than /3-catenin 
within this cell type is borne out by the larger standard deviation observed for y-catenin 
stained cells (16 vs 12, /*<0.01, n=3).
In summary, this section of data shows that y-catenin and /3-catenin are oppositely 
localised in early haematopoiesis suggesting distinct functions and independent 
regulation o f translocation in CD34+ cells. The distribution of both proteins is similar in 
granulocytic and monocytic differentiation despite reciprocal directions o f translocation. 
A small subset o f monocytes exhibited a unique and strong nuclear localisation of y- 
catenin suggestive of an exclusive role within this context.
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Figure 3.31 - Direct comparison of y-catenin and /3-catenin subcellular localisation 
in haematopoietic cells.
Summary bar graphs of A) y-catenin and B) /3-catenin subcellular localisation in 
haematopoietic cells (n=3 for each cell type). Percentage represents average protein 
localisation in that compartment per cell. Data represents mean ± 1SD obtained from 
each data set.
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3.5 Discussion
3.5.1 The expression profiles of catenins are similar in normal 
haematopoietic development
This study represents the first comprehensive assessment of catenin expression in 
human haematopoiesis, and has shown that these proteins may have roles beyond that of 
self-renewal in which they have been associated previously. The expression profiles of 
y- and /3-catenin in human CB and BM were very similar, initially suggesting that they 
may have similar functions. Generally, catenin expression was high in HSC/progenitor 
cells. Amongst differentiated cells, expression was highest in granulocytic and 
monocytic cells, lower in lymphocytes and absent in terminally differentiated 
erythrocytes. These data suggested catenins may serve particularly important functions 
in both early haematopoietic development and myelopoiesis. It remains unknown 
whether the coordinated regulation o f these proteins represents predominantly 
transcriptional or post-translational processes. Publicly available gene expression level 
data5 suggests mRNA levels of both y- and /3-catenin are retained during myeloid 
development; implicating post-translational mechanisms in the alteration of overall 
catenin level during development. To investigate the contribution o f post-translational 
mechanisms, of which y- and /3-catenin are known to share (Salomon et al., 1997; 
Aberle et al., 1997; Orford et al., 1997; Kodama et al., 1999; Sadot et al., 2000; Kolligs 
et al., 2000), one could employ inhibitors to key components o f the CDC and monitor 
the levels o f both catenins. Such inhibitors would include Lithium Chloride (LiCl) 
which is known to inhibit GSK-3 and CK-2 (Stambolic et al., 1996; Davies et al., 
2000), or peptide aldehydes (such as MG132) which are capable of inhibiting the 
proteasome (Lee and Goldberg, 1998). Alternatively, these components could also be 
‘knocked-out’ in vivo using transgenic mice to assess the contribution o f each in 
regulating catenin level during normal haematopoiesis.
Studies using murine models null for y- and/or /3-catenin suggest that these proteins 
have redundant roles in both short- and long-term haematopoiesis (Cobas et al., 2004;
5 http://www.ncbi.nlm.nih.gov/Reoprofiles
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Jeannet et al., 2008; Koch et al., 2008). In contrast, current data o f this study would 
argue for important roles in more than one stage of haematopoietic development. The 
shortcomings o f these papers are critically appraised in the more relevant discussion o f 
Chapter 5, however, these experiments focused on the general reconstitution capacity o f 
catenin-deleted haematopoietic progenitor cells, rather than any specific developmental 
abnormalities. This investigation was tailored to analyse catenin expression within 
specific developmental subsets, which was found to be dynamic, rather than 
uniform/absent (which could have been expected from functionally redundant proteins).
Evidence from this study conflicts with studies showing that /3-catenin protein 
expression decreases with development (Simon et al., 2005; Yeung et al., 2010). These 
studies analysed the expression o f endogenous /3-catenin protein using in vitro cultured 
CD34+ human haematopoietic progenitor cells. They showed, by time-course Western 
blotting, that although /3-catenin expression was readily detectable in early 
undifferentiated progenitor cells (in agreement with us), this expression was down- 
regulated and virtually absent in later differentiated cultures (in contrast to the 
upregulation observed in this study). Reasons for this apparent discrepancy may be 
related to sample preparation and the inclusion o f bulk haematopoietic cell populations, 
whereas this analysis was tailored to a specific lineage by flow cytometry. Further, 
similar experiments conducted in this study (featured later in Figure 5.12 o f Chapter 5) 
have shown (at worst) maintenance o f /3-catenin (and y-catenin) expression in later 
differentiated haematopoietic cultures from progenitor cell level.
The finding that /3-catenin expression is high in primitive haematopoietic progenitor 
cells is in keeping with /3-catenin’s well documented role as a transcriptional mediator 
of self-renewal within this cell type (Reya et al., 2003; Zhao et al., 2007; Holmes et al., 
2008; Congdon et al., 2008). Such a role in these cells has not been documented 
previously for y-catenin even though results from this study and others suggest y-catenin 
may have transcriptional activity (Simcha et al., 1998; Kolligs et al., 2000; Williams et 
al., 2000; Zhurinsky et al., 2000a; Muller-Tidow et al., 2004; Maeda et al., 2004; 
Fukunaga et al., 2005). No significant differences in expression o f y- or /3-catenin were
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observed between the two respective types o f primitive CD34+ haematopoietic cell 
(CD34+38'LT-HSC and CD34+38+ committed progenitor cells). If anything a slight rise 
in expression was associated with CD34+CD38+ progenitor cells which would fit with 
the apparent rise in expression associated with myeloid differentiation. These findings 
are in agreement with Jamieson et al. (Jamieson et al., 2004) who, using a similar 
method, detected no discernable differences in /3-catenin expression between HSC and 
committed progenitor cells.
The finding that y- and /3-catenin expression actually increases with haematopoietic 
differentiation is perhaps in contrast to the pattern of expression observed in other 
normal tissues. In the gut, a small pool o f stem cells (termed Paneth cells) reside in the 
intestinal crypts with high self-renewal potential and thus high /3-catenin expression 
(Batlle et al., 2002; Van de Wetering et al., 2002). These cells continually replenish the 
high-tumover o f differentiated villus epithelium which have abrogated self-renewal 
capability and thus low /3-catenin expression (Clevers, 2006).
Lower levels o f catenin protein were identified in lymphocytes, a finding partly backed 
up by Chung et al. (Chung et al., 2002) who noted a low level o f  /3-catenin protein in 
normal peripheral blood T-cells. Furthermore removal of y-catenin seems to have no 
consequences for thymocyte development (Goux et al., 2005). A number of studies 
have implicated canonical Wnt signalling in effective lymphopoiesis (Reya et al., 2000; 
Pongracz et al., 2006; Dosen et al., 2006; reviewed by Staal and Sen, 2008). The 
finding that expression of either catenin was completely absent in terminally 
differentiated erythrocytes is in agreement with a study o f the erythrocyte proteome that 
found no catenins present (Pasini et al., 2006). Indeed, there is little evidence that Wnt 
signalling can influence erythrocytes.
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3.5.2 Catenins are both similarly and reciprocally localised in normal 
haematopoietic development
The investigations into catenin subcellular localisation by CLSM were crucial in 
attempting to link function to the overall levels observed in the initial part o f the study. 
Intriguingly, y- and /3-catenin exhibit reciprocal localisation in CD34+ cells suggesting 
distinct functions and independent regulation o f translocation in early haematopoiesis. 
Nuclear exclusion of y-catenin at this early stage o f haematopoiesis would imply a 
structural role in these cells. A function with which y-catenin is known to participate is 
in adhesion both within adherens junctions (reviewed by Takeichi, 1990) and 
desmosomes (Koch and Franke, 1994; Lewis et al., 1997). However, to our knowledge 
such homotypic (same cell to cell) adhesive junctional structures are not present or 
relevant for haematopoietic cells. Heterotypic (joining of two different cell types) 
adhesion has previously been reported for haematopoietic cells (Allport et al., 2000) and 
is known to anchor HSC/progenitor cells within BM stroma. However whether this 
interaction is governed by cadherin-catenin complexes is unresolved and there remains 
considerable debate as to whether cadherins (e.g. N-cadherin) are actually expressed on 
HSC (Kiel et al., 2007; Hooper et al., 2007; Haug et al., 2008; Kiel et al., 2009; 
Hosokawa et al., 2010; Li and Zon, 2010). Irrespective of this the y-catenin signal 
detected in CD34+ cells by CLSM did not appear to be exclusively membranous. It is 
plausible that this cytosolic localisation may represent a primed reservoir o f y-catenin 
that is nuclear translocated upon myeloid differentiation.
That /3-catenin is predominantly nuclear localised in CD34+ cells strongly suggests a 
transcriptional function in early haematopoiesis. This is in keeping with the wealth of 
documented evidence implicating /3-catenin with a role in self-renewal in these cells 
(Reya et al., 2003; Willert et al., 2003; Jamieson et al., 2004; Zhao et al., 2007; Holmes 
et al., 2008; Kim et al., 2009; Nemeth et al., 2009), and this study is not the first to 
image /3-catenin in the nuclei o f HSC by CLSM (Jamieson et a l , 2004; Congdon et al.,
2008). An interesting observation made (but not so much for y-catenin) was the extra- 
nuclear presence of intense foci of/3-catenin staining (as seen in Figure 3.25A and B ). It 
is unknown whether these punctate aggregates represent genuine biological 
phenomenon or staining artefact. Such aggregates have been observed in other studies
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utilising /3-catenin immunofluorescence by CLSM and have been suggested to be 
indicative of genuine biological events. A study by Kim et al. (Kim et al., 2003b) 
concluded that the foci represent cytoplasmic vesicles containing /3-catenin and other 
Wnt signalling components such as Axin and DVL. Alternatively, a study by Dashwood 
et a l (Dashwood et al., 2005) demonstrated that the aggregates contained /3-catenin 
localised within lysosomal vesicles.
The presence of y- and /3-catenin in the nuclei o f differentiated granulocytes in similar 
nuclear/cytosolic (N/C) ratios is particularly interesting for two reasons. Firstly, the 
localisation o f both catenins suggests reciprocal directions o f translocation from 
HSC/progenitor level. That is, y-catenin translocated from cytoplasm to nucleus, whilst 
/3-catenin appeared to have shifted from nucleus to cytoplasm. This implies that a tightly 
regulated mechanism exists governing the nuclear entry or exit o f both catenins in 
normal haematopoiesis, and that this system can act independently for each catenin 
(discussed further below). Secondly, the increased presence o f y-catenin, and retained 
expression o f /3-catenin, in the nucleus would insinuate a potential transcriptional role 
within granulocytes. Although infrequently reported, translocation of y-catenin has been 
observed elsewhere in normal development whereby nuclear localisation of y-catenin 
was found to be important for anterior axis duplication within developing Xenopus 
embryos (Kamovsky and Klymkowsky, 1995; Rubenstein et al., 1997). In granulocytes, 
the highest level o f nuclear catenin was evident in relatively immature CD15+ subsets 
which had just began, but not finished, the process of nuclear segmentation (see Figure 
3.27B). A  study by Serinsoz et al. (Serinsoz et al., 2004) appeared to partly corroborate 
these observations by also noting high /3-catenin expression in immature granulocytic 
cells, albeit by immunohistochemistry rather than CLSM. This finding would suggest 
that any potential transcriptional activity of y- and /3-catenin would be more relevant to 
early granulopoietic development. Such a hypothesis is interesting given that severely 
reduced LEF-1 (of which both catenins are known to bind in order to transduce a Wnt 
stimulus) in granulopoiesis leads to congenital neutropenia (CN; (Skokowa et al., 
2006)). In this study the highest level o f LEF-1 in healthy individuals was present in 
promyelocytes (similar to catenins) and CN arrested promyelocytes exhibited defective 
expression o f the well established catenin target genes cyclinDl (Shtutman et al., 1999),
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myelocytomatosis oncogene (c-myc or myc; (He et al., 1998)) and survivin (Kim et al., 
2003a). However to infer such a connection would be highly speculative, especially 
given that LEF-1 has been shown to have /3-catenin independent activity through the 
transforming growth factor (3 (TGF-/3) (Nawshad and Hay, 2003) and Notch (Ross and 
Kadesch, 2001) pathways, and may be activated by other unknown catenin-like 
molecules (reviewed by Staal and Luis, 2010).
The CD14+ monocytes represented the most morphologically diverse subset analysed 
and the distribution o f catenin was also heterogeneous. O f particular interest were the 
large degrees o f nuclear translocation exhibited by y-catenin within these cells, indeed 
the largest observed o f all the analysed subsets. Specifically, a rare subgroup (<10%) of 
the CD14+ monocyte pool exhibited intense and heavy nuclear localisation o f y-catenin 
(featured in Figure 3.29E  and F). This subgroup is highly likely to represent cells 
responsible for generating the ‘shoulder’ o f  intense fluorescence observed consistently 
in monocyte MFI histograms (example in Figure 3.18E). Although distribution o f (3- 
catenin was similar in monocytes, nuclear localisation to the same intensity was not 
observed suggesting an exclusive transcriptional role for y-catenin within these cells. 
Incidentally, a study by Tickenbrock et al. (Tickenbrock et al., 2006) would agree with 
the distribution of /3-catenin observed in these cells, with their investigations also 
detecting cytosolic and nuclear forms by CLSM.
Initially, it was queried whether this unique monocytic sub-group could represent an 
‘activated’ population following exposure to a stimulus such as bacterial 
lipopolysaccharide (LPS), interferon-y (IFN-y) or tumour necrosis factor-o; (TNF-cv), 
thus implicating y-catenin in a potential immune function. Such a role has been 
implicated for /3-catenin and Wnt signalling previously in monocytes (Monick et al., 
2001; Staal et al., 2008; George, 2008; Otero et al., 2009). However, an overnight 
incubation with IFN-y appeared to not significantly promote the nuclear translocation o f 
y-catenin in isolated human monocytes (data not shown). Alternatively, given the 
consistent nuclear morphology (smooth oval or often kidney-bean shaped) of this 
subgroup, these monocytes could represent a developmental intermediary (as previously
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characterised by (Meuret et al., 1974)), requiring the transcriptional capabilities o f y- 
catenin at this stage o f monocyte/macrophage differentiation. However, recent studies 
have suggested that the make-up of the monocyte population is actually far more 
complex than initially presumed (reviewed by Gordon and Taylor, 2005 and Robbins 
and Swirski, 2010) and therefore these cells could represent a developmental subset 
(though this would have to be substantiated through use o f additional markers). There 
seems to be a degree of consensus amongst a number o f studies that catenins, and more 
general Wnt signalling, contribute to the trans-endothelial migration o f monocytes 
(Sandig et al., 1997; Allport et al., 2000; Thiele et al., 2001; Tickenbrock et al., 2006; 
Lee et al., 2006). Indeed the level o f y-catenin was actually shown to fluctuate within a 
VE-cadherin adhesion complex during this physiological process (Allport et al., 2000). 
One study showed frizzled receptors (which bind a Wnt ligand) expressed on 
monocytes, which no doubt contributed to the Wnt-3A mediated increase o f /3-catenin 
observed in these cells (Tickenbrock et al., 2006). This reaction was shown to increase 
the adhesive properties of monocytes to endothelial layers, although a lack o f Wnt target 
gene expression (c-myc and connexin43) implied this was not a transcriptional-mediated 
effect of /3-catenin. In a similar investigation by Lee et al. (Lee et al., 2006) lithium 
chloride treatment of THP-1 cells (monocytic cell line) enhanced adhesion to 
endothelium, but again this could not be attributed to any transcriptional upregulation o f 
established adhesion molecules. Conversely, Thiele et a l (Thiele et al., 2001) proposed 
that /3-catenin could not be involved with cadherin-mediated adhesion because they 
failed to detect any such molecules on human monocytes, and furthermore failed to 
observe any activation o f the TCF/LEF promoter upon induction o f /3-catenin. An 
adhesive function for y-catenin in this unique subgroup o f monocytes does not seem 
likely from findings o f this study given that y-catenin is intensely nuclear localised. 
Such a function would require y-catenin to be distributed to the membrane as seen for a- 
and /3-catenin during this process (Sandig et al., 1997), though the monocytes in these 
experiments were not in contact with endothelium.
Characterisation of y-Catenin and /3-Catenin Expression in Normal
Haematopoiesis
3.5.3 Multiple mechanisms could regulate the nuclear localisation of 
catenin in haematopoietic development
The movement of proteins (especially those as large as catenin ~85-90kDa) in and out 
of the nucleus is a tightly regulated process. In the case of the classical import pathway, 
a protein’s nuclear localisation sequence (NLS) binds an NLS receptor comprising two 
cytosolic proteins: importin-ce and importing, which subsequently docks the complex to 
a nuclear pore by binding nucleoporins (reviewed by Nigg, 1997). The protein is then 
translocated through the nuclear pore utilising the small soluble GTPaseRan/TC4 
(Melchior et al., 1993; Moore and Blobel, 1993) and plO (Moore and Blobel, 1994; 
Paschal et al., 1996), in an energy-dependent process. Studies have suggested that the 
central armadillo domains of /3-catenin (and hence y-catenin) are sufficiently similar to 
the HEAT6 repeats of the importing central domain to allow nuclear translocation of 
these proteins through direct interaction with nuclear pore proteins (Fagotto et al., 1998; 
Yokoya et al., 1999). However, this has been challenged more recently by a study 
showing /3-catenin cannot associate with nuclear pore proteins (Suh and Gumbiner, 
2003), and it seems unlikely that unregulated entry of /3-catenin would be desirable in 
normal cells. Indeed this study and others (Cong and Varmus, 2004; Krieghoff et al.,
2006), are incompatible with unregulated entry of p and y-catenin and it is doubtful that 
NLS or even nuclear export sequences (NES) exist for either catenin.
Nuclear chaperone proteins have been documented to assist nuclear translocation or 
export of proteins. A wealth o f candidates have been proposed to regulate the nuclear 
localisation o f catenin, including APC (Henderson, 2000; Henderson and Fagotto, 
2002), Axin (Cong and Varmus, 2004; Wiechens et al., 2004), Chibby (Li et al., 2010), 
mothers against decapentaplegic homo log 3 (Smad-3) (Zhang et al., 2010), menin (Cao 
et al., 2009), zinc finger protein 639 (ZASC-1) (Bogaerts et al., 2005), insulin-like 
growth factor-1 (IGF-1) (Chen et al., 2005), Presenilin-1 (Raurell et al., 2006), pygopus 
(Townsley et al., 2004a) and B-cell CLL/lymphoma-9 protein (BCL-9) (Krieghoff et 
al., 2006). Interestingly, TCF-4 (Maeda et al., 2004; Krieghoff et al., 2006) and LEF-1
6 HEAT repeats are tandemly repeated, 37-47 amino acid long modules occurring in a number of 
cytoplasmic proteins, including the four name-giving proteins huntingtin, elongation factor 3 (EF3), the 
65 Kd alpha regulatory subunit of protein phosphatase 2A (PP2A) and the yeast PI3-kinase TORI. HEAT 
repeats form a rod-like helical structure and appear to function as protein-protein interaction surfaces.
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(Behrens et al., 1996; Huber et al., 1996; Simcha et al., 1998) have also been shown to 
translocate y-catenin and /3-catenin to the nucleus. Given that these molecules are the 
target complex for Wnt signalling, and the fact they carry an NLS, raises the intriguing 
possibility o f a ‘piggy back’ mechanism for catenins en route to transducing a Wnt 
signal. The finding that some o f the aforementioned chaperones interact with /3-catenin, 
but not y-catenin, would fit with the apparent reciprocal localisation of /3-catenin and y- 
catenin observed during haematopoietic development. Since none o f the above 
candidate shuttling mechanisms have been examined within a haematopoietic context it 
is difficult to identify which of these potential mechanisms are operating within this 
context.
Post-translation modification o f /3-catenin is also known to affect its translocation. 
Whilst serine/threonine phosphorylation o f the catenin NH2-terminus targets the 
molecule for degradation, phosphorylation (especially of tyrosine residues) has been 
reported to promote it’s nuclear translocation and enhance transcription ( Bonvini et al., 
2001; Piedra et al., 2001; Ilan et al., 2003; Bourguignon et al., 2007; Wu et al., 2008). 
This has also been demonstrated in a haematopoietic context with FLT-3 (Kajiguchi et 
al., 2007). In AML, FLT-3 internal tandem duplication and tyrosine kinase domain 
mutations (FLT3-ITD and FLT3-TKD, respectively) were shown to increase tyrosine 
phosphorylation o f /3-catenin, relative to wt FLT-3 receptor, leading to nuclear 
accumulation.
As well as nuclear import mechanisms, it is likely that nuclear export mechanisms may 
be just as relevant for regulating nuclear levels of y- and /3 -catenin in normal 
haematopoietic subsets. Many o f the candidate chaperone proteins described in the 
above section have also been linked with transporting catenin out o f the nucleus 
including APC (Henderson, 2000), Axin (Wiechens et al., 2004), and menin (Cao et al.,
2009). Additionally, a novel nuclear /3-catenin binding protein, Ran binding protein 3 
(RanBP-3), was discovered by Hendriksen et al. to antagonise TCF-4 mediated 
transactivation in human cell lines by re-localising active /3-catenin from the nucleus to 
the cytoplasm (Hendriksen et al., 2005). Interestingly, one report has shown that whilst
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APC and Axin enrich /3-catenin in the cytoplasm, and TCF and /3-catenin co-activators 
(BCL9 and Pygopus) increase nuclear /3-catenin, they do not accelerate the export or 
import rate of /3-catenin (Krieghoff et al., 2006). This would suggest that regulation o f 
/3-catenin (and indeed y-catenin) subcellular localisation could represent a dynamic 
balance between shuttling and retention. Thus, it is tempting to speculate that many o f 
the haematopoietic cells exhibiting high nuclear catenin may also harbour high levels o f 
the nuclear binding partners such as TCF4, pygopus and BCL-9.
Finally, in a related theme, junctional proteins (such as cadherin and Q'-catenin) have 
been frequently shown to negatively regulate the nuclear level o f catenin (and hence 
Wnt signal transduction), by sequestering it from the nucleus and to adhesion 
complexes at the cell membrane instead (Fagotto et al., 1996; Simcha et al., 1998; 
Orsulic et al., 1999; van Hengel et al., 1999; Giannini et al., 2000; Gottardi et al., 2001; 
Stockinger et al., 2001; Nelson and Nusse, 2004; Gottardi and Gumbiner, 2004). 
Establishment o f the cadherin expression profile (type and level) for haematopoietic 
cells (of which there is much debate) would first have to be performed before such a 
mechanism could be proposed for the regulation o f catenin localisation observed in 
developmental subsets.
In summary, this chapter has provided the first comprehensive assessment o f the 
expression of y- and /3-catenin in normal haematopoiesis. Most notably, it seems neither 
of the proteins has HSC/progenitor restricted expression and are thus likely to serve 
roles in more developed haematopoietic cells. This study has also raised important 
questions of the precise role y-catenin in myeloid differentiation, and how subcellular 
localisation o f catenin is regulated, issues of which are addressed in Chapter 5. 
However, it is next important to examine if, and how, normal expression o f these 
proteins is dysregulated in acute myeloid leukaemia which is investigated in the 
following chapter.
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4 - Characterisation of y-Catenin 
Expression in Acute Myeloid 
Leukaemia and Implications 
 for Patient Survival
4.1 Introduction
The previous chapter examined the developmental expression of y-catenin and 
determined the subcellular localisation of expression. Such information, however, is not 
available for primary AML blasts. Evidence from this laboratory and others suggests y- 
catenin is dysregulated in AML (Zheng et al., 2004; Muller-Tidow et al., 2004; Tonks 
et al., 2007), particularly in the presence of aberrant translocation products (see 
introductory section 1.3.3% but little is known of its pathological relevance.
It remains to be determined if y-catenin protein is dysregulated in primary AML blasts 
and how this compares with normal levels in haematopoietic progenitor cells. If  protein 
expression is abnormally high (which the mRNA levels would suggest (Tonks et al.,
2007)) then it is necessary to characterise the subcellular location of this protein within 
these malignant cells. Knowledge o f the intracellular distribution provides an indication 
o f the functional significance o f overexpression with a nuclear presence implying a 
transcriptional function. The previous chapter has suggested not only that y-catenin (and 
/3-catenin) is capable o f shifting localisation with development, but that this is a tightly 
regulated process in normal haematopoiesis. How this system is maintained, if at all, in 
AML cells remains unknown.
The inappropriate nuclear translocation o f /3-catenin in colon cancer, arising from 
mutations in the adenomatous polyposis coli (APC) protein (Korinek et al., 1997; Morin 
et al., 1997), is a well characterised pathological mechanism, although there appears to 
be no clear consensus on the prognostic influence (Hugh et al., 1999; Chung et al.,
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2001; Baldus et al., 2004; Wong et al., 2004; Wong et al., 2005; Martensson et al., 
2007; Elzagheid et al., 2008; Horst et al., 2009). Whether y- or /3-catenin have a 
pathological role in AML is not well established, although dysregulated /3-catenin 
expression has previously been identified in AML blasts and linked with an adverse 
prognosis (Ysebaert et al., 2006; Xu et al., 2008). However, for such a heterogeneous 
disease, these studies were very small and thus unlikely to be definitive.
How y-catenin expression (mRNA or protein) contributes to the pathology o f AML is 
thus far unanswered and by no means (despite homology with /3-catenin) predictable. 
Although one study has suggested y-catenin is a mediator of self-renewal in 
leukaemogenesis (Zheng et al., 2004) (supported by unpublished data from this 
laboratory, see Appendix 6), other studies in different disease settings have associated y- 
catenin with a tumour suppressor role (Aberle et al., 1995; Simcha et al., 1996; 
Charpentier et al., 2000; Polychronopoulou et al., 2002; Breault et al., 2005; Misaki et 
al., 2005; Shiina et al., 2005). The large number of patient samples and clinical 
information available through the AML trials will allow this question to be addressed.
Finally, evidence exists (in other contexts) that these proteins are capable o f influencing 
not only total levels of one other, but also their respective subcellular locations 
(Salomon et al., 1997; Miller and Moon, 1997; Simcha et al., 1998; Sadot et al., 2000; 
Zhou et al., 2007; Li et al., 2007). Therefore if the stringent regulation o f /3 and y- 
catenin observed in normal haematopoiesis is lost in AML this could give rise to 
cooperating or even opposing functions in AML. For this reason it is important to 
analyse the expression and location of both these catenins.
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4.2 Aims
In order to establish whether y-catenin expression is dysregulated in AML, and whether 
this has prognostic implications for the patient, the aims of this chapter were:
1) To validate a large cohort of AML patient y-catenin mRNA values, and 
determine the effect o f mRNA expression on patient survival by correlation with 
AML clinical parameters.
2) To establish how y-catenin protein is expressed in AML blasts relative to normal 
haematopoietic progenitor cells.
3) To examine the subcellular localisation o f y-catenin expression in AML blasts 
and compare this with /3-catenin, and then to observations made for normal 
haematopoiesis.
4) To investigate the significance of the subcellular localisation of y- and /3-catenin 
protein on AML patient survival using a similar analysis to above (point 1).
4.3 Materials and Methods
4.3.1 The statistical analysis of the effect of y-catenin mRNA expression on 
AML patient survival
4.3.1.1 The validation o f Affymetrix microarray mRNA values by qRT-PCR
Before a large cohort of patient y-catenin mRNA expression values could be used for 
patient survival analysis it was first necessary to validate these values using an 
alternative mRNA assay. Affymetrix (California, USA) Micro Array Suite version 5 
(MAS5.0)-normalised (as described in Liddiard et al., 2010) y-catenin mRNA values 
from Affymetrix HGU133A GeneChip® hybridization were validated using quantitative 
Reverse Transcriptase - Polymerase Chain Reaction (qRT-PCR).
Patient RNA (of high quality, as assessed by Agilents Bioanalyser 2000 as in (Haferlach 
et al., 2010)) isolated by Trizol lysis and reverse transcribed into cDNA as described
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elsewhere (Tonks et al., 2007; Haferlach et al., 2010), was already available from a 
random selection o f 19 AML patient samples (from the main cohort of 243 patients in 
Table 4.2 below). For each AML sample, a 10/d qRT-PCR reaction was prepared 
containing 50ng cDNA, 1/d FastStart DNA SYBR Green I master mix (Roche), 3mM 
MgCb, 500nM forward and reverse y-catenin or ABL (Abelson murine leukaemia viral 
oncogene homo log 1) primers (Eurofins MWG Operon, Ebersberg, Germany, see Table 
4.1) and made to volume with water. A 40-cycle qRT-PCR was performed on a 
LightCycler 2.0 (Roche) with an annealing temperature of 60°C. The relative level of y- 
catenin mRNA in each AML patient sample was assessed based on the 2'AACt method 
(Schmittgen and Livak, 2008), summarised in Equation 4.1 below. Briefly, the level of 
y-catenin mRNA was normalised between samples by taking the Cj (cycle threshold) 
value (the cycle number whereby the fluorescence detection becomes greater than 
background and exponential) and subtracting the Cj level obtained from a housekeeping 
internal control gene, in this case ABL. The degree o f correlation between the two 
techniques was assessed using Pearson’s correlation coefficient (R) with the software o f 
section 2.8.
Relative mRNA level GOI = C tg o /  -  C t / c g
Where;
Ct = Cycle threshold 
GOI = Gene of interest 
ICG = Internal control gene
Equation 4.1 -  Equation based on 2'AACt method for calculating relative mRNA 
level for a gene of interest
Table 4.1 - Primers used for qRT-PCR validation of Affymetrix microarray.
5 ’-ACTGAACTCC ACCGACCAAC-3 ’ 3’-CACCCTGGAGAGAGAAGCTG-5’
5 ’-CCCAACCTTTTCGTTGC ACTGT-3 ’ 3 ’-CGGCTCTCGGAGGAGACGTAGA-5 ’
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4.3.1.2 The clinical endpoints used in statistical analysis o f  AML patient 
survival
To determine the relevance of y-catenin mRNA dysregulation on AML patient 
prognosis, merged MAS5.0 normalised RNA values previously obtained from 
Affymetrix HGU133A and HGPlus 2.0 GeneChip® hybridisations (Tonks et al., 2007) 
were correlated with available patients survival data for 243 AML patients enlisted in 
the MRC/NCRI AML trials 10 to 15. Demographic and clinical details of the AML 
patient cohort, such as age, sex and French-American-British (FAB) type are featured in 
Table 4.2 below.
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Table 4.2 - Clinical data for 243 AML patients included in y-catenin mRNA survival analysis.
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4.3.1.3 Statistical techniques used to assess AML patient survival
Statistical analyses were kindly assisted by Dr. Robert Hills using a previously 
described statistical model (Gale et al., 2005) and SAS version 9.1.3 software (SAS 
Institute Inc., Buckinghamshire, UK). The Wilcoxon 2-sample test (for continuous 
data), Mantel-Haenszel test for trend (for ordinal data), and the chi-square test (for 
heterogeneity) were used to test for differences in clinical and demographic data by y- 
catenin mRNA level. Kaplan-Meier life tables were constructed for survival data and 
were compared by means o f the log-rank test. Follow-up was up available for the vast 
majority o f  patients, and the small number of patients lost to follow-up were censored at 
the date they were last known to be alive. Analysis o f time-to-event data was performed 
using standard log-rank methods and odds ratio (OR) plots. Univariate analysis was 
used to examine the association between y-catenin mRNA level and CR rate, and 
univariate Cox models were used to analyze OS, DFS, and RR. Univariate models were 
adjusted for known baseline diagnostic variables including age, white blood cell count, 
sex, WHO performance status, de novo/secondary disease and cytogenetic risk group, 
with interaction for each with y-catenin mRNA level tested using Pearson’s correlation 
coefficient (R). Because o f multiple testing, the level o f significance was set at / ><0.05 
for all tests. All P  values are 2 tailed. Odds Ratio (OR) and 95% confidence intervals 
(Cl) are quoted where relevant. In all cases an OR <1 indicates a benefit for patient 
prognoses, whilst OR >1 are indicative o f adverse patient prognoses.
4.3.2 Source of primary AML blasts and normal CD34+ haematopoietic 
cells
Peripheral blood (PB) or bone marrow (BM) was obtained from AML patients enrolled 
in the MRC-NCRI AML clinical trials following informed consent. Mononuclear cells 
(containing AML blasts) were isolated and cryopreserved in the tissue bank according 
to clinical trial protocol as previously described (Pallis et al., 2001). AML samples were 
rapidly thawed (2.2.5) and assessed for a minimum of 75% viability as judged by light 
microscopy prior to use in experiments. Normal human neonatal cord blood (CB) was 
obtained as described in section 2.2.3 and the CD34+ haematopoietic progenitor cell 
population enriched to over 85%, as described in section 2.4.
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4.3.3 The determination of y-catenin protein level in AML blasts versus 
normal CD34+ haematopoietic progenitor cells
To establish whether y-catenin protein expression (like mRNA) was dysregulated in 
primary AML blasts, total levels were compared to that from normal human CD34+ 
haematopoietic progenitor cells. Whole cell protein homogenate was isolated (2.6.1) 
from 54 individual AML blast samples (for patient demographic and clinical details see 
Table 4.3) and CD34+ cells (from 3 separate CB samples) and Western blotted as 
described in sections 2.6.3-2.6.7. To compare y-catenin protein expression (as 
determined by densitometry) from AML blasts and CD34+ cells, all samples were first 
normalised to /3-actin to control for minor differences in protein loading. To control for 
variation in transfer and detection sensitivity between gels, actin-normalised values 
were further normalised to the signal obtained from the 20kDa band on the protein 
ladder. This marker was always derived from the same batch and loaded in the same 
way (2 0 /d) on each gel, thus acting as a marker of consistency on each gel immuno- 
blotted. A K562 lysate served as a positive control for the primary y-catenin antibody, 
as the previous chapter has shown these cells contain high levels of endogenous y- 
catenin.
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Table 43 - Clinical data for the 54 AML patients included in whole blast y-catenin protein analysis.
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4.3.4 The determination of y- and j3-catenin subcellular location in AML 
blasts
The subcellular localisation o f /3 and y-catenin in AML blasts were assessed by CLSM 
(y-catenin only) and Nuclear/Cytosol (N/C) Western blotting as follows below.
4.3.4.1 The determination o f y-catenin subcellular expression in AML blasts by
CLSM
For subcellular expression analysis by CLSM, cells were pre-labelled with the CD34-PE 
mouse monoclonal antibody featured in Table 3.2 using the associated method of 
section 3.3.5.2. AML cells were then intracellularly stained for y-catenin using the 
optimal conditions highlighted in section 3.3.5.3 with the necessary modifications 
required for CLSM analysis as described in 3.3.7.3. CLSM images were acquired and 
analysed as before in sections 3.3.7.4 and 3.3.7.5, respectively. The blasts of five AML 
patient samples were analysed in total all o f which were FAB type MO or M l.
4.3.4.2 The determination o f  y- and (3-catenin subcellular localisation in AML
blasts by Western blotting
For subcellular analysis o f catenin by N/C Western blotting, 59 AML samples were 
processed as described in methods section 2.6.2. Demographic and clinical details were 
available for 49 patients of this cohort and are featured in Table 4.4. Nuclear and 
cytosolic homogenate were Western blotted and analysed as in sections 2.6. 3-2.6. 7. The 
mouse monoclonal antibodies used to detect y- and /3-catenin by immuno-blotting are 
described in section 3.3.3. The normalisation technique described above (4.3.3) was 
again applied to allow y- and /3-catenin localisation comparisons between AML samples 
blotted on different gels. The correlations between cytosolic/nuclear y-catenin and or 
cytosolic/nuclear /3-catenin, was assessed using Spearman’s rank correlation coefficient 
(R) test and the degree of significance obtained via the Student’s t-test.
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Table 4.4 - Clinical data for 49 AML patients included in N/C fractionated catenin protein analysis
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4.3.5 The correlation of Affymetrix microarray mRNA values with y- 
catenin protein from Western blotting
It was necessary to determine any correlation between y-catenin mRNA and y-catenin 
protein level within AML blasts. To examine this, cytosolic protein values from the 
fractionated AML samples of section 4.3.4 {Table 4.4), were compared with 
corresponding microarray values (obtained from section 4.3.1), where available. The 
degree of correlation between normalised y-catenin mRNA and normalised cytosolic 
protein expression was assessed by means of a Spearman’s rank correlation coefficient 
(R) test and the degree o f significance obtained via the Student’s t-test.
4.3.6 The effect of y- and j8-catenin localisation on AML patient prognosis
To investigate whether the specific localisation of y- or /3-catenin protein to the 
cytoplasm or nucleus had any implications for AML prognosis these values were used 
for survival analyses. Respective, normalised cytosolic and nuclear protein values for y- 
and /3-catenin, were generated from the 49 patients (featured in Table 4.4) o f section 
4.3.4, were each correlated with survival parameters measured within the MRC/NCRI 
AML trials, exactly as outlined above {4.3.1.2 and 4.3.1.3).
4.4 Results
4.4.1 The validation of microarray derived y-catenin mRNA levels by 
qRT-PCR
In order to utilise y-catenin mRNA values from a cohort o f 243 AML trial patients for 
survival analyses it was first necessary to validate these values using qRT-PCR. A 
random selection o f 19 patients from within the bigger cohort featured in Table 4.2 were 
compared for y-catenin expression between microarray and qRT-PCR. A highly 
significant correlation (R=0.85, P<0.001) was found between MAS5.0 normalised RNA 
values from the Affymetrix HGU133A GeneChip® hybridization and the relative y- 
catenin mRNA level obtained from qRT-PCR cycle threshold analysis {Figure 4.1). 
This finding would suggest that the level of y-catenin mRNA detected by microarray 
closely reflects the actual level present within primary AML patient blasts.
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Figure 4.1 - The validation of y-catenin mRNA detection by m icroarray using 
qRT-PCR.
The correlation between Affymetrix microarray and qRT-PCR in the detection o f y- 
catenin mRNA in AML blasts of 19 patients. MAS5.0 normalised y-catenin values from 
each patient by microarray are compared to ABL normalised y-catenin values for the 
corresponding sample obtained from qRT-PCR. Pearson’s correlation coefficient (R) 
gives the degree of correlation between the two techniques,* /*<().0 0 1 .
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4.4.2 y-Catenin mRNA expression is associated with poor prognosis in 
AML
To examine the consequences o f y-catenin mRNA expression on AML patient survival, 
MAS5.0 normalised RNA values previously obtained from Affymetrix HGU133A and 
Plus 2.0 GeneChip hybridisations (Tonks et al., 2007), were correlated with clinical data 
for the same 243 AML patients enlisted in the UK AML trials. It should be noted that 6  
patients that were not intensively treated were removed from the final analysis, in order 
to avoid any survival bias.
Statistical analysis o f AML patient demographic data (median follow up 64 months, 
range 7 months to 17 years) showed that y-catenin gene expression was significantly 
associated (PO .O l) with favourable cytogenetics (chromosomal aberrations indicative 
of a good prognosis including t( 15; 17), t(8;21) and inv(16)). Although not reaching 
statistical significance, there also appeared to be trends for y-catenin gene level to be 
linked with a better WHO performance status (P=0.07) and lower AML patient age 
(P=0.l).
Following adjustment of the clinical data for the known baseline diagnostic variables 
outlined in section 4.3.1.3, statistical analysis o f AML survival data revealed a 
significant reduction in CR rate in association with higher y-catenin mRNA levels (OR 
1.25 per log increase, P<0.05, Cl 1.03-1.51). Importantly, the analysis further 
demonstrated that this lower CR rate appeared to arise from more resistant disease (OR 
1.60 per log increase, P<0.01, Cl 1.18-2.18). No discernible effects on RR, DFS or OS 
for AML patients were observed.
This data imply that although y-catenin mRNA expression is associated with favourable 
prognostic indicators, as a single entity it is associated with an adverse prognosis for the 
AML patient.
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4.4.3 y-Catenin protein level is dysregulated in AML blasts versus normal 
CD34+ haematopoietic cells
To gauge the overall level of y-catenin protein dysregulation in AML blasts, relative 
levels from whole cell extracts of AML patient samples were compared to the levels 
present in normal human cord blood derived CD34+ haematopoietic progenitor cells. 
Owing to the low frequency of CD34+ cells within cord blood and the limited 
availability o f sufficiently large samples, just 3 samples were available from which to 
generate protein lysates. Figure 4.2A shows that y-catenin was abundant within these 
cells (in accord with 3.4.2.1). Further, a similar multiple-banding pattern as previously 
observed for the protein lysates of AML cell lines was also observed {Figure 3.10). 
These samples generated a mean normalised y-catenin protein expression value o f 
10.3±4.9.
Of the 54 AML samples Western blotted 10 were removed from analysis because the 
protein level was too low in concentration to reliably quantitate (y-catenin and (3-actin) 
leaving 44 samples in total. As can be seen from the representative Western blot 
featured in Figure 4.2B, the range o f protein expression and banding observed for y- 
catenin within the AML samples was heterogeneous and because o f this the overall y- 
catenin expression from the AML cohort (mean 32.8, med 2.2, range 0.2-279.0, n=44) 
was not significantly different from values obtained from normal CD34+ progenitor 
cells (mean 10.3, med 11.4, range 5.0-14.6, n=3, P=0.2). However, taking a threshold o f 
2 standard deviations above the normal mean ( X  + 2SD) as a marker for y-catenin 
overexpression, it can be observed from Figure 4.3 that 9 o f 44 AML samples fall into 
this overexpression category. Using the same method but subtracting 2SD from mean ( X  
- 2SD) a similar proportion (8/44) of blasts were found to underexpess y-catenin relative 
to normal CD34+ progenitor cells.
These data show that although the majority o f AML samples express y-catenin within a 
normal range, around 20% of AML patients demonstrate over- and underexpression o f 
the protein.
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Figure 4.2 - The expression o f y-catenin protein in norm al C D 34+ cells and A M L  
blasts.
A) Representative Western blot showing y-catenin protein expression obtained from 
normal haematopoietic progenitor cells (n=3) and B) from AML blasts (n=15). Patient 
samples marked with * indicate an overexpression of y-catenin protein relative to the 
normal CD34+ cells. Actin detection shows relative protein loading between samples.
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Figure 4.3 - Comparison of y-catenin protein expression between normal CD34 
cells and AML blasts.
Normalised protein values obtained from normal human cord blood derived CD34+ 
progenitor cells (n=3) and AML blasts (n=44) as determined from densitometric 
analysis. Black and red solid lines represent respective means from each cohort, whilst 
black dashed line amongst AML values represents the threshold o f X + 2SD obtained 
from normal cells, used to define y-catenin overexpression.
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4.4.4 The subcellular localisation of y- and /3-catenin expression in AML 
blasts
4.4.4.1 y-Catenin is aberrantly localised to the nucleus ofMO/1 AML blasts
To assess whether y-catenin protein localisation in AML was different from that 
observed in normal haematopoiesis, subcellular localisation in normal CD34+ progenitor 
cells (3.4.3.1) was compared to that observed in AML blasts. For a fair comparison, 
AML blasts were required which, developmentally, most closely resembled their normal 
CD34+ progenitor cell counterparts. For this, MO or Ml FAB-type samples were utilised 
since these undifferentiated leukaemias are developmentally most closely matched with 
CD34+ cells.
As described in section 3.4.3.7, normal CD34+progenitor cells demonstrated an average 
nuclear y-catenin localisation of 10%±4 (n=3) (Figure 4.4A). The average nuclear 
localisation of y-catenin in MO/1 blasts was 18%±7 (n=5) which was significantly 
greater (P<0.05). Representative images of CD34^ AML blasts displaying y-catenin 
nuclear localisation are exhibited in Figure 4.4B, and are also present (plus further 
images) in the Chapter 4 section of the supplementary disc, within Folder /, Fields 
1.2-1.8. These images clearly show a ‘hazy’, ‘grainy’ y-catenin signal within the (TO- 
PRO-3 ) nuclear region, which is not apparent in the CD34+ progenitor cells (Figure 
3.23) which lack any discemable nuclear y-catenin signal over background.
These data imply that y-catenin is aberrantly nuclear translocated in MO/1 
undifferentiated AML.
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Figure 4.4 - The subcellular localisation of y-catenin in MO/1 blasts by CLSM.
A) Summary o f average nuclear y-catenin protein localisation in normal CD34+ 
haematopoietic progenitor cells (n=3) versus MO/1 AML blasts (n=5), as given by 
CLSM. *JP<0.05. Error bars represent SD from each data. B) Various CLSM fields 
(overleaf) showing y-catenin localisation in MO/1 AML blasts with I) phase contrast, II) 
nuclear (blue), III) y-catenin (green), and IV) merged images.
Characterisation of y-Catenin Expression in Acute Myeloid
Leukaemia and Implications for Patient Survival Chapter 4
C haracterisation of y-Catenin Expression in Acute Myeloid
Leukaemia and Implications for Patient Survival Chapter 4
4.4.4.2 The subcellular localisation o f  y- and (3-catenin protein is dysregulated 
in both undifferentiated and differentiated AML
Once CLSM had identified nuclear y-catenin within a small group o f AML patient blast 
samples it was necessary to expand the number and type o f AML samples analysed. 
N/C Western blotting provided a more time- and labour-effective method for analysing 
multiple AML samples, and its efficacy for detecting nuclear translocation of catenin 
had been validated in section 3.4.1.6.
Figure 4.5A shows the subcellular localisation o f y and P-catenin protein expression in 
normal human haematopoietic cells versus the localisation in undifferentiated (Figure 
4.5B) and differentiated AML blast samples (Figure 4.6A and B). The large cell number 
required for N/C fractionation meant in vitro expansion o f normal CD34+ 
haematopoietic progenitor cells was necessary. Day 5 cultured CD34+ cells are 
predominantly CD34+ blasts while day 13 cells consist largely o f  immature white cell 
precursors.
Figure 4.5A shows how y- and /3-catenin protein is highly expressed in day 5 and day 13 
cultured haematopoietic cells which approximately encompass the range o f 
differentiation seen in M0-M5 AML. As with freshly isolated CD34+ cells this was 
mainly cytoplasmically localised. When compared to the expression observed in 
differentiated and undifferentiated AML blasts (Figure 4.5 and Figure 4.6, respectively) 
a diverse range o f y- and /3 -catenin protein intensity, banding pattern and translocation 
can be observed among all the samples; though again the majority o f catenin expression 
was cytoplasmically localised. Given the lack o f control replicates (and thus no mean or 
standard deviation), an upper threshold o f 5-fold the level o f  catenin obtained from 
normal cells was set as the marker for overexpression in AML cells. This value was 
used because the ‘X+2SD’ overexpression threshold set in the above section (4.4.3) 
actually represented 5-fold the mean obtained from normal CD34+ cells. A similar 
variation was assumed for normal cells in this analysis. Using this cut off, it was found 
that 18 o f 59 AML samples (31%) overexpressed cytoplasmic y-catenin compared to 
normal controls, a proportion not too dissimilar (2 0 %) to that obtained for total catenin
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in the above section (4.4.3). A similar number o f samples (18/59, 31%) were also found 
to have higher levels of nuclear translocated y-catenin. The same analysis for /3-catenin 
expression showed that a similar frequency of AML samples, 17/59 (29%) 
overexpressed the cytosolic form, whilst a higher proportion 22/59 (37%) exhibited 
elevated nuclear p-catenin. An interesting observation made for both catenins (but 
perhaps more accentuated for y-catenin) was the differential migration pattern of protein 
bands between the cytosolic and nuclear fractions. The significance of this multiple 
banding is investigated and discussed further within Chapter 5. A more detailed FAB 
type breakdown (for those patients where clinical data is available (49/59)) of catenin 
overexpression in AML samples is featured in Table 4.5.
Table 4.5 - Breakdown of y- and /3-catenin overexpression between FAB types of 
AML samples N/C fractionated.
9/26 (35%) 3/10(30%) 6/13(46%)
Examples = (Figure 
4.5B, patient lanes 
c, g, h, i, k, 1 and n)
(Figure 4.6A, 
patient lanes c and 
g)
(Figure 4.6B, 
patient lanes b, d, e 
and g)
8/26 (31%) 3/10(30%) 7/13 (54%)
(Figure 4.5B, 
patient lanes h, i, j, 
k and 1)
(Figure 4.6A , 
patient lanes b, c 
and e)
(Figure 4.6B, 
patient lanes c, e 
and g)
2/26 (8 %) 7/10 (70%) 5/13 (38%)
(Figure 4.5B, 
patient lanes g and
j)
(Figure 4.6A, 
patient lanes a, b, e 
and g)
(Figure 4.6B, 
patient lanes d, e 
and g)
5/26 (19%) 6 / 1 0  (60%) 7/13 (54%)
(Figure 4.5B, 
patient lanes h, i, 
and j)
(Figure 4.6A, 
patient lanes b, c, d, 
f  and g)
(Figure 4.6B, 
patient lanes b, c, e 
and g)
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Figure 4.5 - The subcellular localisation of y-catenin and /3-catenin in normal 
haematopoietic progenitor cells versus undifferentiated AML.
A) The subcellular localisation of y- and (3-catenin protein within in vitro cultured and 
expanded primary human haematopoietic cells. CB-derived CD34+ haematopoietic 
progenitor cells were purified and cultured in vitro for the time period indicated. B) 
Representative N/C Western blots showing the subcellular localisation of y- and /3- 
catenin in selected MO/1 AML blasts. Detection of j3-actin and histone HI provide an 
assessment of fractionation purity and loading.
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Figure 4.6 - The subcellular localisation of y-catenin and /3-catenin in differentiated 
AML by N/C western blotting.
Representative N/C Western blots showing the subcellular localisation of y- and /3- 
catenin in selected A) M2 and B) M4/5 AML blasts. Detection o f /3-actin and histone 
HI indicate the level of purity and protein loaded within each fraction.
Characterisation of y-Catenin Expression in Acute Myeloid
Leukaemia and Implications for Patient Survival Chapter 4
4.4.5 The level of y- and /3-catenin protein correlate in AML blasts
During the analysis o f  N/C fractionated samples in the above section (4.4.4.2) a number 
of potential relationships for y- and /3-catenin were observed. Table 4.6 summarises the 
relationships analysed, the degree o f correlation obtained and the level of significance 
for each. As illustrated in Figure 4.7A, a correlation existed between the level o f 
cytosolic y-catenin and the extent o f nuclear translocation within AML blasts (R=0.63, 
PO.OOOl). A similar relationship (although not as strong) also existed for cytosolic and 
nuclear /3-catenin (R=0.56, P<0.001) and is shown in Figure 4 .7B. This would suggest 
that, in contrast to normal haematopoiesis, the level o f cytosolic expression o f both 
catenins determines the degree o f nuclear translocation.
Figure 4.8A indicates an association between the level o f  cytosolic y-catenin and the 
level o f  cytosolic /3-catenin within the same AML samples (R=0.51, P<0.01). No 
significant correlation could be found between the level o f cytosolic y-catenin and the 
corresponding level o f nuclear /3-catenin (R=0.29, P=0.75). However, as shown in 
Figure 4.8B the levels o f  nuclear /3-catenin were significantly higher (P<0.05) when 
comparing the cytosolic y-catenin overexpressing cohort as a whole (mean 13.1±19.2; 
range 0.0-80.0, median 7.3) with the rest o f the cohort (5.6±6.9; range 0.0-26.3, median 
3.9).
The final relationship examined was between the levels o f translocated nuclear y- 
catenin and nuclear /3-catenin within AML samples. This relationship demonstrated a 
modest correlation (R=0.3, ^<0.05). When the cohort was split (as above) and the level 
o f nuclear /3-catenin compared between samples overexpressing nuclear y-catenin 
(18/59) versus otherwise normal/low levels (Figure 4.8C) the AML cohort exhibiting 
normal/low nuclear y-catenin level demonstrated an average nuclear /3-catenin level of 
5.8±6.7 (range 0-26.3, median 4.9) whilst the high nuclear y-catenin group had a 
statistically significantly higher mean of 15.6±22.2 (range 0-80.0, median 8 .6 , P<0.05).
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Overall, the data o f both this section and 4.4.4 above, suggest that both y- and /3-catenin 
protein expression is aberrantly localised in AML when compared to normal 
haematopoiesis. The results further imply that the cytosolic levels of both y- and /3- 
catenin are indicative o f their respective nuclear level. Finally, the data has identified a 
correlation between y- and /3-catenin protein, in both the cytosolic and nuclear 
compartments.
Table 4.6 - The relationships between y- and /3-catenin in AML blasts.
0.63 <0.0001
0.56 <0.001
0.51 <0.01
0.29 0.75 (not 
significant)
0.30 <0.05
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Figure 4.7 - The influence of cytosolic catenin level on nuclear translocation in 
AML blasts.
A) The correlation between the cytosolic level o f y-catenin and the degree of nuclear 
translocation in AML blasts, *P<0.0001. B) The correlation between the cytosolic level 
of /3-catenin and the degree of nuclear translocation in AML blasts, **P<0.001.
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Figure 4.8 - The relationship between y- and /3-catenin protein in AML blasts.
A) The relationship between cytosolic levels of y-catenin and jS-catenin protein within 
AML blasts, *P<0.01. B) The level of nuclear /3-catenin protein associated with AML 
blasts overexpressing cytosolic y-catenin protein versus normal/low cytosolic y-catenin 
protein, **P<0.05. C) The level of nuclear /3-catenin protein associated with AML 
blasts overexpressing nuclear y-catenin versus normal/low nuclear y-catenin, **P<0.05. 
Units are arbitrary.
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4.4.6 y-Catenin mRNA level does not correlate with y-catenin protein level
Although y-catenin mRNA values had been validated by qRT-PCR in AML blasts, it 
remained to be observed whether mRNA level correlated with y-catenin protein level 
within AML blasts. This was by no means a certainty given the high degree o f post- 
translational regulation which catenins (y and p) are subject to in normal homeostasis 
and disease.
To investigate this the 30 AML patient samples for which microarray data was available 
(from the cohort featured in Table 4.4, section 4.4.4.2) were compared with 
corresponding y-catenin protein expression values determined from Western blotting. 
Figure 4.9A shows that no significant correlation (R=0.06) was observed between y- 
catenin protein and mRNA level within AML blasts. Although a correlation could not 
be obtained, it was o f interest to know if higher mRNA levels were generally indicative 
o f higher protein levels. To examine this, the mRNA values obtained from the cohort 
above were divided into two groups based around the median (low mRNA versus high 
mRNA expression) and the y-catenin protein level compared between the two groups by 
means o f a Mann-Whitney test. As seen in Figure 4.9B, the high y-catenin mRNA 
group demonstrated a mean protein expression level o f  10.6±10.7 (range 0.4-34.8, 
median 7.5) which was higher than the mean of the low y-catenin mRNA group 6.6±7.1 
(range 0.9-23.9, median 3.2), but this difference was not significant (P=0.3). It was also 
necessary to examine whether evidence existed in the small patient cohort o f a 
relationship with y-catenin mRNA/protein and the main clinical parameter found to be 
affected in 4.4.2\ CR status. As shown in Figure 4.10A, the 30 patients where 
microarray data was available demonstrated significantly higher (P<0.05) y-catenin 
mRNA in the non-CR (mean 1.5, range 0.6-2.1, median 1.6) compared with the CR 
achieving cohort (mean 1.2, range 0.4-1.9, median 1.2). Figure 4.10B shows a similar, 
but non-significant (P=0 .1 ), difference was observed when analysing the y-catenin 
protein values. Generally, higher y-catenin protein expression was found in the non-CR 
(mean 9.9, range 0.8-34.8, median 6 .8 ) versus CR patient group (mean 5.9, range 0.2- 
24.0, median 3.3).
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Taken together, these data suggest that although higher y-catenin mRNA expression is 
generally associated with a higher y-catenin protein level, the actual degree o f 
correlation is poor. This would mean the survival phenotype obtained in section 4.4.2 is 
not necessarily related to y-catenin protein expression, though the relatively small 
number o f comparisons made could mean that the poor correlation arises from sampling 
error.
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Figure 4.9 - The correlation of y-catenin mRNA with y-catenin protein level.
A) Scatter plot showing the lack of correlation between y-catenin protein (derived from 
Western blotting) and y-catenin mRNA expression (derived from microarray) in AML 
blasts. Red dotted line shows division of cohort analysed in B. B) Box and whisker plot 
showing general level of cytosolic y-catenin protein in low y-catenin mRNA versus high 
y-catenin mRNA group.
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Figure 4.10 - The level of y-catenin mRNA and protein expression associated with 
CR status of N/C Western blotted patients.
A) Box and whisker plot showing the y-catenin mRNA status between patients 
achieving and not achieving CR (P<0.05). B) Similar plot but showing the y-catenin 
protein status between CR and non-CR patient group.
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4.4.7 The expression of y- and /3-catenin protein is not significant for 
prognosis in AML
The lack o f concordance between y-catenin mRNA and protein expression meant that 
the survival analysis performed with 237 patients in 4.4.2 was not necessarily a reliable 
indicator o f y-catenin protein expression. Therefore a survival analysis was necessary 
solely using protein values. To this end, cytosolic and nuclear protein expression values 
obtained from the patients o f section 4.4.4.2 were used in conjunction with clinical data 
where available (49 o f 59 patients, see Table 4.4), using the same strategies outlined in 
4.3.1.3.
The statistical analysis o f  AML patient clinical data (median follow up 64 months, 
range 7 months to 17 years) for fractionated AML blast samples is summarised in Table 
4.7 below. Briefly, cytosolic y-catenin protein values showed no significant relationship 
with any patient survival parameter, however, potential trends (highlighted by orange 
shaded boxes) were identified between higher y-catenin expression and poor CR rate 
and worse OS. No trends or statistically relevant associations could be found between 
nuclear levels o f y-catenin protein and any o f  the clinical parameters assessed. Similar 
trends were also between higher cytosolic /3-catenin protein expression and poor CR 
rate and worse OS. A statistically significant association (red-shaded box) was 
identified between cytosolic /3-catenin and adverse DFS, however the large confidence 
intervals bring into question the reliability o f this relationship. Finally, nuclear /3-catenin 
expression failed to reach statistical significance for all survival parameters, but trends 
were observed between higher nuclear /3-catenin and lower CR rate and increased RD.
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Table 4.7 - Summary of relevant findings from survival analysis of cytosolic and 
nuclear y- and /3-catenin.
OSCR RD DFS
2.11(0.43-10.37) 
P=0.3
1.59(0.60-4.27) 
P=0. 3
NS NS
NS NS NS NS
1.80(0.47-7.00)
P=0.3
1.55 (0.77-3.12) 
P=0.2
NS 12 .2 ( 1.3 8 - 10 8 . 1)
P<0.01
NS NS1.53(0.83-2.79)
P=0.2
1.72(0.74-3.98) 
P= 0.2
Survival param eter
Localised
catenin
C ytosolic
y-catenin
N uclear
y-catenin
C ytosolic
/3-catenin
N uclear
/3-catenin
Clinical parameters include complete remission (CR), overall survival (OS), resistant 
disease (RD), and disease-free survival (DFS). Odds ratios and 95% confidence 
intervals (in parentheses) are listed with associated significance values included below. 
NS = not significant.
4.5 Discussion
4.5.1 y-Catenin mRNA expression confers an adverse prognosis but does 
not correspond with the protein level present in AML blasts
This study sought to characterise y-catenin protein expression in primary AML blasts 
for the first time, and draw comparisons with the expression previously observed in 
normal haematopoietic development (Chapter 3). Aberrant activation o f the 
Wnt/catenin pathway has been implicated in a number o f solid cancers including breast 
(Lin et al., 2000), colon (Korinek et al., 1997; Morin et al., 1997) and liver (Monga, 
2009). Further, whilst there is plenty of evidence suggesting haematological 
malignancies such as AML (Simon et al., 2005; Wang et al., 2010; Yeung et al., 2007), 
chronic lymphocytic leukaemia (CLL) (Lu et al., 2004), chronic myeloid leukaemia 
(CML) (Jamieson et al., 2004; Zhao et al., 2007; Abrahamsson et al., 2009), acute 
lymphoblastic leukaemia (ALL) (Khan et al., 2007; Nygren et al., 2007) mantle cell 
lymphoma (Gelebart et al., 2008) and multiple myeloma (MM) (Sukhdeo et al., 2007; 
Qiang et al., 2009) arise partly due to constitutive activation o f the Wnt//3-catenin 
pathway, it remains to be established whether there is y-catenin involvement in human 
AML. Using a cohort of 243 AML trial patients and associated clinical data, this study 
analysed y-catenin mRNA gene expression for correlation with clinical outcome.
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Despite the association o f y-catenin expression with a good risk sub-type (RUNX- 
1/ETO expression (Zheng et al., 2004; Muller-Tidow et al., 2004; Tonks et al., 2007)), 
analyses o f survival correcting for this bias showed that y-catenin mRNA level was 
significantly associated with a poor CR rate (arising from resistant disease); there was 
no evidence o f any association with age at diagnosis, WBC or sex. These data indicated 
that it may be y-catenin that is primarily dysregulated and prognostic at mRNA level, 
unlike /3-catenin which was not identified as significantly dysregulated in our previous 
microarray studies (unpublished data).
In order to validate the Affymetrix GEP data, y-catenin mRNA was analysed by qRT- 
PCR which confirmed that the micro array did reflect y-catenin mRNA level. However, 
analysis o f  y-catenin protein expression by Western blot or flow cytometry did not 
correlate with mRNA expression. This is not entirely unexpected given the post- 
translational mechanisms which are known to regulate y-catenin protein stability. Lack 
of agreement between mRNA and protein level has been previously reported for both y- 
catenin (Bradley et al., 1993; Kowalczyk et al., 1994; Papagerakis et al., 2004) and /3- 
catenin (Aberle et al., 1997; Ysebaert et al., 2006; Gandillet et al., 2011). The study by 
Ysebaert et al. (Ysebaert et al., 2006) found /3-catenin mRNA level did not correspond 
with protein level and attributed this to the post-translational modifications that are 
active in AML cells. Discordance between mRNA and protein level has also been 
frequently observed in other contexts (Schindler et al., 1990; Ranganathan et al., 1998; 
Gygi et al., 1999; Chen et al., 2002; Greenbaum et al., 2003; Lee et al., 2003; Pascal et 
al., 2008). On the other hand, in model systems concordance o f y-catenin mRNA and 
protein levels has been demonstrated. Miiller-Tidow et al. (Muller-Tidow et al., 2004) 
observed y-catenin overexpression in leukaemic cell lines expressing common fusion 
proteins, such as promyelocytic leukaemia/retinoic acid receptor a  (PML/RARo) or 
RUNX-1/ETO; and in the latter case this has also been demonstrated in primary 
haematopoietic cells (Zheng et al., 2004; Tonks et al., 2007). In this study patients 
expressing RUNX-1-ETO were not distinguished by high y-catenin at the protein level, 
however further AML samples with a CBF abnormality would be needed to be analyse 
this relationship further.
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The lack o f concordance between y-catenin mRNA and protein may indicate that the 
adverse CR phenotype obtained from survival analyses either represents a chance 
finding, or that factors promoting y-catenin mRNA may also influence the expression o f 
an alternative protein impacting on CR rate. Alternatively the lack o f correlation could 
arise from sampling error o f the patients included in the correlation analysis since 
higher protein levels did show a trend towards reduced CR (.Figure 4.1 OB). 
Fundamentally, in comparison with the microarray analysis (243 patients), analysis o f y- 
catenin protein expression and localisation (49 samples) lacked the power to 
significantly demonstrate any association with outcome at the protein level. It is 
estimated at least 1 0 0  additional patients would need to be analysed to establish whether 
the trends observed have biological significance, and this may reflect the heterogeneity 
o f this disease and/or the lack o f any strong influence o f y-catenin protein expression on 
treatment outcome. The lack o f any strong survival influence from nuclear y- or (3- 
catenin has been noted before both in renal cell carcinoma (Aaltomaa et al., 2004) and 
also in colon cancer where cytosolic catenin is instead found to be more prognostically 
significant (Maruyama et al., 2000; Norwood et al., 2010).
The failure to observe any survival effect for nuclear /3-catenin expression is perhaps a
little surprising at first given its associated role with driving self-renewal/proliferation in
leukaemic cells (Jamieson et al., 2004; Zhao et al., 2007;Hu et al., 2009; Abrahamsson
et al., 2009; Wang et al., 2010; Yeung et al., 2010; Siapati et al., 2011). /3-Catenin has
also frequently been reported as overexpressed in primary AML blasts (Chung et al.,
2002; Serinsoz et al., 2004; Simon et al., 2005; Chen et al., 2009) and invariably linked
with poor survival (Ysebaert et al., 2006; Xu et al., 2008). Indeed, Xu et al. found
nuclear /3-catenin protein to be associated with unfavourable cytogenetics (-7/-7q),
lower CR rates, and worse overall survival, whilst Ysebaert et al. (Ysebaert et al., 2006)
found more general /3-catenin expression to be an independent prognostic marker
predicting poor event-free survival and shorter overall survival. However it must be
noted that these AML survival studies featured small patient numbers (<100) which are
too small in such a heterogeneous malignancy to be truly definitive. Regardless,
although these proteins serve essential roles in AML pathology, there is evidence to
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suggest they do not necessarily govern chemo-sensitivity and hence influence the 
survival outcome (Gandillet et al., 2011).
4.5.2 y-Catenin is aberrantly localised in primary AML blasts
From Chapter 3, it was clear that subcellular distribution o f y-catenin may play a role in 
normal haematopoiesis. This study is the first to report nuclear y-catenin expression in 
AML. This study observed an increase in nuclear y-catenin expression when compared 
to normal CD34+ progenitor cells suggesting that nuclear y-catenin expression 
represents an abnormality for FAB type MO/1 (undifferentiated) AML. Since nuclear y- 
catenin is a feature o f more differentiated cells 3.4.3, the same cannot be said o f the 
differentiated AML patients analysed (M2-M5).
Understanding the significance o f this nuclear y-catenin is a more challenging 
proposition. Does it represent a transcriptionally active form ?  y-Catenin’s ability to 
bind and activate TCF/LEF complexes (albeit with less efficiency than /3-catenin) has 
been demonstrated before in other model systems (Simcha et al., 1998; Kolligs et al., 
2000; Williams et al., 2000; Zhurinsky et al., 2000a; Maeda et al., 2004; Fukunaga et 
al., 2005). Within a haematopoietic context, the study o f Muller-Tidow et al. (Muller- 
Tidow et al., 2004) identified direct activation o f the c-myc promoter by increased y- 
catenin expression. Alternatively could its presence in the nucleus represent a 
functionally redundant form that has merely escaped a saturated degradation system? 
Nuclear expression has been linked with suppression o f Wnt mediated transcription 
(Miravet et al., 2002; Garcia-Gras et al., 2006). The former study identified binding 
sites on TCF-4 for both (3- and y-catenin, but demonstrated that interactions involving y- 
catenin actually hindered the transcriptional activity o f the complex in various epithelial 
cell lines.
It was less surprising to observe nuclear forms o f /3-catenin in fractionated AML blasts 
given that nuclear beta catenin has been identified in many haematological malignancies 
including CML (Jamieson et al., 2004; Abrahamsson et al., 2009), myelodysplastic 
syndrome (MDS) (Xu et al., 2008) MM (Sukhdeo et al., 2007), ALL (Khan et al., 2007;
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Nygren et al., 2007) and CLL (Lu et al., 2004). This protein is already known to be 
present and transcriptionally active in nuclei o f  normal HSCs (Reya et al., 2003; 
Jamieson et al., 2004; Scheller et al., 2006; Kirstetter et al., 2006; Holmes et al., 2008; 
Congdon et al., 2008). The data in Chapter 3 also demonstrated nuclear localisation o f 
/3-catenin in progenitor cells. Nuclear /3-catenin has already been identified in AML 
blasts (Simon et al., 2005; Xu et al., 2008; Wang et al., 2010; Gandillet et al., 2011). 
Interestingly, in the study by Xu et al. they reported a similar detection rate o f nuclear 
/3-catenin as this study (22/54 [41%] Vs 22/59 [37%]), albeit by a very different 
immunohistochemical method. Additionally, nuclear beta catenin has also been 
frequently documented within the wider cancer field including colon (Korinek et al., 
1997; Morin et al., 1997; Brabletz et al., 1998; Brabletz et al., 2000; Maruyama et al., 
2000; Kobayashi et al., 2000; Jung et al., 2001) liver (Nhieu et al., 1999), malignant 
melanoma (Rimm et al., 1999) and prostate cancers (Jaggi et al., 2005).
4.5.3 The expression of y- and /3-catenin protein correlate in AML
This study represents the first to identify a positive correlation between y- and /3-catenin 
protein expression in primary AML blasts. The finding that cytosolic y- and /3-catenin 
protein levels correlate should perhaps not be so surprising given that the stability o f  the 
two proteins is regulated by a common process (see introductory sections 1.3.1 and 
1.3.4). Hence, should any o f  these components be dysregulated in AML then a 
concomitant rise in both y- and /3-catenin might be expected. When observing 
expression o f each catenin individually, it was interesting to find that cytosolic level 
determined the nuclear level in AML blasts. This is in contrast, to observations in 
normal haematopoiesis, where nuclear catenin localisation was independent o f increased 
cytosolic expression. This implies whatever mechanism is active in normal 
haematopoietic cells regulating catenin translocation (described in length in Chapter 3 
discussion 3.5.3) is relaxed or dysfunctional in AML. Indeed, loss o f such tight 
regulation would leave the cell vulnerable to the wealth o f candidate molecules (inside 
and outside o f the Wnt signalling cascade) that have been proposed to alter catenin level 
and localisation, including FLT-3 (Tickenbrock et al., 2005; Kajiguchi et al., 2007), 
prostaglandin E2 (PGE2) (Castellone et al., 2005), protein kinase A (PKA) (Hino et al., 
2005), phosphatase and tensin homologue (PTEN) (Persad et al., 2001), Ras-related C3
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botulinum toxin substrate 1 (Rac-1) (Wu et al., 2008), Notch (Hayward et al., 2005), 
Roof plate-specific Spondin 1 (R-spondin-1) (Wei et al., 2007), v-Akt murine thymoma 
viral oncogene homologue (Akt) (Monick et al., 2001) and growth arrest-specific gene 6  
(Gas-6 ) (Goruppi et al., 2001).
A degree o f correlation was also found between y- and /3-catenin expression in the 
nucleus o f AML samples. It is unknown whether this relationship represents an 
inevitable ‘side-effect’ o f  the increased cytosolic levels o f  both proteins in these cells, or 
a co-ordinated re-localisation as has been previously reported for nuclear y- and /3 - 
catenin in other contexts (Simcha et al., 1998; Maeda et al., 2004; Li et al., 2007). This 
issue is investigated further in Chapter 5.
4.5.4 Multiple-banding of y- and /3-catenin is observed upon Western 
blotting of primary AML samples
As observed in the whole cell Western blotting o f AML cell lines in Chapter 3 (see 
Figure 3.10), multiple banding o f y-catenin and (to a lesser extent) /3-catenin was 
exhibited in the N/C fractionated lysates o f AML blasts and normal human 
haematopoietic cells. This type o f multiple banding has been observed previously for 
both y-catenin (Zheng et al., 2004; Muller-Tidow et al., 2004; Tonks et al., 2007) and /3- 
catenin (Chung et al., 2002; Simon et al., 2005; Ysebaert et al., 2006) in haematopoietic 
cells. Indeed, the study by Simon et al. also N/C Western blotted primary AML blasts 
(albeit by a different protocol) and obtained a similar variation in intensity and 
migration o f /3-catenin protein bands. Intriguingly, the migration o f catenin bands in this 
study was often different between nuclear and cytosolic fractions o f the same patient 
samples. It is highly likely that this multiple-banding pattern is indicative o f a key 
mechanism involved in the regulation o f catenins. The fact the patterns are inconsistent 
between AML (N/C) samples implies that this process may be dysregulated in 
malignancy. Exactly what mechanism this could represent is unknown. One possible 
explanation is that these bands correspond to differentially phosphorylated catenin 
molecules (see 3.5.3), as demonstrated previously for catenins in Western blotted
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samples (Ruff et al., 1997; Sukhdeo et al., 2007). This possibility is investigated further 
in Chapter 5.
Mutations in catenin protein are unlikely to be the cause o f the multiple banding, not 
least because only one such mutation has ever been reported for y-catenin in cancer 
(Caca et al., 1999). Furthermore, this was a small missense mutation to a potential 
phosphorylation site in the amino terminus, and is thus unlikely to seriously modify the 
overall protein structure to an extent where it would migrate differently through a gel 
compared to the wt form. No significant isoforms o f y- or /3-catenin exist or have been 
reported in normal human biology either.
Finally, a less exciting possibility is that these multiple migratory forms between 
cytosol and nuclear fractions may actually represent artefact generated by the respective 
lysis buffers o f the N/C fractionation kit. Such a cause is difficult to investigate given 
the manufacturer’s secrecy over the constitution o f these buffers, and is perhaps 
irrelevant given that other studies have observed the same banding patterns using 
alternative lysing techniques.
In summary, this study has shown for the first time that y-catenin protein expression is 
dysregulated in some cases o f  AML. Patient survival data would indicate that y-catenin 
mRNA expression is associated with a worse prognosis in AML, however this clinical 
phenotype could not be substantiated because o f discordance between y-catenin mRNA 
and protein level. Contrary to normal haematopoiesis, y-catenin protein is frequently 
localised to the nuclei o f  undifferentiated AML blasts, and unlike normal cells, 
translocation appears to be influenced by cytosolic accumulation. A correlation between 
y- and /3-catenin has been identified in the cytosol (and to a lesser extent in the nuclei) 
o f AML blasts, suggesting they are co-ordinately dysregulated. The next chapter seeks 
to investigate whether the relationship between y- and /3-catenin in AML blasts 
represents a correlative or causative association and, related to this, whether y-catenin 
contributes individual or combinatory effects to AML pathology.
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5 - Examination into the 
Functional Role of y-Catenin 
in Haematopoietic Cells
5.1 Introduction
Given the limited number o f studies on y-catenin in normal haematopoiesis and AML, 
many o f the results from Chapters 3 and 4 have been observational in nature. Thus, the 
main purpose o f Chapter 5, is to establish the functional roles o f y-catenin in both 
normal haematopoiesis and AML pathology.
The data o f Chapter 3 suggested that y-catenin has a role in both the early and late 
stages o f haematopoietic development. Further, preliminary experiments o f this 
laboratory (Tonks et al., 2007) suggested that ectopic expression of y-catenin in normal 
human CD34+ haematopoietic cells led to modest increases in self-renewal, although no 
significant effect on myeloid differentiation was observed. To complement these 
studies, it was necessary to assess the importance o f y-catenin for normal myeloid 
development by using an shRNA approach to deplete endogenous y-catenin in normal 
human haematopoietic progenitors. Previous studies in mice would suggest that the loss 
of y- and/or /3-catenin has no consequences for normal haematopoiesis (Cobas et al., 
2004; Koch et al., 2007; Jeannet et al., 2008), however, these studies only examined the 
functionality o f these knockout cells in a repopulation assay and did not examine the 
developmental capacity o f these cells. Further, the consequence o f y-catenin 
underexpression in human haematopoietic cells has not been previously studied.
Chapter 4 identified a correlation between the expression of y- and /3-catenin protein in
AML blasts. Although evidence exists suggesting these catenins can influence the level
and subcellular localisation o f one another in other settings (Salomon et al., 1997;
Simcha et al., 1998; Zhurinsky et al., 2000a; Miravet et al., 2003; Maeda et al., 2004;
Fukunaga et al., 2005; Li et al., 2007; Shimizu et al., 2007) no such relationship has
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been reported within a haematopoietic or leukaemic context. To address this, y-catenin 
was ectopically expressed in both normal human progenitors and myeloid leukaemia 
cell lines with the capacity to undergo chemically-induced differentiation (Tsuchiya et 
al., 1982; Hass et al., 1989). Such investigations would explore the inter-dependence 
between y- and /3-catenin proteins and the consequences o f such a relationship for the 
development o f these cells.
The discovery that y-catenin translocation in normal progenitors is apparently tightly 
regulated raises the question o f the mechanisms regulating this process. One such 
mechanism to be assessed is the ability o f y-catenin to respond to a Wnt stimulus. 
Members o f  the Wnt family o f glycoproteins are known to be active throughout normal 
haematopoiesis (Austin et al., 1997; Van den Berg et al., 1998) and capable o f 
stabilising /3-catenin expression (mainly Wnt3A; (Dosen et al., 2006; Kim et al., 2009)). 
Interestingly, Wnt signalling proteins have also been found to be dysregulated in acute 
leukaemias and Wnt-mediated stabilisation (leading to nuclear translocation) o f (3- 
catenin has also been observed within this context (Simon et al., 2005; Tickenbrock et 
al., 2005; Nygren et al., 2007; Tickenbrock et al., 2008; Kawaguchi-Ihara et al., 2008). 
Such a phenomenon has not been reported for y-catenin in haematopoietic cells, and it 
will be interesting to observe whether this could be contributing to the correlation 
between /3- and y-catenin.
Related to the above, is the investigation into the cause o f multiple catenin bands in 
Western blotting which may inform how the level and localisation o f catenins are 
regulated in haematopoietic cells. It is outside the scope o f this study to investigate all 
the potential causes o f  the multiple protein banding, however this chapter seeks to 
investigate one o f the potential causes; differential phosphorylation. There is a wealth o f 
evidence demonstrating that phosphorylation o f catenin is crucial in regulating activity, 
turnover and translocation o f the protein (see 3.5.3 and 4.5.3).
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5.2 Aims
In order to better understand the functional roles of y-catenin in normal haematopoiesis 
and AML pathology, the aims o f this chapter are:
1) To use an established model o f in vitro haematopoiesis, to examine the effects o f 
y-catenin silencing on normal haematopoietic development.
2) To investigate how the modulation o f y-catenin expression affects the level and 
subcellular localisation o f /3-catenin in normal and leukaemic cells.
3) To examine the consequences of y-catenin overexpression/silencing on the 
induced differentiation o f monocytic cell lines.
4) To explore the possible mechanisms regulating the translocation o f y-catenin 
from cytosol to nucleus in haematopoietic cells.
5) To establish the possible causes o f the multiple banding o f catenin protein
observed during Western blotting.
5.3 Materials and Methods
5.3.1 Investigation into the function of y-catenin in normal haematopoiesis
The full strategy o f this experiment and endpoints are outlined in the following sections 
and summarised in Figure 5.1.
5.3.1.1 Modelling haematopoiesis in vitro
The comprehensive characterisation o f the HSC immunophenotype and vastly improved 
purification techniques for their isolation (by fluorescence activated cell sorting (FACS) 
or immunogenic magnetic beads) has permitted developmental studies o f these cells
outside o f the body. Furthermore, pioneering work o f researchers in the 1970’s
identified the medium, growth factors (GF) and cytokines necessary to culture 
haematopoietic cells in vitro (Pike and Robinson, 1970; Iscove et al., 1971; Chervenick
and Boggs, 1971; Metcalf, 1971; Metcalf et al., 1974; Dao et al., 1977a; Dao et al.,
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1977b). Specifically, many o f these studies highlighted the importance o f specific 
soluble colony stimulating factors (CSF) in bringing about the growth and 
differentiation o f  specific haematopoietic lineages. Since these fundamental discoveries, 
many laboratories have optimised combinations and concentrations of growth factors 
necessary to model their particular area o f haematological interest in vitro. In particular, 
pioneering work from this laboratory has resulted in the development o f an effective 
model o f in vitro human myeloid differentiation using such GFs and cytokines as IL-3, 
SCF, GM-CSF and G-CSF (Darley et al., 1997; Darley and Burnett, 1999; Tonks et al., 
2004).
The in vitro differentiation o f HSC into mature progeny such as neutrophils, monocytes, 
and macrophages can be effectively monitored through the cell surface cluster of 
differentiation (CD) expression. Such molecules not only serve important functions for 
the cell (e.g. cell signalling receptors), but also provide accurate information as to the 
cell type, function and stage o f differentiation. The expression pattern o f CD antigens 
on specific developing haematopoietic lineages has been well characterised and can be 
easily detected by fluorochrome-conjugated antibodies using flow cytometry. 
Morphological assessment can be used in conjunction with CD marker expression to 
confirm the extent o f differentiation. The use of cytochemical stains such as May- 
Griinwald-Giemsa allow the differential staining o f cytosol and nucleus, such that the 
morphological changes associated with development can be identified by basic light 
microscopy. Exploiting all o f  the aforementioned parameters, plus the relative ease with 
which HSCs can be retrovirally transduced, means a powerful model is available to 
assess the impact o f single gene changes, such as y-catenin, on normal haematopoietic 
development.
5.3.1.2 In vitro culture o f  normal human primary haematopoietic cells
Normal CB-derived CD34+ HPC were isolated and enriched as outlined in section 2.4. 
Following isolation (designated day 0), CD34+ cells were cultured overnight at a 
density o f 2xl05/ml in supplemented IMDM (containing 1% BSA fraction V, 20% FBS, 
45pM  BME, 360jUg/ml 30% iron-saturated human transferrin, lOOIU/ml penicillin, and
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100/xg/ml streptomycin) containing 50ng/ml huIL-3, huSCF, huFLT-3L and 25ng/ml 
huIL-6 , huG-CSF and huGM-CSF, at 37°C with 5% CO2 . These conditions were 
necessary to stimulate the cell cycle in an otherwise largely quiescent population in 
preparation for retroviral transduction (2.5.3). Once retroviral transduction was 
complete, unless otherwise stated, CD34+ cells were sub-cultured in supplemented 
IMDM containing 5ng/ml huIL-3, huG-CSF and GM-CSF, and 20ng/ml huSCF, and 
maintained at 2x l05/ml as before until day 21 o f in vitro culture. Cells were sub­
cultured every 2-3 days or when cells reached confluence (~ lx l0 6/ml).
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Days 1 + 2
P O K . M M  MBy-Catenin shRNA
Purification of normal human CD34+ 
haematopoietic progenitor cells from 
cord blood
Day 4
Retroviral transduction of progenitor 
cells with control or y-catenin shRNA
1
Day 3
FACS sorting of transduced cells (if required) and 
harvesting of cells into fresh growth factor- and 
cytokine-supplemented medium
Assessment of GFP expression 
(transduction efficiency) by flow cytometry 
and recovery
I
Days 7 ,10 ,14 ,17  and 21 
Cell counts/Cell morphology/Immunophenotypic analysis
Figure 5.1 - Strategy for investigation into effect o f y-catenin silencing on 
haem atopoietic developm ent.
Summary flow diagram showing the experiments performed and time points used in 
examining the effect of y-catenin knockdown on development of human CB-derived 
haematopoietic progenitor cells.
Day 0
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5.3.1.3 Establishment o f y-catenin silencing system in normal human primary 
haematopoietic cells
In order to repress y-catenin protein expression in normal human primary 
haematopoietic cells and follow the effects o f this loss on growth and differentiation, a 
vector (vPGKpuroU3U6-y-catenin-shRNA) encoding y-catenin short hairpin RNA 
(shRNA) was employed. {Figure 5.2A; kind gift o f Professor Martin Ruthardt, Goethe- 
University o f Frankfurt, Germany (Zheng et al., 2004)).
ShRNA is one o f  the mechanisms exploited by researchers in the last decade to bring 
about gene silencing through RNA interference (RNAi). RNAi is an evolutionary 
conserved biological response in mammalian cells to the introduction o f exogenous 
double stranded RNA (dsRNA) that occurs during viral invasion (reviewed by Hannon 
and Rossi, 2004 and Tomari and Zamore, 2005). Initial discoveries in C. elegans 
revealed that injection of dsRNA resulted in the subsequent repressed expression o f 
genes with complimentary sequences to the dsRNA introduced (Fire et al., 1991; Fire et 
al., 1998). ShRNA are designed as inverted nucleotide repeat sequences containing an 
intra-molecular stem-loop structure. They can be introduced into eukaryotic cells 
through retroviral expression constructs and are continually expressed from RNA 
polymerase II or III (U6 ) promoters. The subsequent hairpin structure produced is 
recognised and cleaved at the ‘loop’ by the enzyme Dicer generating 30bp (or less) 
small interfering RNA (siRNA). These siRNA are then incorporated into the RNA- 
induced silencing complex (RISC) which unwind the double strands (ATP-dependent) 
and use the antisense siRNA to target and continually degrade the complimentary 
mRNA (in this case y-catenin mRNA).
The vector described above utilised puromycin resistance as a selectable marker o f gene 
transduction, which although appropriate for selection in cell lines, is not suitable for 
use in developing primary human haematopoietic cells. This is due to the artefactual 
effects on development arising from drug selection, which could mask any potential 
phenotype generated by a gene of interest (as observed in pilot studies, data not shown). 
To circumvent this problem, the puromycin selection cassette and associated PGK
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promoter were excised from the retroviral backbone and replaced with a PGK promoter 
driving expression o f GFP (originating from pRRLSIN.cPPT.PGK/GFP.WPRE; Figure 
5.2B, kind gift o f  Dr. James Matthews, Cardiff University). The sub-cloning process 
involved is summarised within Figure 5.2, and essentially used many o f the sub-cloning 
techniques fully described in methods section 3.3.1.
Retrovirus encoding y-catenin shRNA (vPGK/GFP-y-catenin shRNA) was generated as 
described in section 2.5.2 and subsequently used to infect normal human CD34+ 
haematopoietic cells on day 1 and 2 o f  in vitro culture as described in section 2.5.3. 
After 2 rounds o f retroviral infection, transduced CD34+ cells were harvested into fresh 
culture medium as in 5.3.1.2 (day 3) and allowed to recover. Cells were analysed by 
flow cytometry to determine infection frequency as below in 5.3.1.5.
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Figure 5.2 - T he rep lacem ent o f  the purom ycin-resistance cassette w ith  G FP as a 
reporter gene for vP G K U 3U 6.
A) The vPGKpuroU3U6-y-catenin-shRNA plasmid contains inverted repeats o f 21 
nucleotides (corresponding to 1862-1882 bp of the human y-catenin gene) separated by 
a 10 nucleotide spacer (Zheng et al., 2004). The associated control plasmid contains 
shRNA to the LacZ gene (not present in the human genome). The puromycin resistance 
cassette was excised using EcoKl and Clal restriction endonucleases (red boxes) by 
first cutting with Clal and blunting with DNA polymerase I large (Klenow) fragment 
and then subsequently cutting with EcoRl to create open vector with heterologous ends 
(EcoRl-blunt). B) PGK/GFP was removed from pRRLSIN.cPPT.PGK/GFP.WPRE 
using a double Sail EcoRl digest (red boxes) by first cutting with Sail and blunting (as 
A) and then subsequently cutting with EcoRl to create ends compatible with the 
processed vector. The EcoRl -blunt PGK/GFP cassette was then ligated into 
vPGKpuroU3U6 with DNA ligase and transformed in competent E.coli. The newly 
created plasmid was designated vPGK/GFP-y-catenin shRNA (or -LacZ-shRNA for 
control).
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5.3.1.4 Fluorescence activated cell sorting o f  developmental subsets o f
transduced cells
In order to isolate discrete subpopulations o f lineage committed haematopoietic 
progenitor cells, a minimum of 2x106 transduced cells (at day 4 in vitro culture) were 
resuspended in PBS (containing 10% FBS) and passed through a 40 pM  cell strainer 
(BD). Cells were then flow sorted between 5,000-10,000 events per second using a 
MoFlo high speed cell sorter (Dako Cytomation), to over 98% GFP positivity. Pre- and 
post-cell sorting analysis o f GFP+ by flow cytometry was performed to validate 
successful cell sorting.
For a more in-depth analysis of discrete developmental sub-populations of transduced 
progenitor cells a more complex day 4 sort strategy was adopted. To achieve this, cells 
were immuno-stained with anti-human CD13-PE (clone TUK4, Dako) and CD36-APC 
(clone CB38, BD) as described in section 33.5.2. These markers are capable of 
discriminating the main myeloid progenitor cells and hence are termed ‘lineage 
discriminators’. The growth o f lymphoid cells is not supported by the culture conditions 
employed and are phenotypically absent from these cultures. Following staining, cells 
were washed and Figure 5.8 shows the flow cytometric gating strategy for cell sorting 
of the target populations identified.
5.3.1.5 Immunophenotypic analysis o f transduced human haematopoietic cells 
Retrovirally transduced CD34+ haematopoietic cells were cultured in vitro for 21 days 
under cytokine conditions favourable for myeloid cell growth. On days 7, 10, 14, 17 
and 2 1 , cultures were analysed for expression o f specific cell surface markers indicative 
of lineage and maturation state. All replicates were stained with the lineage 
discriminator antibodies CD13 (Clone WM15, Bio legend) and CD36 (Clone SMO, 
Ancell, Minnesota, USA), plus one additional PE-conjugated antibody o f the selection 
listed in Table 5.1, which served as specific markers of differentiation. FSC and SSC 
characteristics were also recorded for all cells analysed. Cells were immunostained as 
outlined in section 3.3.5.2. Multi-parameter flow cytometric measurements were 
acquired on the Accuri® C6  flow cytometer in conjunction with CFlow software
200 | P a g e
Examination into the Functional Role of y-Catenin in Haematopoietic I er
Cells_______________________________  I P
version 7.5 (Accuri Cytometers, Cambridgeshire, UK). Post-acquisition analysis o f flow 
cytometric data was performed using FCS Express V3 (De Novo Software, California, 
USA). Debris was excluded from all analyses on the basis of forward- and side-scatter 
characteristics, whilst specific individual sub-populations were identified using the 
gating strategies illustrated in Figure 5.5.
Table 5.1 - Antibodies used in immunophenotypic analysis of in vitro cultured 
human haematopoietic cells.
IgG-PE (Clone MOPC-21, BD) Non-specific binding
CD15-PE Granulocytes
CD14-PE (Clone TUK4, Dako) Monocytes
CD163-PE (Clone GHI/61, BD) Macrophages
GlyA-PE Erythrocytes
CD34-PE Progenitor cells
5.3.1. 6  Assessment o f cell morphology 
In conjunction with immunophenotypic analysis, morphological assessment of in vitro 
cultured haematopoietic cells also occurred at the fixed time-points identified above 
(5.3.1.5). Approximately 2x104 cells were resuspended in 250/ul of 1 x PBS and 
centrifuged at 60 x g for 5 minutes onto a glass slide using a Cytospin 3 (Thermo 
Shandon, Cheshire, UK). Slides were stained with May-Grimwald-Giemsa using an 
ABX Pentra DX120 automated cell stainer (Horiba Medical Diagnostics, Northampton, 
UK). With this stain, nuclei and basophilic granules appear a dark blue or purple, whilst 
the cytoplasm and eosinophilic granules appear a pale pink/red. The cytospun cells were 
mounted in one drop of Dibutyl Phthalate in Xylene mountant (DPX) and coverslipped. 
Cells were viewed with a Zeiss AXIOSKOP microscope (Carl Zeiss Ltd, Hertfordshire, 
United Kingdom) using 40X and 100X oil immersion objectives.
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5.3.2 The influence of y-catenin expression on /8-catenin subcellular 
localisation
To assess how the level and subcellular localisation of y-catenin protein may affect the 
level and localisation of /3-catenin protein in normal and leukaemic cells, the following 
subcellular fractionation procedures were carried out.
5.3.2.1 In primary cell cultures 
In order to provide ectopic expression of y-catenin protein in CD34+ haematopoietic 
progenitor cells the PINCO vector described in section 3.3.1 {Figure 3.1) was used. CB- 
derived CD34+ progenitor cells were purified and transduced with GFP (control) or y- 
catenin DNA as in sections 2.4.2 and 2.5.3, respectively. Transduced cells were cultured 
up to 5 days in vitro (last day at which cultures were substantially CD34+) and N/C 
fractionated as described in 2.6.2. Cytosolic and nuclear homogenate were immuno- 
blotted (sections 2.6.3-2.6.7), for respective levels and localisation o f y- and /3-catenin. 
The conditions for y-catenin detection are described in section 3.3.3. However a 
different mouse monoclonal to /3-catenin (Clone 14, BD) was used at 250ng/ml. For 
assessment of fraction purity and protein loading /3-actin and histone HI were employed 
as in section 3.3.7.2.
53.2.2 In leukaemia cell lines
Leukaemic cell lines are immortalised, clonal cultures of cells that were originally 
transformed from leukaemia patients. They provide a tractable and unlimited source o f 
haematopoietic cell material for which to analyse the effects of exogenously expressed 
proteins. The background of existing genetic mutations within these cells makes them 
an appropriate model for studying proteins o f interest within a leukaemic context. 
However, given that many these genetic abnormalities remain uncharacterised and are 
extremely heterogeneous between individual cell lines means there are limitations to 
any experimental conclusions which may be drawn from them.
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The following leukaemic cell lines were used:- HEL, THP-1, U937 and K562 pBabe- 
Puro control and y-catenin cell lines (created in 3.3.2, and shown in Figure 3.10). Each 
cell type was N/C fractionated (alongside the respective pBabe-Puro control), and 
Western blotted as outlined above (5.3.2.1). In addition to the above, a K562 cell line 
expressing the original y-catenin silencing construct (vPGKpuroU3U6-y-catenin- 
shRNA, featured in Figure 5.2A) was also processed as above.
5.3.3 The effect of y-catenin and j3-catenin expression on induced 
differentiation of monocytic cell lines
The monocytic cell lines U937 and THP-1 can be induced to differentiate into 
monocytes/macrophages upon addition of phorbol esters such as 1 2 -0 - 
Tetradecanoylphorbol 13-acetate (TPA) (Tsuchiya et al., 1982; Hass et al., 1989). The 
pBabe-Puro control and pBabe-Puro-y-catenin transgenic lines o f THP-1 and U937 
created in section 3.3.2 were again utilised. In addition, THP-1 and U937 cell lines were 
transduced (as in section 2.5) to express y-catenin shRNA (vPGKpuroU3U6-y-catenin- 
shRNA, featured in Figure 5.2A) and the /3-catenin degradation-resistant mutant ((3- 
catAN89) described in 3.3.4.2 (giving a total of 8  cell lines that were studied).
5.3.3.1 Establishment o f cell line morphology and immunophenotype prior to 
TPA treatment
Prior to TPA-induction (see 5.3.3.2 immediately below), 2x106 cells from each cell line 
were N/C fractionated and Western blotted for y- and /3-catenin (as per 5.3.2.1) to assess 
the level and location of each protein at the start of the assay. Cells were cytospun as 
above (5.3.1.6) to establish cell morphology prior to TPA-induction. Each cell line was 
assessed immunophenotypically for monocytic/macrophage cell surface expression 
markers to establish the extent of differentiation before TPA treatment. As described in 
section 3.3.5.2, cells from each cell line were immunostained with anti-human CD 14- 
FITC (Clone TUK4, Dako), CDllb-PE (Clone 2LPM19c, Dako) and CD13-APC. 
Immuno-labelled cells were analysed as above (5.3.1.5) with the threshold for cell 
surface staining set with the isotype- and manufacturer-matched irrelevant control 
antibodies.
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5.3.3.2 TPA treatment o f cell lines 
A total o f 2x106 cells from each transgenic cell line were resuspended in 10ml of the
5 2 •appropriate culture medium (see Table 2.1) at a density o f 2x10 /ml, in a 25cm tissue 
culture flask. All flasks were inoculated with 40nM TPA, mixed well, and cultured 
overnight at 37°C with 5% CO2 . The following day, all TPA treated cell lines received 
the identical morphological, protein, and immunophenotypic assessment that was 
performed pre-TPA-induction (5.3.3.1).
5.3.4 Investigation into the effect of a Wnt stimulus on y-catenin 
expression
To investigate whether y-catenin, like /3-catenin, was capable o f responding to a Wnt 
signal, levels and localisation o f both proteins were observed after treatment with 
recombinant Wnt glycoproteins. Recombinant murine/human Wnt3A (concentration 
unknown) was obtained by harvesting conditioned medium from Wnt3A-transduced 
murine L-cells (generously donated by Dr. Kenneth Ewan, Cardiff University (Willert 
et al., 2003)). Recombinant human Wnt5A was purchased from R&D systems 
(Abingdon, UK). Each test condition is outlined in Table 5.2 below. In each case, wild- 
type K562 cells were resuspended at a density o f 4xl05/ml in the appropriate medium, 
and incubated overnight at 37°C with 5% CO2 . The following day, 2x106 K562 cells 
from each test condition were N/C fractionated and Western blotted as above (5.3.2.1).
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Table 5.2 - The test conditions used on K562 cells to ascertain y-catenin response to 
a Wnt stimulus.
Untreated (control) 5 ml N/A
Wnt3A 2.5ml 2.5ml Wnt3A conditioned medium
Wnt5A 5 ml 500ng/ml recombinant Wnt5A
2.5ml Wnt3A conditioned
Wnt3A + Wnt5A 2.5ml medium, plus 500ng/ml 
recombinant Wnt5A
5.3.5 Determination of cause of multiple banding pattern of y-catenin in 
Western blotting
To investigate whether the differential phosphorylation status of y-catenin protein was 
responsible for the multiple banding pattern observed in Western blotting, y-catenin 
protein was immunoprecipitated and then de-phosphorylated.
5.3.5.1 Immunoprecipitation o f y-catenin protein
Whole cell protein homogenate was generated from lxlO6 K562 cells as outlined in 
section 2.6.1, except the homogenisation buffer was replaced with a calf intestinal 
alkaline phosphatase (CIP) extraction buffer (25mM HEPES pH 7.8, 300mM NaCl, 
1.5mM MgC12, 1% Triton® X-100, 0.1 mM dithiothreitol, 1 protease inhibitor tablet) to 
provide optimal conditions for the CIP (New England Biolabs) used in the de­
phosphorylation step below (5.3.5.2). Protein was quantified using the Bradford’s assay 
of 2.6.3.
Immobilised Protein G sepharose beads were washed in 1ml o f TBS with centrifugation 
at 16,000 x g  for 1 minute. Pelleted beads were resuspended in TBS to generate a 50% 
bead slurry prior to ‘pre-clearing’ of the K562 protein lysate. ‘Pre-clearing’ removes the
Examination into the Functional Role of y-Catenin in Haematopoietic Chapter 5
non-specific protein binding to the sepharose beads, thus improving the signal-to-noise 
ratio. To achieve this, 100/d of Protein G slurry was incubated with 500/d (containing 
600/xg protein) K562 lysate, under gentle agitation at 4°C for 1 hour.
At the same time, the Protein G bead: y-catenin antibody complex was generated by 
taking 100/d o f Protein G bead slurry and combining with 3.2pg of rabbit polyclonal y- 
catenin antibody (#2309s, Cell Signalling) under gentle agitation for 1 hour at 4°C. 
Upon completion of ‘pre-clearing’, beads were pelleted by centrifugation as above, and 
the cleared lysate supernatant aspirated and split between four Eppendorfs. Three o f the 
cleared lysate tubes each received 33pl o f Protein G bound y-catenin antibody, the other 
remaining free of antibody to serve as a negative control. All tubes were incubated 
overnight under gentle agitation at 4°C. The following day, the three tubes containing 
conjugated beads were washed 3 times with 500/d ice cold TBS each followed by 
centrifugation as above. Pelleted beads were resuspended in 30/d TBS before 
proceeding to de-phosphorylation o f immuno-precipitated protein.
5.3.5.2 De-phosphorylation o f  immunoprecipitated y-catenin protein
Of the three tubes containing bead-bound protein, tube 1 was designated the ‘control’ 
and received 5/d PBS. Tube 2 was designated ‘low-de-phosphorylation’ and received 
10U (1/d) CIP, whilst Tube 3 represented ‘high de-phosphorylation’ and received 100U 
(10/d) CIP. CIP dephosphorylates serine, threonine and tyrosine residues on proteins. 
Tube 4 served as a ‘Cleared lysate’ control and also received 5/d PBS. All tubes were 
incubated at 37°C for 2 hours. The de-phosphorylation reaction was stopped by adding 
200/d TBS to each tube (not tube 4) and pelleting the beads by centrifugation as above. 
CIP contaminating supernatant was removed and discarded before resuspending the 
bound protein in TBS, and Western blotting all tubes as in steps 2.6.4-2.6.7. Purified y- 
catenin was detected using the mouse monoclonal of 3.3.3, whilst efficiency of 
dephosphorylation was assessed using a rabbit polyclonal antibody to phosphotyrosine 
(#T1325, Sigma).
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5.4.1 The function of y-catenin in normal haematopoietic development
5.4.1.1 y-Catenin protein knockdown perturbs human monocyte/macrophage
development
In order to determine the role of y-catenin in normal haematopoiesis it was necessary to 
knockdown endogenous levels of y-catenin protein within a model of in vitro human 
haematopoiesis and examine the consequences for normal development. To optimise 
and validate this approach K562 cells were used because of their tractability and high 
endogenous levels of y-catenin. The time-course Western blot o f Figure 5.3 reveals how 
the y-catenin shRNA retroviral construct (featured in Figure 5.2) was capable o f stable 
knockdown of 76%±5% of y-catenin protein in K562 cells over the 31 days tested.
Day 6 Day 10
A
Day 20
A
Day 28
A
Day 31
A
f  Y  Y Y Y ^
LacZ y-Cat j  LacZ y-Cat [ LacZ y-Cat [ LacZ y-Cat I LacZ y-Cat I
y-Catenin
Actin
W ~  B
♦
Figure 5.3 - The use of y-catenin shRNA to knockdown y-catenin protein 
expression in K562 cells.
Western blotting of K562 whole cell lysates retrovirally transduced with either y-catenin 
shRNA or corresponding LacZ shRNA control. Change in y-catenin protein expression 
in knock-down cultures can be observed compared to mock-transduced control cells. 
Actin was used as a measure of equal protein loading between sample pairs.
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Following successful validation of y-catenin protein knockdown, CD34+ haematopoietic 
progenitor cells were retrovirally transduced with either LacZ control or y-catenin 
shRNA and cultured in vitro for 21 days. Morphological, immunophenotypic and 
developmental assessments were performed at regular time-points throughout the 
experiment as summarised in Figure 5.1. In terms of growth rate, no significant 
difference was observed between control and y-catenin knockdown (y-cat KD) cells 
throughout the entire 2 1  days, as depicted by the cumulative fold expansions featured in 
Figure 5.4 below.
2000 LacZ control shRNA
-*-G ainm a-caten in  shRNA
=  1600 -
=  1200  - 
C L
800 -
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Days in culture
Figure 5.4 - The effect of y-catenin silencing on growth of haematopoietic cells.
Growth curve comparing the cumulative fold expansion of haematopoietic cultures 
retrovirally transduced with either LacZ control (blue line) or y-catenin shRNA (red 
line). Data indicate mean ± 1 SD.
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In order to closely monitor the differentiation of transduced haematopoietic cells, 
specific cell surface marker expression was assessed by flow cytometry. The analytical 
strategy is outlined in Figure 5.5.
Using this strategy a number o f key developmental abnormalities were identified in the 
y-cat KD cells and are summarised in Figure 5.6. At the earliest time-point assessed 
(day 7) there appeared to be negligible differences between the two cultures as deduced 
from all the differentiation parameters previously described (5.3. J. 5). At day 10 a lower 
frequency o f CD13+CD36+ (monocytic) events were present in the y-cat KD culture 
(14.6% versus 25.9%, respectively) as shown in Figure 5.6A. Also identified at this 
time-point, and observable in Figure 5.6A, was an enrichment of erythroid progenitors 
(CD13'CD36+) compared to control cells (34.1% versus 21.2% respectively). 
Unfortunately, further comparison between the erythroid-lineage committed cells o f 
both cultures was not possible after day 1 0  given the requirement for erythropoietin 
(absent from this culture) for further development. The granulocytic lineage 
(CD13+CD36 ) proportion of the culture appeared approximately equal between the two 
cultures at this time-point and indeed remained so for the entirety of the assay.
Given the above observations subsequent analysis at subsequent time-points focussed 
on the development of the CD13+CD36+ monocytic cells. Figure 5.6B shows how the 
proportion of monocytic cells in the y-cat KD culture remained 1.3-2.2-fold lower than 
in the control culture. Immunophenotypic abnormalities were also observed: Figure 
5.6C shows a marked and progressive increase (2.5-3.0-fold higher than controls) in the 
percentage of CD13+CD36+ cells expressing the granulocytic antigen, CD15, from days 
14-21. In contrast, Figure 5.6D shows little difference in the expression o f the 
monocytic marker, CD 14. Finally, it was noted from around day 14 onwards that y-cat 
KD monocytes exhibited lower FSC and SSC (Figure 5.6E and F  respectively), 
suggesting smaller and less granular cells than present in control cultures.
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Analysis of cell morphology by May-Griinwald-Giemsa staining of leukocytes was used 
in conjunction with flow cytometric measurements to assess the differentiation of cells. 
At day 21 of culture, total GFP+ events were FACS sorted from both cultures (nearly all 
CD13+ at this point), cytospun onto glass slides, stained, and examined by light 
microscopy. The morphology, as represented in Figure 5.7A and B, appeared to 
corroborate the immunophenotypic data described above. As anticipated LacZ shRNA 
control cultures (A) were dominated by macrophages with rare mature granulocytes 
(with hyper-segmented nuclei). Conversely, the y-cat KD culture (B) was deficient in 
macrophages instead exhibiting predominantly cells of granulocytic morphology (band- 
from and hyper-segmented neutrophils). The prevalence o f granulocytic cells within this 
culture validates the increase in CD 15 expression (see above) and the lower SSC and 
FSC measurements are in keeping with the predominance of smaller cells in the y-cat 
KD culture. To see further morphology images of both cultures please consult sub­
folder 1 of Folder 1 from the main Chapter 5 section of the supplementaty CD.
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Figure 5.5 - Strategy for immunophenotyping of transduced haematopoietic cells.
Preliminary steps involved A) exclusion of debris and B) gating of GFP positive cells. 
C) Use o f ‘lineage discriminators’ (CD13 and CD36) to identify 3 sub-populations of 
lineage-committed haematopoietic cells: monocytic (mono: CD13+CD36+), erythroid 
(ery: CD13 CD36+) and granulocytic (gran: CD13CD36). D-F) Each of these subsets 
was then gated and examined for cellular characteristics such as size (FSC) and 
granularity (SSC) or for specific cell surface markers of differentiation such as CD 15 or 
CD14.
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Figure 5.6 - The effect of y-catenin silencing on the development of haematopoietic cells.
A) Representative CD13 versus CD36 contour plots from day 10 of culture comparing 
lineage frequency between I) LacZ control and II) y-catenin shRNA transduced 
haematopoietic cells. B) Frequency of CD13+CD36+ events in LacZ control and y- 
catenin shRNA transduced cultures over 21 days. C-F) Differentiation profile of LacZ 
and y-catenin shRNA transduced monocytic cells (CD13+CD36+) showing direct 
comparison of percentage CD 15 and CD 14 cells present in each culture, followed by 
forward and side scatter comparison (n=l for all).
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Figure 5.7 - The effect of y-catenin silencing on differentiation of haematopoietic 
cells.
Representative cell morphology of A) LacZ control shRNA and B) y-catenin shRNA 
transduced haematopoietic cells following 21 days of in vitro culture. Cells were 
cytospun onto glass slides and May-Griinwald-Giemsa stained. Morphology is shown at 
lOOx and 400x magnification. Annotations denote: Mac=macrophage,
Mono=monocyte, Gran=granulocyte, MM=metamyelocyte and BF=band-form 
neutrophil.
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5.4.1.2 y-Catenin deficient monocytes fa il to complete monocytic/macrophage 
differentiation and instead develop granulocytic characteristics
The above data indicated a potential aberration in monocyte/macrophage differentiation. 
To further characterise the nature of this defect, the experiment was repeated but 
focusing specifically on GFP+ monocyte progenitors (CD34+CD13bright) which were 
sorted on day 4 following retroviral transduction (see Figure 5.1). This reduced any 
ambiguity in the interpretation o f the results (e.g. whether the lower frequency o f 
progenitors arising from y-catenin silencing was due to changes in cell survival, 
proliferation or transdifferentiation). Figure 5.8 shows the gating strategy adopted.
Figure 5.9 shows that CD34+CD13bright y-cat KD monocytes displayed a modestly 
enhanced proliferative capacity in the final time-points (days 14-21) o f the assay. These 
differences were relatively small and would not have been observed in the bulk culture 
assessment made in 5.4.1.1. Immunophenotypic analysis again showed a consistent 
reduction (1.1-1.9-fold lower) in the proportion of CD13bnghtCD36+ monocytic cells 
present in y-cat KD cultures, relative to controls {Figure 5.10A). The representative day 
14 contour plot of Figure 5.10B indicates that a loss o f CD13brightCD36+ events in the y- 
cat KD culture is concomitant with an enrichment o f the CD13+CD36' region 
(granulocyte/progenitor compartment). There appeared to be little difference in the 
differentiation profile of CD13+CD36" cells between both cultures. Both cultures 
displayed lower CD13, CD36, FSC, SSC, and CD14 measurements than obtained in the 
CD13bnghtCD36+ region, as would be expected in this ‘granulocytic’ region.
In the CD13brightCD36+ region, a higher proportion of cells expressed the granulocytic 
antigen, CD 15, in y-cat KD cultures from day 7 onwards (starting 4-fold higher, 
peaking at 16-fold higher on day 14, Figure 5. IOC). The identity o f these cells 
remained ambiguous however, as they also maintained high expression o f the 
monocytic marker, CD 14, which was not dissimilar from controls (except for a 1.3-fold 
higher level at day 17, Figure 5.10D). Finally, as also identified in the previous assay 
and demonstrated in Figure 5.10E and F  respectively, FSC and SSC measurements 
were again lower in y-cat KD monocytes particularly at later time-points (days 14-21).
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It should also be noted that no significant retention of CD34 expression, or aberrant 
expression of GlyA (for mature erythrocytes) was detected in either monocyte culture. 
Unfortunately, immuno-staining with CD 163 (a marker of macrophages) failed at each 
of the time-points assayed, despite the presence of macrophages in mature monocyte 
cultures. This was probably due to reagent quality issues. A colony assay was also 
performed immediately after the day 4 FACS sort (not described in methods) to explore 
the developmental fate o f single progenitor cells, however, this assay failed due to a 
preparative error in the media formulation arising from inadequate deionisation of the 
BSA component.
As before, the assessment o f cell morphology appeared to support the 
immunophenotypic data. To observe the full range of developing monocyte morphology 
from day 7 to 21, consult sub-folders 2-6 o f Folder 1 from the main Chapter 5 section 
of the supplementary CD. Briefly, very minor morphological differences between the 
two transduced monocyte cultures were present at day 7 and 10 assessments. The 
morphology observed in Figure 5.11 from day 17 shows that LacZ shRNA control 
transduced cells (A) exhibited classic macrophage or monocyte morphology, as seen in 
previously {Figure 5.7A) and shows that under normal conditions CD13bnght progenitors 
give rise to predominantly cells o f the monocyte/macrophage lineage. Conversely, the 
y-catenin shRNA transduced monocytes (B) was dominated by the presence of cells 
exhibiting a pale ‘macrophage-like’ cytoplasm, but with a ruffled, uneven cell 
membrane and displaying granulocytic (often hyper-segmented) nuclear morphology. 
These cells appeared smaller, less granular and more vacuolated (an indicator of in vitro 
culture physiological stress) than their normal developmentally-matched counterparts. 
These observations confirmed the biphenotypic staining pattern seen above in that the 
cells appeared to have both granulocytic and monocytic features. Taken with the 
previous section, these data would imply that y-catenin expression is important for 
normal monocytic development. y-Catenin deficiency appears to prevent macrophage 
differentiation instead resulting in dysplastic cells with granulocytic/monocytic 
characteristics.
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Figure 5.8 - The isolation and purification of monocytic lineage-committed 
haematopoietic progenitor cells.
The sequential gating strategy adopted using the high speed cell sorter to purify a 
monocyte committed subpopulation of retrovirally transduced CD34+ haematopoietic 
progenitor cells following retroviral transduction (day 4). A) Firstly, cell debris was 
excluded using FSC versus SSC parameters before, B) exclusion o f doublets by use of 
pulse width. C) Retrovirally transduced cells were gated on the basis o f GFP positivity. 
D) Monocytic lineage-committed haematopoietic progenitors were identified by cell- 
high surface expression of CD13 (using the CD13bnghtCD36+ definitive monocyte 
population to set the CD13 threshold (Tjonnfjord et a l , 1996)).
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Figure 5.9 - The effect of y-catenin silencing on growth of monocytic cells.
Growth curve comparing the cumulative fold expansion of day 4 FACS sorted 
CD13bnght(CD36+/') monocytic cells retrovirally transduced with either LacZ control or 
y-catenin shRNA (n=l).
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Figure 5.10 - The effect of y-catenin silencing on the development of monocytic cells.
A) Comparison of percentage CD13brightCD36+ events detected in LacZ control and y- 
catenin shRNA transduced monocyte populations over 21 days. B) Representative 
contour plots from day 14 comparing CD 13 and CD36 expression in day 4 sorted 
differentiating monocyte populations transduced with I) LacZ control and II) y-catenin 
shRNA. C-F) Differentiation profile of LacZ and y-catenin shRNA transduced 
monocytic cells (using CD13bnght gate illustrated in A) showing direct comparison of 
percentage CD 15 and CD 14 cells present in each culture, followed by forward and side 
scatter comparison (n=l for all).
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Figure 5.11 - The effect of y-catenin silencing on differentiation of monocytic cells.
Representative day 17 cell morphology showing differences between A) LacZ control 
shRNA and B) y-catenin shRNA transduced cells. Cells were cytospun onto glass slides 
and May-Grunwald-Giemsa stained. Morphology is shown at lOOx and 400x 
magnification. Annotations denote: Mac=macrophage, Mono=monocyte,
Gran=Granulocytes with hyper-segmented nuclei, MM=metamyelocyte, and 
Vac=vacuolated cytoplasm.
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5.4.2 The influence of y-catenin expression on jS-catenin localisation
The previous chapter identified a potential correlation between the level of y-catenin 
and /5-catenin protein within primary AML blasts. It was thus necessary to examine the 
capacity of y-catenin to influence /3-catenin level and localisation in both normal and 
leukaemic cells.
5.4.2.1 Ectopic y-catenin fails to stabilise or translocate endogenous (3-catenin 
in normal haematopoietic cells
To test the capacity for y-catenin to influence /3-catenin level and localisation in normal 
haematopoietic cells, CB-derived CD34+ progenitor cells were retrovirally transduced 
with a y-catenin overexpression vector and N/C fractionated on day 5 of culture (whilst 
still predominantly CD34+) and also on day 13 day o f culture. Protein extracts were 
prepared and assessed for /3-catenin protein level and subcellular localisation.
Figure 5.12 demonstrates ~3-fold overexpression of y-catenin protein in day 5 and day 
13 haematopoietic cells. Interestingly, overexpression induced a similar pattern of 
multiple banding as in control cells making it unlikely that this banding pattern arose 
non-specifically. In neither day 5 or day 13 cells did overexpression result in increased 
nuclear translocation of y-catenin with these cells. y-Catenin overexpression induced 
slight 1.4- and 1.1-fold increases in (3-catenin cytoplasmic expression, however, further 
comparisons would have to be made to establish the significance o f such minor 
perturbations. As expected day 5 cells contained low but detectable levels o f nuclear /3- 
catenin that were undetectable in day 13 cells. No significant increase in nuclear 
translocation of /3-catenin protein was observed in y-catenin overexpressing cells at 
either time-point.
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Figure 5.12 - The effect of y-catenin overexpression on level and subcellular 
localisation of /3-catenin in normal haematopoietic cells.
Western blot of cytosolic and nuclear homogenate from day 5 and day 13 in vitro 
cultured haematopoietic progenitor cells demonstrating the localisation of y-catenin 
protein and the subsequent localisation of /(3-catenin protein. Arrows and associated 
numerals show the fold-change in expression versus transduced control cells. Actin and 
Histone HI show the purity and loading of each fraction.
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5.4.2.2 Ectopic y-catenin serves mainly to stabilise nuclear (3-catenin in 
leukaemic cell lines
It was also necessary to test the extent to which y-catenin could influence /3-catenin 
level and localisation within a leukaemic setting. To this end, the leukaemic cell lines 
created in Chapter 3 (Figure 3.10) to express ectopic y-catenin were N/C fractionated 
and inspected for /3-catenin level and subcellular distribution. In addition to these, a 
K562 line was also generated expressing y-catenin shRNA (Figure 5.2A). The outcome 
of this experiment is summarised in Figure 5.13. U937 showed a response to y-catenin 
overexpression characteristic of normal progenitors i.e. augmented expression did not 
promote nuclear translocation of y-catenin or /3-catenin. As with normal cells some 
stabilisation o f cytoplasmic /3-catenin was observed which is in keeping with the far 
greater level o f overexpression of y-catenin achieved in these cells. All the other lines 
examined (HEL, THP-1 and K562) displayed an abnormal response where y-catenin 
overexpression was associated with various degrees o f y-catenin nuclear translocation. 
In each case, this was also accompanied by a similar enhancement o f /3-catenin 
translocation which appeared unrelated to the change in cytosolic levels o f /3-catenin 
(e.g. HEL and U937 cells where /3-catenin translocation is independent o f cytosolic /3- 
catenin levels). These data suggest that nuclear translocation o f y-catenin may also 
promote or stabilise /3-catenin in the nucleus. Conversely, the y-catenin shRNA 
construct reduced K562 cytosolic and nuclear y-catenin by 90% but had only a modest 
effect on /3-catenin expression and translocation. However, endogenous levels of 
nuclear /3-catenin were very low in this cell line, making further reductions or fold- 
changes difficult to reliably quantitate. It is also possible that any loss of /3-catenin could 
be fatal for K562 cells and so the cells which have been puro-selected and assayed 
could represent cells were able to maintain /3-catenin expression.
The effect of y-catenin knock-down on /3-catenin expression was also analysed in the 
context of THP-1 and U937 cells (see Figure 5.14 and Figure 5.17 in section 5.4.3 
below). These cell lines expressed much lower levels of y-catenin and so the level of 
knock-down was less pronounced (see also below). In this context there was no 
consistent effect on cytosolic levels of /3-catenin. Nuclear levels o f /3-catenin were 
however reduced, though in all lines the endogenous levels o f nuclear /3-catenin were
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low, making quantification o f fold-changes difficult to accurately determine. 
Interestingly, ectopic expression o f the mutant form o f degradation-resistant /3-catenin 
(/3-catAN89) in these cell lines also lead to the stabilisation and translocation of y- 
catenin {Figure 5.14 and Figure 5.17). This suggests a reciprocal relationship between 
the two catenins within a leukaemic setting, although U937 cells again behaved like 
‘normal’ cells demonstrating limited translocation and weak influence o f catenins on 
one another.
To summarise the two preceding sections o f data, while it would appear that ectopic y- 
catenin expression is incapable o f significantly modulating /3-catenin localisation in 
normal haematopoietic cells, in a leukaemic context y-catenin expression is much more 
influential in regulating both /3-catenin level and localisation. Generally, an increase in 
y-catenin protein frequently led to stabilisation o f /3-catenin protein. More consistently, 
changes in the nuclear translocation o f y-catenin gave rise to corresponding changes in 
the expression in the localisation o f  /3-catenin. Therefore, the independent regulation o f 
translocation that is apparent in normal haematopoiesis (see Chapter 3) is not evident in 
leukaemic cells.
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Figure 5.13 - The effect of y-catenin overexpression on the level and subcellular 
localisation of /3-catenin in leukaemic cell lines.
Cytosolic and nuclear homogenates from various leukaemic cell lines expressing 
ectopic/silenced y-catenin protein or respective controls. Level and localisation of y- 
catenin is shown along with the resulting level and localisation of /3-catenin. Arrows and 
associated numerals show the respective fold-changes in expression versus transduced 
control cells. Red cross represents no fold-change or unquantifiable due to difficulties in 
band detection. Actin and Histone HI show the purity and loading of each fraction.
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5.4.3 The effect of y-catenin expression on induced differentiation of 
monocytic cell lines
The previous two sections of data highlighted that; firstly, y-catenin appeared to be 
important for normal monocytic differentiation and secondly that y-catenin was capable 
of modulating /3-catenin level and localisation in leukaemic cell lines. Since THP-1 and 
U937 are capable of monocytic differentiation upon exposure to phorbol esters 
(Tsuchiya et al., 1982; Hass et al., 1989), such as TPA, the effect of ectopic y-catenin 
expression on this response was examined. In addition to the THP-1 and U937 
transgenic lines used in the above section (5.4.2.2), two more were created for each cell 
line including; y-catenin knock-down (y-cat KD using construct of Figure 5.2), and 
mutant /3-catenin (/3-catAN89, section 53.4.2) overexpressing cells. Each cell line was 
assessed for y- and /3-catenin localisation, plus state of monocytic differentiation (by 
flow cytometry and cell morphology) prior to TPA treatment, and then re-assessed for 
the same characteristics following overnight exposure to TPA.
5.4.3.1 THP-1 cells overexpressing y-catenin fa il to differentiate upon TPA 
induction
Figure 5.14A shows the level and subcellular distribution o f each catenin in each o f the 
THP-1 variants created prior to TPA induction. Level and localisation of each catenin in 
the control and y-catenin overexpressing lines was similar to that described above 
(5.4.2.2). In the newly created THP-1 y-cat KD cells, 70% and 90% reductions in 
cytosolic and nuclear y-catenin protein respectively, resulted in a 60% decrease in 
nuclear /3-catenin but a 3.6-fold increase in the cytosolic form o f /3-catenin. The /3- 
catAN89 THP-1 cell line was capable o f inducing a 10.4-fold, and a more modest 1.2- 
fold, increase in the respective levels of cytosolic and nuclear mutant /3-catenin. 
Interestingly this corresponded to a 3.6-fold stabilisation of cytosolic y-catenin along 
with a 2 .6 -fold increase in nuclear y-catenin.
Figure 5.14B shows the level and localisation of catenin proteins in THP-1 cells 
following overnight treatment with TPA. A subtle TPA-mediated increase in /3-catenin
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protein was observed in THP-1 cells upon treatment, but this did not significantly alter 
the localisation of both proteins as observed in the cell lines prior to treatment.
Figure 5.15 shows the immunophenotypic profile of each THP-1 cell line prior to and 
following TPA treatment. The THP-1 control line, as seen in Figure 5.15A, was found 
to already express the monocytic marker CD 14, which was unaffected upon TPA 
treatment. Cell surface expression of the myeloid protein, CD lib , was at background 
levels on untreated control cells, but was strongly induced (56-fold) following TPA 
treatment. In contrast, CD 14 was not detectable on THP-1 pBabe-Puro-y-catenin cells 
(Figure 5.15B) and was only weakly induced by TPA. Similarly C D llb  could not be 
significantly induced upon phorbol ester treatment. The THP-1 y-cat KD cells, featured 
in Figure 5.75C, differed from control in that these cells expressed C D llb  prior to 
induction a feature also shared by THP-1 /3-catAN89 cells (Figure 5.15D), but in other 
respects both these lines were similar to control cells. CD 13 cell surface expression was 
also examined (data not shown) and could not be induced by TPA in any of the THP-1 
lines assayed.
May-Griinwald-Giemsa staining was used in assistance with flow cytometric data to 
assess the extent of monocytic differentiation in THP-1 cell lines. Figure 5.16A shows 
the normal morphology o f THP-1 cells, which were dominated by dark staining 
monoblasts with a high nuclear: cytosol ratio. After an overnight incubation with TPA 
these cells differentiated into larger, mature monocyte or macrophage looking cells with 
pale cytoplasm and a lowered nuclear: cytosol ratio. The cytosol of these cells also 
appeared vacuolated, an indicator of the physiological stress. The morphology displayed 
in Figure 5.16B, for y-catenin overexpressing THP-1 cells appeared to validate the flow 
cytometric analysis. The culture prior to TPA treatment seemed to contain smaller, very 
dark staining blasts which looked more primitive than the monoblasts present in the 
control culture consistent with the reduced expression o f CD 14. These cells failed to 
differentiate following TPA treatment, and maintained blast-like morphology again 
consistent with the reduced CD14 and absent C D llb  expression. Unlike control cells, 
these cells also failed to become plastic-adherent following differentiation induction.
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Although the THP-1 y-cat KD cells appeared different in terms of colour (due to 
differences in uptake of May-Griinwald-Giemsa) the actual morphology was not 
dissimilar to that of control THP-l’s (Figure 5.16C). The THP-1 y-cat KD culture 
appeared to differentiate similarly to the controls, becoming adherent and increasing the 
presence of large vacuolated macrophage-like cells. The final THP-1 cell line 
overexpressing mutant /3-catenin {Figure 5.16D) appeared darker in colour, smoother in 
shape with a higher nuclear:cytosol ratio (untreated). Upon TPA-induction, visible signs 
of differentiation were apparent as before, however, there appeared to be a large number 
of undifferentiated monoblasts still present in the culture. To see the full range of THP- 
1 cell line morphology, pre- and post-TPA induction, please refer to Sub-Folders 1-4 of 
Folder 2 from the main Chapter 5 section of the supplementary CD.
To summarise at this point, it appeared the capacity of THP-1 cells to undergo induced 
monocytic differentiation is inversely related to the extent of nuclear catenin expression. 
Given that the expression of nuclear y- and /3-catenin is interconnected, it is difficult to 
confidently conclude which catenin (or if both) is dominant in driving the differentiation 
block. The case for each catenin being responsible is discussed further in section 5.5.3. 
Also, it seems the y-catenin overexpression/silencing phenotypes exhibited in THP-1 
cell lines are not consistent with the observations in primary haematopoietic cells 
(discussed further in 5.5.4).
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Figure 5.14 - Subcellular localisation of y-catenin and 0-catenin in THP-1 cells 
before and after TPA treatment.
N/C Western blots showing the level and localisation of y- and (3-catenin protein in 
transduced THP-1 cell lines A) prior to and B) after TPA treatment. Arrows and 
associated numerals show the respective fold-changes in expression versus transduced 
control cells, once normalised from the amount of protein loaded on each lane. Actin 
and Histone HI show the purity and loading of each fraction. Note that control is under­
loaded in B so banding intensity does not correspond with corrected fold change values.
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Figure 5.15 - Immunophenotyping of transduced THP-1 cells following TPA 
treatment.
Histograms showing the cell surface expression of CD 14 and CD1 lb on THP-1 cells: 
A) control, B) y-catenin overexpressing, C) y-cat KD and D) /3-catAN89. Black 
histograms represent staining on untreated THP-1 cells, red histograms TPA-treated 
cells, and blue histograms indicate staining from isotype-matched control antibody.
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Figure 5.16 - Cell morphology of transduced THP-1 cells following TPA treatment.
Untreated and TPA-treated THP-1 cells cytospun and May-Griinwald-Giemsa stained. 
Morphology shown for THP-1 cells: A) control, B) y-catenint, C) y-cat KD and D) /3- 
catAN89 DNA. Annotations as in Figure 5.11 except MB=monoblast and Gho=Ghost 
cells (smeared isolated nuclei with no cytosol). Morphology is shown at 400x.
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5.4.3.2 The inability o f catenin to nuclear translocate in U937 cells means 
normal differentiation upon TPA induction
Figure 5.17A shows the level and subcellular distribution o f each catenin in each o f the 
U937 cell lines variants created prior to TPA induction. As with THP-1 cells the level 
and localisation of each catenin in the control and y-catenin overexpressing lines have 
been described previously (5.4.2.2). The U937 cells expressing y-catenin shRNA 
reduced the already very low endogenous y-catenin levels by 40% in both the cytosol 
and nucleus, which also lowered cytosolic and nuclear /3-catenin by 40% and 70% 
respectively. The U937 /3-catAN89 cells induced a 6.3-fold increases in cytosolic (3- 
catenin (which as for y-catenin overexpression) had little consequence for nuclear (3- 
catenin localisation. As expected, the nuclear /3-catenin in all U937 cells always 
migrated to a lower molecular weight (~75kDa) than the nuclear /3-catenin observed in 
control and y-catenin overexpressing variants of other cell lines (~85kDa, see Figure 
5.13). As mentioned later, these truncated fragments are likely to possess limited 
transcriptional capability (5.5.3.1 and 5.5.6).
Following overnight treatment with TPA (Figure 5.17B) no major changes were 
observed in the level and localisation of y-catenin protein across U937 lines, apart from 
the U937 y-catenin overexpressing line where a notable increase in nuclear y-catenin 
was prevalent (from 1.9- to 6 .8 -fold).
Flow cytometric data, as shown in Figure 5.18, were not particularly useful in the 
assessment o f U937 monocytic differentiation upon TP A-induct ion. The 
myeloid/monocytic markers CD14, CD1 lb  and CD13 appeared to be expressed on most 
U937 cell lines assayed, but none seemed to be markedly induced upon TPA exposure. 
The U937 y-cat KD exhibited the largest increases in all three myelo/monocytic markers 
upon TPA exposure as evidenced in Figure 5.18C, which interestingly also harboured 
the lowest level o f nuclear /3-catenin among these cell lines.
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The cell morphology, as given in Figure 5.19, was more useful in interpreting the extent 
of TPA-induced monocytic differentiation in each U937 line. To see the full range of 
U937 cell line morphology, pre- and post-TP A induction, please refer to Sub-Folders 1- 
4 of Folder 3 from the main Chapter 5 section of the supplementary CD. Normal U937 
morphology (untreated image of Figure 5.19A) shows how the majority of the cells are 
monoblasts similar to THP-1 cells except for a slightly lower nuclear: cytosol ratio. The 
morphological differences occurring through TPA exposure are quite subtle but include 
a further lowering o f the nuclear: cytosol ratio and a paler vacuolated cytoplasm. There 
was an increase in the frequency of adherent macrophages and mature monocytes in the 
culture, although not as pronounced as for THP-1 cells. This extent of monocytic 
differentiation generated by TPA treatment appeared to be approximately equal in all 
U937 cultures as depicted in Figure 5.19A, B, C, and D. If anything the U937 y-cat KD 
culture demonstrated a slightly increased frequency of differentiated 
monocytic/macrophage cells, however more replicates and differential morphology 
counts would be required to validate this observation.
To summarise, this section of data shows there is a very clear difference in the 
respective abilities of THP-1 and U937 cells to differentiate upon TPA stimulation. This 
correlates with a clear difference in the abilities of the two cell lines to translocate full- 
length nuclear y-or (3-catenin upon manipulation o f these proteins. This would be 
consistent with the hypothesis that THP-1 cells have a much greater ability to influence 
nuclear catenin levels which in turn influences the differentiation potential. Conversely, 
U937 cells cannot modulate nuclear catenin to the same degree, and hence have reduced 
influence on differentiation potential.
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Figure 5.17 - Subcellular localisation of y-catenin and /3-catenin in U937 cells 
before and after TPA treatment.
N/C Western blots showing the level and localisation of y- and /3-catenin protein in 
transduced U937 cell lines A) prior to and B) after TPA treatment. Arrows and 
associated numerals show the respective fold-changes in expression versus transduced 
control cells once normalised from the amount of protein loaded on each lane. Red cross 
represents no fold-change Actin and Histone HI show the purity and loading of each 
fraction.
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Figure 5.18 - Immunophenotyping of transduced U937 cells following TPA treatment.
Histograms showing the cell surface expression of CD14, CDl lb and CD13 on U937 
cells transduced with A) control, B) y-catenin overexpressing, C) y-cat KD and D) (3- 
catAN89. Black histograms represent staining on untreated U937 cells, red histograms 
TPA-treated cells, and blue histograms indicate staining from isotype-matched control 
antibody.
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Figure 5.19 - Morphology of transduced U937 cells following TPA treatment.
Untreated and TPA-treated U937 cells cytospun and May-Griinwald-Giemsa stained. 
Morphology shown for U937 cells retrovirally transduced with A) control, B) y-catenin 
overexpressing, C) y-cat KD and D) /3-catAN89 DNA. Annotations as in Figure 5.16.
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5.4.4 y-Catenin accumulates and translocates in haematopoietic cells upon 
an exogenous Wnt signal
It has been previously well documented that stimulation o f the Wnt signalling cascade 
by an external Wnt ligand leads to an increase in the free cytoplasmic pool o f /3-catenin 
which subsequently translocates to the nucleus. Historically, in haematopoietic cells this 
has been demonstrated using Wnt3A. It remains unreported whether an exogenous Wnt 
signal is capable o f influencing the level and subcellular localisation o f y-catenin protein 
within a haematopoietic context. To investigate this K562 cells were incubated 
overnight with recombinant Wnt3A and/or the Wnt antagonist, Wnt5A, and examined 
for y- and /3-catenin protein.
Figure 5.20 shows Wnt3A generated a 15-fold induction o f cytoplasmic /3-catenin 
(relative to untreated cells) which subsequently stabilised a 9.9-fold increase in nuclear 
translocation, as expected. Treatment with Wnt5A failed to influence /3-catenin level or 
localisation. Treatment with both recombinant Wnt factors caused an 18-fold induction 
of cytoplasmic /3-catenin and a 9.9-fold shift in nuclear /3-catenin, which was 
presumably driven by the overriding effects o f the Wnt3A signal.
Wnt3A exposure also stimulated 4- and 2-fold increases in respective levels of cytosolic 
and nuclear y-catenin as also shown in Figure 5.20. Similarly to /3-catenin, cytosolic y- 
catenin was unaffected by Wnt5A treatment whilst nuclear levels actually showed a 
modest 60% reduction. Incubation with both Wnt proteins led to 4- and 2-fold increases 
in cytoplasmic and nuclear y-catenin, respectively. Again, it can be assumed this was 
primarily an overriding effect o f the Wnt3A exposure.
Given that y-catenin can respond and translocate upon exposure to an external Wnt 
stimulus, could this (or any other secreted factor) explain the differential nuclear y- and 
/3-catenin translocation observed between THP-1 and U937 cell lines (see 5.4.2 and 
5.4.3)? To examine this, growth medium from THP-1 control and pBabe-Puro-y-catenin 
cultures was harvested at confluence, mixed equally with fresh medium and incubated
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with U937 control cells overnight. The following day, U937 cells were N/C fractionated 
and inspected for y- and /3-catenin level and localisation. Figure 5.21 shows how an 
overnight incubation o f U937 cells with THP-1 medium did not significantly increase 
the degree of nuclear translocation of y- or /3-catenin proteins.
Taken together, this section o f data shows for the first time that exogenous Wnt signals 
are capable o f influencing the level and subcellular distribution of y-catenin within 
haematopoietic cells. However, this finding cannot explain the discrepancy between the 
respective abilities o f  THP-1 and U937 cells to nuclear translocate y- and /3-catenin 
protein.
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Figure 5.20 - The effect of Wnt3A and Wnt5A on the subcellular localisation y- 
and /3-catenin expression.
Fractionation of K562 cells into cytosolic and nuclear lysates to determine the 
subcellular localisation of y- and /3-catenin protein in response to Wnt stimuli. Arrows 
and associated numerals show the fold-change in expression versus untreated control 
cells. Red cross represents no fold-change or unquantifiable due to difficulties in band 
detection. Actin and Histone HI show the purity and loading o f each fraction.
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Figure 5.21 - The effect of THP-1 conditioned medium on the level and localisation 
of catenins in U937 cells.
Medium from confluent THP-1 pBabe-Puro control and pBabe-Puro-y-catenin cells was 
harvested and mixed 1:1 with fresh RPMI medium, and incubated with U937 pBabe- 
puro-y-catenin cells overnight. Western blot shows cytosolic and nuclear fractions from 
U937 cells from each condition and the respective level and localisation of y- and /?- 
catenin. Detection of Actin and Histone HI provided an assessment o f purity and 
protein loading of each fraction.
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5.4.5 The multiple-banding of y-catenin is unlikely due to differential 
phosphorylation status
It had been frequently observed during this project that Western blotting o f y-catenin 
protein (and /3-catenin to a lesser extent) had exhibited a multiple-banding pattern in 
both normal and leukaemic cells. Knowledge of the cause o f this banding was likely to 
provide insight as to how these proteins are regulated in normal and malignant 
haematopoietic cells. It was hypothesised that differential phosphorylation status o f the 
protein may be responsible for the variations in migratory speed through a gel. 
Therefore, to test this hypothesis, y-catenin protein was immunoprecipitated from K562 
cell lysate (where multiple-banding is known to be present) and de-phosphorylated 
using CIP enzyme.
If the number of phosphate groups present on the catenin molecule was responsible for 
the varying migratory forms, then it was anticipated that removal o f all phosphate 
groups by CIP would lead to a uniform formation of y-catenin protein bands. Figure 
5.22A shows how y-catenin was successfully purified from K562 cell lysate (lane 1 
from lane 4), but how both low (10U CIP, lane 2) and high (100U CIP, lane 3) de­
phosphorylation reactions failed to alter the multiple-banding pattern of y-catenin 
protein when Western blotted. A dose-dependent increase in the intensity o f y-catenin 
protein bands (relative to untreated controls) was observed between protein lanes treated 
with low and high CIP concentrations however the significance of this is unknown. To 
validate the efficacy o f the de-phosphorylation reaction, the immunoprecipitated protein 
was probed with a phospho tyro sine antibody. Phosphorylated tyrosine residues, could 
not be detected around the migratory region of untreated (still phosphorylated) y-catenin 
protein. Faint bands were detected in the CIP-treated lanes, however this is likely to 
represent residual y-catenin protein signal that was remaining from the initial detection 
of purified y-catenin protein. Thus, there is no confirmation that the specific de­
phosphorylation of y-catenin protein actually occurred. However, and shown in Figure 
5.22B and C, phosphotyrosine was detected on an unknown high molecular weight 
protein which had immunoprecipitated with y-catenin. This protein was around 180- 
200kDa in size and exhibited clear phosphotyrosine signal in the untreated lane (1)
Examination into the Functional Role of y-Catenin in Haematopoietic ,
■ nllr *
which became heavily reduced in the high and low CIP-treated lanes. This finding 
would suggest that the dephosphorylation step by CIP was effective.
In conclusion, these data would suggest that differential phosphorylative forms of y- 
catenin molecule are not responsible for the multiple-banding of y-catenin protein 
observed in Western blotting o f normal and malignant haematopoietic cells. However, 
these experiments are unable to decisively confirm whether specific de-phosphorylation 
of y-catenin protein truly occurred.
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Figure 5.22 - The isolation and de-phosphorylation of y-catenin protein.
A) Whole cell lysate Western blots of K562 cells demonstrating immuno-precipitated y- 
catenin protein (lanes 1-3) and otherwise unpurified but cleared K562 lysate (lane 4). 
Lanes 2 and 3 were treated with low (10U) and high (100U) concentrations o f CIP, 
respectively. Control lanes 1 and 4 were treated with PBS only. B) The same Western 
blot but probed with a phospho-tyrosine antibody. The efficiency of the CIP-induced 
de-phosphorylation step was assessed by observation of an unknown, non-specific 
protein band (red box) which is further magnified in C). Phospho-tyrosine residues 
appeared to be undetectable within the migratory region of y-catenin protein.
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5.5 Discussion
5.5.1 y-Catenin expression during normal haematopoietic is indispensible 
for proper monocyte/macrophage development
Knock-down studies o f y-catenin protein in a model o f normal haematopoiesis have 
highlighted a potential novel role for y-catenin in effective monocyte/macrophage 
development. y-Catenin-deficient CD34+ progenitor cells retain the differentiation 
capacity to generate CD13brightCD36+ monocyte-lineage committed progenitors, but fail 
to develop into mature macrophages. These findings support the data in Chapter 3 (see 
3.4.2), whereby (unlike /3-catenin) an increase in y-catenin expression was observed in 
CD14+ monocytes which also exhibit the highest levels of nuclear y-catenin o f all the 
lineages analysed (3.4.3.5 and 3.4.3.7). This would imply that y-catenin has an 
important transcriptional function within these cells that is indispensible for normal 
macrophage development.
The finding that y-catenin deficient monocytes fail to generate macrophages, and 
instead develop granulocytic characteristics is consistent with a transcriptional role in 
lineage fate. It is frustrating that the colony assays failed, as this would have confirmed 
whether any lineage-bias was present at a clonal level. Granulocytic and monocytic 
lineages are closely related and there is evidence that commitment to either lineage 
requires both expression and suppression o f lineage-specific or -irrelevant transcription 
factors, respectively, as evidenced previously in HSC (Hu et al., 1997). A number o f 
transcription factors have been implicated in normal monocyte/macrophage 
differentiation including CCAAT-enhancer-binding proteins (CEBP), PU.l and RUNX- 
1 as reviewed by Valledor et al., 1998. These data would imply that lineage- 
enforcement occurs throughout haematopoietic development, and that y-catenin could 
be involved in this process to promote macrophage development. Catenins have been 
implicated in such a process previously by Baba et al. whereby a constitutively active 
form o f /3-catenin in normal myeloid or lymphoid progenitors generated uncommitted 
progenitors with multi-lineage differentiation potential (Baba et al., 2005). 
Inappropriate gene expression was observed with /3-catenin directly increasing the
expression o f CEBPo; but reducing early B-cell factor (EBF), and paired box protein 5
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(Pax-5) in order to generate myeloid cells from lymphoid progenitors. This would 
insinuate a degree o f plasticity in late haematopoietic development for which there is 
some evidence in monocytic cells (Montanari et al., 2005; Ungefroren et al., 2010). It 
would be tempting to speculate that y-catenin could have an influence on some of the 
aforementioned transcription factors, however such a claim could only be affirmed by y- 
catenin knock-down studies incorporating gene expression profile microarrays. Similar 
studies have been conducted in this laboratory previously albeit using the y-catenin 
overexpression model. In these studies (Liddiard et al., submitted) y-catenin positively 
regulated the activity o f myc-target protein 1 (myc-Tl), which was found to 
preferentially promote monocytic over granulocytic colony formation. This gene 
represents an obvious candidate to monitor in future y-catenin knock-down studies.
These data, and those from Chapter 3, are in conflict with mice studies whereby 
constitutive deletion of y- and or /5-cat enin was o f no consequence to short-term or long­
term haematopoiesis (Cobas et al., 2004; Jeannet et al., 2008; Koch et al., 2008). These 
studies principally focused on the ability of y-//5-catenin knock-out (KO) 
HSC/progenitor cells to reconstitute sub-lethally irradiated mice, rather than analysing 
the developmental capacity o f specific lineages. Also, despite armadillo proteins being 
evolutionary conserved between species it is conceivable that catenins may have 
different functions in a mouse compared to that of a human. The study by Koch et al. 
seemed to concentrate on absolute numbers o f cell lineages, and observed no difference 
in the proportion o f long term-HSC (LT-HSC), short term-HSC (ST-HSC), or multi- 
potent progenitor cells (MPP) between normal and KO mice. However they failed to 
examine the detailed morphological and immunophenotypic changes associated with 
individual lineages as this study did, and such an in vivo model would be incapable of 
detecting macrophage abnormalities, since they do not circulate but normally reside in 
tissues. A similar study by Jeannet et al. also examined the reconstitution efficiency of 
catenin KO cells in mice, with the same limitations as described above. In addition, they 
found the Wnt signalling pathway remained active in the combined absence of y- and /5- 
catenin, and attributed this to the presence o f other ‘catenin-like’ with Wnt transducing 
capability. However, the data o f this study would imply that the specific presence of y- 
catenin is still required for effective macrophage development.
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5.5.2 y-Catenin significantly modulates the level and localisation of /S- 
catenin in cell lines, but not primary human haematopoietic cells
The correlation between y- and /3-catenin in primary AML blasts, revealed in Chapter 4, 
led us to hypothesise that the expression of these proteins may be in some way inter­
connected. Ectopic expression o f y-catenin in leukaemic cell lines has shown this 
protein to be causative in modulating both the level and subcellular localisation of /3 - 
catenin in leukaemic cells. Generally, the effect of stabilising cytosolic and nuclear y- 
catenin in cell lines appeared to be a concomitant stabilisation of cytosolic and nuclear 
/3-catenin respectively. These findings would agree with a number o f other studies in 
differing contexts whereby y-catenin was competent in influencing the level and 
localisation of/3-catenin. (Salomon et al., 1997; Miller and Moon, 1997; Simcha et al., 
1998; Zhurinsky et al., 2000a; Maeda et al., 2004; Li et al., 2007). To our knowledge, 
this study represents the first to demonstrate this process is active in haematopoietic 
cells.
Some of the above studies have postulated that y-catenin may be able to stabilise /3- 
catenin expression by saturating the degradation components (catenin destruction 
complex (CDC) and proteasome) thus increasing the signalling competent pool of (3- 
catenin within the cell. This hypothesis remained applicable to three of the four cell 
lines tested, with HEL cells displaying the only exception o f decreased cytosolic /3- 
catenin in response to ectopic y-catenin. Although the majority of high y-catenin 
expressing AML samples co-express higher /3-catenin (Figure 4.8A), HEL cells may 
represent the AML cases whereby y- and /3-catenin levels do not correlate. Indeed there 
are many other molecules and mechanisms capable of stabilising/degrading /3-catenin in 
leukaemic cells (other than y-catenin) as previously covered in the Chapter 4 discussion 
{4.5.3). This may explain why a higher degree of correlation was not achieved between 
y- and /3-catenin protein expression in primary AML blasts. A study by Solomon et al. 
(Salomon et al., 1997) using an inducible model of y-catenin expression actually 
demonstrated a 3-5 fold decrease in /3-catenin protein which was further attributed to no 
change in RNA levels, but an increased rate o f post-translational turnover instead.
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A consistent observation across all cell lines analysed, was that nuclear y-catenin level 
dictated the degree o f nuclear translocated /3-catenin regardless o f cytosolic level. This 
degree o f correlation was absent in primary AML blasts, although there remained a 
significant association between higher nuclear /3-catenin expression and high nuclear y- 
catenin expressing samples (Figure 4.8C). The enforced translocation of /3-catenin to 
the nucleus upon ectopic y-catenin expression has been previously reported in other 
non-haematopoietic contexts (Simcha et al., 1998; Maeda et al., 2004; Li et al., 2007). 
None of these studies formally demonstrate a mechanism by which y-catenin achieves 
this, but Maeda and Simcha et al. identified LEF-1 as a chaperone of y- and /3-catenin 
nuclear translocation. The reports by Simcha and Li et a l both hypothesised that the 
increase in nuclear /3-catenin was due to y-catenin’s ability to displace membrane- 
tethered /3-catenin from its junctional partners. Indeed, Li et al. strengthened this theory 
by demonstrating a reduction in the amount o f two such partners (N-cadherin and ot- 
catenin) in the nucleus of y-catenin overexpressing cells, thus reducing their capacity to 
sequester /3-catenin from the nucleus. An investigation by Solomon et al. also 
corroborated this hypothesis by showing y-catenin can effectively substitute with /3- 
catenin for N-cadherin binding in adherens junctions. Despite the evidence for this 
mechanism in other contexts, it cannot be assumed such a process is active in 
haematopoietic cells given the degree of uncertainty as to whether such adhesion 
complexes or junctional proteins are relevant in this tissue. Indeed evidence exists to 
suggest that such junctional components are expressed poorly in haematopoietic cells 
but are not functional (Yang et al., 2009).
Whichever mechanism is responsible for co-localising y- and /3-catenin to the nucleus in 
most leukaemic cell lines, it is clearly not active in U937 cells. Despite a large influx of 
cytosolic y-catenin (which in turn stabilised cytosolic /3-catenin), neither catenin is 
significantly translocated to the nuclei o f these cells. In this sense, U937 cells more 
closely resemble the tight control exhibited in normal CD34+ haematopoietic 
progenitors, rather than leukaemic cells where expression level governs the degree of 
nuclear translocation. It is likely that y-catenin-mediated stabilisation o f nuclear /3- 
catenin represents a pathological phenomenon since this relationship was absent in 
normal day 5 or day 13 primary haematopoietic cells. Ectopic expression of y-catenin
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failed to nuclear translocate and did not affect the subsequent localisation of /3-catenin 
protein, suggesting a stringent regulatory mechanism remained functional. This would 
fit well with Chapter 3 CLSM data whereby /3-catenin could be found independently of 
y-catenin in the nuclei o f CD34+ haematopoietic progenitor cells. Clearly there is 
another degree of complexity to this regulatory system however, given that CLSM 
studies also demonstrated y- and /3-catenin appeared to translocate in a reciprocal 
manner upon myeloid differentiation. It is conceivable that a finely tuned balance 
between nuclear catenin import and export mechanisms (discussed in detail in Chapter 
3 discussion section 3.5.3) is present in normal haematopoietic tissues, which is either 
disturbed or lost altogether in leukaemic cells.
Finally, it was observed that ectopic /3-catenin (albeit a truncated stabilised form) could 
also increase y-catenin expression and nuclear translocation in leukaemic cells. Clearly 
this phenomenon must also be context-dependent, given that the studies by Maeda and 
Simcha (Simcha et al., 1998; Maeda et al., 2004) failed to detect any influence of /3- 
catenin on y-catenin level and localisation. In Simcha’s study, they attributed this failure 
to the fact that the MDCK, 293T and SK-BR-3 used in their experiments all express 
desmosomes, which is an exclusive location for y-catenin for which /3-catenin cannot 
substitute (Bierkamp et al., 1996; Ruiz et al., 1996; Bierkamp et al., 1999). These 
structures are absent from haematopoietic cells and so may explain the apparent 
discrepancies between the studies. The finding that /3-catenin induction can also raise 
the level of cytosolic y-catenin is consistent with the concept outlined above. That is, 
ectopic expression of either y- or /3-catenin in the cytosol is capable of saturating the 
degradation components, and causing a concomitant increase in endogenous levels of 
the other catenin. Evidence has been presented showing that y- and /3-catenin levels 
correlate in primary AML blasts, however identifying which of the two catenins is the 
primary abnormality is much more difficult to address. Alternatively it cannot be 
excluded that in primary AML generally high levels o f y and /3-catenins arise from a 
defect in the common degradation machinery; indeed, if the above hypothesis is correct, 
the fact that the degradative mechanism is so easily saturated in leukaemic cells 
(compared with the lack of any significant effect of ectopic y-catenin on /3-catenin levels 
in normal cells) implies that this process is generally compromised in AML.
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5.5.3 Enforced nuclear translocation of full-length /3-catenin mediated by 
y-catenin is capable of blocking differentiation in leukaemic cells
The experiments o f this chapter have not only shown the correlation between y-and /3- 
catenin may arise from cross-stabilisation in leukaemic cells, but have also provided 
some insight as to how this relationship may contribute to the leukaemogenic process. 
Ectopic expression o f y-catenin in THP-1 cells resulted in significant nuclear 
translocation o f both catenins which subsequently failed to undergo monocytic 
differentiation upon TPA-induction, whilst U937- y-catenin cells (with barely detectable 
nuclear /3 or y-catenin) underwent monocytic differentiation as ‘normal’. If it is truly the 
nuclear contribution o f catenin that dictates this phenotype, then a similar question to 
that raised above is evoked: Is the developmental block a direct consequence o f  heavily 
translocated nuclear y-catenin, or an indirect effect o f  stabilising significant levels o f 
nuclear (3-catenin? There is convincing evidence for both cases:
5.5.3.1 Evidence fo r  nuclear (3-catenin mediating the primary differentiation 
block
The degree of monocytic differentiation achieved in each cell line seemed to be 
inversely proportional to the amount o f nuclear /3-catenin present. Increased capacity for 
self-renewal and loss o f differentiation potential is a commonly reported phenotype of 
nuclear /3-catenin. It has been shown to be a potent mediator of self-renewal in normal 
HSC (Reya et al., 2003; Baba et al., 2006; Zhao et al., 2007; Holmes et al., 2008; 
Nemeth et al., 2009; Yeung et al., 2010) and is strongly believed to do the same in LSC 
(Jamieson et al., 2004; Zhao et al., 2007; Hu et al., 2009; Abrahamsson et al., 2009; 
Wang et al., 2010; Yeung et al., 2010). Simon et al. previously reported a perturbation 
in myelomonocytic differentiation both morphologically and immunophenotypically 
when human primary CD34+ progenitor cells were transduced with a constitutively 
active (S37A mutant) form o f /3-catenin (Simon et al., 2005). Like us, they also 
observed an absence o f normal CD 14 induction and the morphological absence of 
macrophages. A disturbance was noted in CD 14 and C D llb  expression in TPA-treated 
THP-1 cells, not just overexpressing y-catenin, but also the THP-1 line expressing 
mutant /3-catenin (/3-catAN89, which had an increased nuclear presence).
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If nuclear /3-catenin was the primary instigator of the developmental block, then one 
might have expected the y-cat KD or /3-catAN89 to recapitulate the phenotype observed 
in the y-catenin overexpressing line. There were signs that TPA-induced monocytic 
differentiation in these transgenic lines was not as efficient as observed in the control 
line (i.e. lower induction o f CD14/CD1 lb  and the presence o f residual blasts). However 
these cell lines (y-cat KD and /3-catAN89) were incapable of inducing the same quantity 
of nuclear /3-catenin as evident in the y-catenin overexpressing THP-1 cells. The pool of 
nuclear /3-catenin induced by y-catenin was representative of where a full-length, 
transcriptionally active form would be expected to migrate (~85kDa). However the 
nuclear /3-catenin species present in y-cat KD and /3-catAN89 THP-1 cells was less 
abundant and much smaller (~70kDa), and it has been questioned previously whether 
these smaller fragments are even capable o f binding or activating TCF/LEF promoters 
with the same efficiency (see 5.5.6 below). One way to definitively resolve this issue 
would be to transduce the same cell lines with a full-length /3-catenin construct capable 
of inducing large volumes o f full-length nuclear /3-catenin, but not y-catenin, and repeat 
the experiment.
5.5.3.2 Evidence fo r  nuclear y-catenin being the primary initiator o f  
differentiation block
y-Catenin has previously been associated with increased self-renewal capacity when 
ectopically expressed in primary haematopoietic progenitor cells (Muller-Tidow et al., 
2004; Zheng et al., 2004; Tonks et al., unpublished data; see Appendix 6). Specifically, 
the study by Miiller-Tidow showed transduction of y-catenin was able to enhance the 
proliferation and clonal growth o f myeloid 32D cells. The same experiment in primitive 
murine haematopoietic progenitor cells preserved an immature phenotype during colony 
growth, indicative o f enhanced self-renewal. However none o f the above studies 
examined the co-level or co-localisation o f /3-catenin meaning the phenotype could have 
arisen through indirect stabilisation o f /3-catenin. Data of this study would suggest that 
increased y-catenin expression is incapable of significantly translocating /3-catenin in 
these primitive cells, however it is conceivable that a small quantity o f translocated 
nuclear /3-catenin (below the detection threshold) could be responsible for self-renewal.
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Alternatively, the self-renewal phenotype may originate from a relatively small 
subpopulation o f CD34+ with the capacity for more extensive /3-catenin translocation.
Regardless, y-catenin itself has been shown by Miiller-Tidow to directly bind the c-myc 
promoter (in the presence o f RUNX-1/ETO fusion protein, an inducer of y-catenin 
protein), indicating that y-catenin does have transcriptional capability independent of /3- 
catenin (Muller-Tidow et al., 2004). More recently, y-catenin has been shown to directly 
mediate the transcription o f survivin on a /3-catenin null background, by complexing 
with TCF and CREB binding protein (CBP) (Kim et al., 2011). Transcriptional 
independence has also been demonstrated outside of the field of haematology. Kolligs et 
al (Kolligs et al., 2000) employed an epithelial cell line (RK3E) to demonstrate y- 
catenin had TCF-LEF-dependent transforming capability through activation o f c-myc, 
which was independent o f /3-catenin. y-Catenin can bind TCF/LEF complexes in cell 
lines o f malignant mesothelioma (NCI-H28, (Maeda et al., 2004)), human embryonic 
kidney (293T, (Williams et al., 2000; Zhurinsky et al., 2000a)), teratocarcinoma (F9, 
(Fukunaga et al., 2005)) and canine kidney (MDCK, (Simcha et al., 1998)). 
Furthermore y-catenin has shown the capacity to bind and activate the promoters of 
cyclinDl and neuronal cell adhesion molecule (Nr-CAM) genes in /3-catenin-null 
embryonic stem cells (Conacci-Sorrell et al., 2002). However, many of these studies 
acknowledge that y-catenin binds and activates TCF/LEF with less affinity and potency 
than /3-catenin.
5.5.4 Disparities, although explainable, are present between the y-catenin 
knockdown phenotypes observed in primary cells and cell lines
The phenotypes observed from y-catenin overexpression and knock-down were 
inconsistent between primary cells and leukaemic cell lines. y-Catenin overexpression 
appeared to block monocytic differentiation in inducible THP-1 cells, whilst producing 
no detectable phenotype in primary haematopoietic cells. Disparity was also observed in 
y-catenin knock-down which perturbed macrophage development in primary cells, yet 
did not affect the differentiation capacity o f THP-1 and U937 cells. These discrepancies 
can be reconciled as follows. Firstly, ectopic expression of y-catenin is unable to
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detectably influence the expression or localisation o f either catenin in primary human 
haematopoietic cells whereas in leukaemic cell lines the effect of y-catenin cannot be 
separated from its effect on the nuclear translocation o f /3-catenin; indeed the 
differentiation block was only observed where ectopic y-catenin expression promoted 
nuclear translocation o f /3-catenin (i.e. in THP-1 but not in U937). Secondly, the lack of 
effect of y-catenin knock-down in cell lines may arise from the fact that TPA induction 
may override the normal control o f  monocyte/macrophage differentiation. Further, in 
the human primary model, the knock-down phenotype appeared to arise from a lineage- 
bias toward developing granulocytic characteristics over macrophage differentiation. 
THP-1 cells and U937 cells are not known to have the capacity for granulocytic 
development; therefore cues to reinforce monocyte/macrophage development through y- 
catenin may be superfluous.
5.5.5 y-Catenin can respond to a Wnt signal in haematopoietic cells
This study has shown for the first time that y-catenin is capable o f responding and 
translocating upon induction o f a Wnt stimulus in haematopoietic cells. Unsurprisingly 
Wnt3A was shown to mediate this, which is in keeping with its proposed association to 
maintain active Wnt signalling both within normal HSC (Austin et al., 1997; Van den 
Berg et al., 1998; Reya et al., 2003; Willert et al., 2003; Luis et al., 2009; Kim et al., 
2009; Luis and Staal, 2009; Luis et al., 2010) and malignant haematopoietic cells 
(Nygren et al., 2007; Tickenbrock et al., 2008; Kawaguchi-Ihara et al., 2008). Indeed, 
Wnt3A was shown to modulate /3-catenin level and localisation in many o f these 
studies. Subsequent studies from this laboratory have shown that mature differentiated 
haematopoietic cells (22 days o f in vitro culture) also remain sensitive to Wnt signals as 
evidenced by an increase in y-catenin expression, but not translocation, when cultured in 
the presence o f Wnt3A conditioned medium (data not shown).
It is known that other Wnt ligands (other than Wnt3A) are active in normal 
haematopoiesis (Austin et al., 1997; Van den Berg et al., 1998; Brandon et al., 2000; 
Sercan et al., 2010; Gallagher et al., 2010), and it is conceivable that they could also 
influence y-catenin level and translocation. Wntl has been shown in mouse and rat cell 
lines to mediate such an effect on y-catenin (Bradley et al., 1993; Papkoff et al., 1996)
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and WntlOB has been shown to increase the growth of haematopoietic precursors in 
mice through activation o f /3-catenin-mediated Wnt signalling (Congdon et al., 2008). It 
is also likely that members o f this family are dysregulated in AML (Majeti et al., 2009), 
and both Wntl and WntlOB as previously mentioned, plus Wnt2B, have been shown by 
Simon et al. to be constitutively active in primary AML patient blasts (Simon et al., 
2005). It is possible that these Wnt ligands could be contributing to the translocation of 
y-catenin in AML blasts, such as those observed in Chapter 4. It was also unsurprising 
to observe little effect o f Wnt5A induction on catenin level and localisation. The action 
of this Wnt family member has been more closely affiliated with the Ca2+-dependent 
non-canonical Wnt signalling cascade, and its activity has even been shown to inhibit 
the canonical pathway in haematopoietic cells (Liang et al., 2003; Nemeth et al., 2007).
Although Wnt3A promoted y-catenin accumulation and nuclear translocation, a 
question remains over the Wnt-mediated transcriptional capabilities o f y-catenin 
independent of /3-catenin: Is the rise and shift in y-catenin merely a by-product o f  /3- 
catenin induction by Wnt3A? Evidence exists showing Wnt3A-mediated TCF/LEF- 
dependent transcription in F9 cells was dependent on /3-catenin, but not y-catenin 
(Shimizu et al., 2008). This paper acknowledges that y-catenin has transcriptional 
function in F9 cells, as previously evidenced by Fukunaga (Fukunaga et al., 2005), but 
shows it is insufficient for Wnt3A signal transduction. To folly elucidate this issue in a 
haematopoietic context, Wnt mediated stimulation of y-catenin would be required on a 
/3-catenin null background (of which in vivo models exist).
Despite demonstrating Wnt glycoproteins can affect the level and localisation o f both 
catenins, this mechanism did not explain the differing inherent abilities o f THP-1 and 
U937 cells to nuclear translocate catenin. It was initially postulated that perhaps THP-1 
cells, and not U937, secrete an exogenous factor (most likely a Wnt factor) that 
promotes the para- and/or autocrine mediated nuclear translocation of catenin within 
these cells. However, incubation o f U937 cells with THP-1 conditioned medium 
exhibited no significant effect on either catenin. Therefore, there is no evidence to 
support that a soluble factor was responsible for governing nuclear import/export within
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these cells. This leaves an internal mechanism responsible for regulating translocation 
and the many proposed mechanisms have already been discussed in length in Chapter 3
(3.5.3).
5.5.6 The multiple banding of catenin is not due to phosphorylation
Preliminary data from this chapter suggests the cause o f multiple catenin banding 
observed in Western blotting is not due to differing states o f catenin phosphorylation. 
Such a theory (initially postulated in the Chapter 4 discussion, 4.5.4) might have fitted 
well given the documented role o f phosphorylation in regulating catenin translocation
(3.5.3), and the presence o f only specific higher molecular weight bands in the nuclear 
fractions of primary AML blast samples and leukaemic cell lines.
The next most likely cause, backed by substantial evidence, is that these multiple bands 
arise from proteolytic cleavage products. Evidence for such a constitutive process is 
supported by the observation that the pattern o f banding remains the same, and only the 
intensity changes, when y-catenin is overexpressed/silenced in leukaemic cell lines 
(Figure 5.13). Such a theory has been formally demonstrated previously for /3-catenin in 
leukaemic cells (Chung et al., 2002; Hwang et al., 2002) and is highly plausible given 
both y- and /3-catenins association with the ubiquitin-proteasome degradation system 
(Aberle et al., 1997). Indeed, further studies have identified ubiquitinated bands o f y- 
and /3-catenin using Western blotting (Salomon et al., 1997; Kitagawa et al., 1999; 
Sadot et al., 2000; Nilkovitch-Miagkova et al., 2001; Song et al., 2003; Yang et al., 
2006; Asimaki et al., 2007). However data from Simcha et al. would imply that y- and 
/3-catenin’s association with the proteasome is not equivalent given that they observed 
only a modest increase in y-catenin protein (relative to /3-catenin protein) upon 
inhibition o f the proteasome using MG 132 treatment (Simcha et al., 1998). Calpain is 
also known to cleave /3-catenin (Hwang et al., 2002; Li and Iyengar, 2002; Rios-Doria 
et al., 2004; Benetti et al., 2005). In these studies various calpain inhibitors (growth 
arrest specific protein 2 (Gas2), calpastatin, calpeptin) or calpain inducers (thapsigargin, 
ionomycin) were deployed and found to influence /3-catenin level and molecular weight. 
However whether this system is also applicable to y-catenin, or even operational in
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haematopoietic cells, is thus far unknown. Caspases have also been shown to cleave and 
generate multiple bands o f both y- and /3-catenin (Herren et al., 1998; Steinhusen et al., 
2000; Ling et al., 2001; Hwang et al., 2002).
If these bands do represent truncated degradation fragments, it evokes the question of 
why such forms should be permitted nuclear entry in leukaemic cell lines and primary 
AML blasts? What possible survival advantage could be conferred to a malignant cell 
by allowing nuclear import o f  a truncated form o f catenin? Of course these fragments 
may represent an inevitable consequence o f catenin overexpression whereby saturated 
or dysregulated degradation and nuclear import/export systems fail to regulate such 
translocation. Sufficient evidence exists to suggest these smaller fragments are 
transcriptionally inept (Steinhusen et al., 2000; Jeannet et al., 2008). Studies o f Jeannet 
showed these smaller fragments to be functionally-redundant and inefficient at binding 
and mediating TCF/LEF-dependent transcription in mice. Some studies have even 
suggested that the presence o f these truncated catenin forms even act in a dominant 
negative manner to transcription mediated by the full length forms (Munemitsu et al., 
1996; Shimizu et al., 2008). For y-catenin specifically, it is known that truncations of 
the NH2 -termini are sufficient to stabilise the protein however all such mutants are 
inferior to the full length in activating TCF (Kolligs et al., 2000). In this same study all 
large deletions o f the NH2 -terminus, COOH-terminus or armadillo repeat domains 3-8 
rendered wt y- or /3-catenin deficient in binding and activating TCF. Indeed the flanking 
termini o f catenins are known to be crucial for proper function of the molecule (Solanas 
et al., 2004), yet Zhurinsky et al. has shown that removal o f them does not prevent the 
central armadillo domain binding DNA even if transcriptionally inactive complexes 
with LEF-1 result (Zhurinsky et al., 2000a).
Conversely, it may be plausible that a truncated form o f catenin might confer some 
oncogenic potential from which a malignant cell could benefit. Such a truncation could 
deprive the molecule o f its CK1/GSK3-/3 consensus site thus inhibiting its 
phosphorylation-mediated degradation, and leading to constitutive activation. Findings 
by Rios-Doria et al. support this possibility (Rios-Doria et al., 2004). In this study, a
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novel 75kDa /3-catenin fragment was identified in metastatic primary prostate tumour 
samples and cell lines, as well as breast cancer cells. This fragment was shown to 
accumulate in the nucleus where it mediated TCF-dependent transcription and even 
exhibited transforming potential.
In summary, this chapter has provided some valuable insight as to the functional role of 
y-catenin in normal haematopoietic development. Contrary to existing evidence, y- 
catenin expression appears to be relevant for normal haematopoietic development and is 
required for macrophage development. In leukaemic cells, y-catenin can mediate /3- 
catenin expression and its nuclear translocation which may promote the developmental 
block observed in differentiation-inducible leukaemic cell lines. y-Catenin has been 
shown to be sensitive to an external Wnt stimulus in haematopoietic cells, though this 
stabilisation/translocation could have arisen indirectly though stabilisation of /3-catenin. 
Finally, it is unlikely that differential phosphorylation o f y-catenin gives rise to 
multiple-banding in Western blotting.
255 | P a g e
Final Discussion I Chapter 6
6 - Final Discussion
Wnt signalling is an evolutionary conserved pathway critical to normal development of 
blood cells and has been found dysregulated in many haematological malignancies 
including AML (reviewed by Mikesch et al., 2007). Specifically, aberrant 
expression/activity o f the Wnt cascade central mediator, /3-catenin, has been implicated 
in such cancers (Chung et al., 2002; Serinsoz et al., 2004; Simon et al., 2005; Ysebaert 
et al., 2006; Xu et al., 2008; Chen et al., 2009; Siapati et al., 2011). Data from this 
laboratory and others have also identified the close homologue y-catenin to be 
dysregulated in primary human AML (Muller-Tidow et al., 2004; Tonks et al., 2007). 
Furthermore, over-expression o f y-catenin in cell lines and in the human cord blood 
haematopoietic cell model results in increased self-renewal (Tonks, unpublished data), 
suggesting this homologue could have a role in AML pathology. The underlying 
mechanisms o f this phenotype remain poorly characterised, and understanding the 
significance of its dysregulation in AML has been hampered by limited knowledge of y- 
catenin’s expression and function in normal haematopoiesis.
6.1 y-Catenin in normal haematopoiesis
The aim of Chapter 3 was to develop an assay capable o f detecting intracellular catenin
(by flow cytometry or confocal microscopy) within discrete subsets o f normal
haematopoietic development. This allowed a comprehensive assessment of y- and /3-
catenin expression and subcellular localisation throughout normal human
haematopoiesis. The data demonstrated that /3-catenin was highly expressed and
nuclear-localised in normal human primitive CD34+ haematopoietic cells, supporting
the existing evidence that p-catenin mediates self-renewal in these cells (Reya et al.,
2003; Baba et al., 2006; Zhao et al., 2007; Holmes et al., 2008; Nemeth et al., 2009). (3-
Catenin expression in lymphocytes was also confirmed, supporting studies linking
active Wnt//3-catenin signalling within these cells (Reya et al., 2000; Pongracz et al.,
2006; Do sen et al., 2006). This study also showed that y-catenin is highly expressed in
HSC and has a similar expression profile to that o f /3-catenin in subsequent
developmental subsets {Figure 3.21 versus Figure 3.22). Unlike /3-catenin, y-catenin
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was nuclear excluded in this cell type {Figure 3.23 versus Figure 3.25) suggesting 
independent regulation of nuclear translocation in early haematopoiesis. The degree of 
structural homology between these molecules and the many shared protein partners, led 
to the hypothesis that y-catenin translocation within the cell would also be similar to p- 
catenin. However, the independent regulation o f nuclear localisation suggests that these 
catenins have independent transcriptional roles in haematopoietic development. 
Interestingly, this study has also shown that neither catenin has HSC-restricted 
expression, given their previous association with self-renewal. Expression o f both 
catenins apparently increased in granulocytic and monocytic development and their 
nuclear localisation would imply a transcriptional role in these differentiated subsets. 
However independence o f function is also indicated by the apparent reciprocal direction 
of catenin translocation during myeloid development where nuclear /3-catenin levels 
declined whilst nuclear y-catenin increased. Interestingly, a sub-population o f CD14+ 
monocytes expressing almost entirely nuclear translocated y-catenin was observed, 
implying a particular transcriptional relevance for y-catenin within this subset. This 
observation may explain the developmental abnormalities obtained upon y-catenin 
protein knockdown within this lineage in the in vitro model o f haematopoiesis (see 
section 5.4.1 and discussion 6.3).
6.2 y-Catenin in AML
Previously, data from this laboratory identified overexpression of y-catenin mRNA in 
AML patient blasts by Asymetrix gene expression profiling (Tonks et al., 2007). The 
AML Affymetrix gene expression profile data is associated with a highly characterised 
clinical database allowing the analysis and correlation of gene expression with a number 
of clinical parameters including DFS, OS, CR rate etc. Chapter 4 o f this study 
correlated y-catenin mRNA expression with these survival parameters and found a 
significant association with poor patient outcome (reduced CR rate arising from 
resistant disease). These findings, despite using mRNA level, are in keeping with the 
small amount o f survival data regarding the prognostic significance /3-catenin protein 
expression in AML. Ysebaert et al, identified /3-catenin protein expression (by 
immunoblotting) as an independent prognostic marker predicting poor event free
survival (EFS) and shortened OS (Ysebaert et al., 2006). The study o f Xu et al, also
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identified an association o f nuclear /3-catenin (by immunohistochemistry) with a 
reduced CR rate (Xu et al., 2008). Although these studies feature small patient cohorts 
and varied analytical techniques they would generally indicate that catenin expression is 
unfavourable in AML. This highlights the context-dependent nature of these proteins 
given that y-catenin appears to serve a tumour suppressor role in other disease settings 
(Aberle et al., 1995; Simcha et al., 1996; Charpentier et al., 2000; Polychronopoulou et 
al., 2002; Breault et al., 2005; Misaki et al., 2005; Shiina et al., 2005). This is likely due 
to the differing adhesive function y-catenin serves within an epithelial context, where 
loss o f such a protein and overall tissue integrity could promote metastasis in epithelial 
tumours.
Catenins are subject to significant post-translational regulation (Zhurinsky et al., 2000b) 
and therefore the degree o f y-catenin protein dysregulation in primary AML cells was 
also analysed. This study shows for the first time that y-catenin protein is dysregulated 
compared with levels in normal HPC. Interestingly, around 20% of AML blast samples 
overexpress y-catenin relative to normal HPC, with a similar proportion also 
demonstrating under expression o f the protein. However, y-catenin mRNA correlated 
poorly with the level of y-catenin protein, thus compromising the reliability o f the 
mRNA survival data. This observation was not entirely unexpected given the post- 
translational mechanisms active in regulating catenin protein stability, and this study is 
not the first to report such a discrepancy for y-catenin (see Chapter 4 discussion, 4.5.1). 
Despite this, there is some evidence that higher mRNA expression was associated with 
higher y-catenin protein, and a lower CR rate even within the smaller patient cohort. 
Extending these studies into a larger cohort may provide stronger statistical evidence.
This chapter also investigated the subcellular localisation of y-catenin protein in AML 
blasts given that a full localisation profile had been established for normal 
haematopoietic cells. In undifferentiated (FAB M0/1) leukaemic blasts y-catenin was 
found aberrantly localised to the nuclei which is in stark contrast to its nuclear exclusion 
displayed in developmentally matched normal CD34+ HPC {Figure 3.23 and Figure 
4.5A). These observations suggest, again for the first time, that y-catenin may contribute 
an aberrant transcriptional function in AML pathology. Nuclear translocation was also 
prevalent in differentiated M2/4/5 FAB types, however the degree o f dysregulation is
hard to define given y-catenin’s increasing nuclear presence in normal differentiated
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myeloid cells. The specific localisation of y- and /3-catenin protein was found to carry 
no statistically significant prognostic relevance, although sample number was small for 
such a heterogeneous disease (<50 patients). Small patient numbers also prevented 
individual survival analyses of y- and /3-catenin expression within specific 
developmental subsets (FAB types) o f AML. Finally, these data identified a positive 
correlation between the levels o f y- and /3-catenin protein in primary AML blasts. 
Although y-catenin has been shown to be capable o f influencing /3-catenin level in 
epithelial cell lines (Rubinfeld et al., 1995; Salomon et al., 1997; Miller and Moon, 
1997; Simcha et al., 1998; Sadot et al., 2000; Zhurinsky et al., 2000a; Maeda et al., 
2004; Li et al., 2007), no such relationship has been demonstrated in primary human 
tumour samples or haematopoietic cells. These data demonstrate that any association of 
y-catenin protein level with clinical outcome in AML may arise indirectly through its 
stabilisation o f /3-catenin.
6.3 Functional roles of y-catenin
As discussed above (see 6.7), the findings o f Chapter 3 suggested y-catenin expression 
has a role in normal haematopoiesis. Further, given that y-catenin protein and 
subcellular localisation is dysregulated in AML, it was important to establish whether 
this had any consequence on haematopoietic development. To examine this hypothesis, 
y-catenin protein expression was suppressed in preliminary experiments utilising an in 
vitro model o f normal human haematopoietic development. HPC committed to 
monocytic development (CD13bnghtCD36+) failed to undergo macrophage 
differentiation and instead developed bi-phenotypic, dysplastic, granulocytic traits 
(CD 15 surface expression, hyper-segmented nuclear morphology within a pale 
monocytic like cytoplasm). These findings implicated y-catenin in a potential 
transcriptional function with respect to lineage fate, potentially mediating the 
suppression o f pro-granulocytic differentiation genes and/or the activation o f pro- 
monocytic genes. Such a role fits with the increased expression of y-catenin observed 
during normal development o f myeloid cells (Figure 3.21), and the increased nuclear 
localisation observed in granulocytes and monocytes (see Figure 3.31 A). The potential 
genes regulated by y-catenin in this context are unknown, however a few candidates 
may be shortlisted. For example, CEBPof is a transcription factor crucial for
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granulocytic differentiation (Smith et al., 1996; Ford et al., 1996) that is specifically 
upregulated in the granulocytic lineage whilst downregulated in the monocytic pathway 
(Radomska et al., 1998). The Wnt//3-catenin signalling pathway has previously been 
linked with its repression in adipogenesis (Ross et al., 2000; Kawai et al., 2007) and 
furthermore CEBPa is known to be repressed in RUNX-l-ETO+ AML (Pabst et al., 
2001), a context where y-catenin expression is also high. It is tempting to speculate that 
the loss of y-catenin in normal development permits re-expression o f CEBPce in the 
monocytic lineage thus leading to the generation of granulocytic traits. Another target 
which y-catenin is known to positively regulate is myc-Tl which preferentially promotes 
monocytic over granulocytic colony formation (Tonks, unpublished data). Again, loss 
of myc-Tl induction in haematopoietic cells through a lack of y-catenin may reverse this 
phenotype so the bias is shifted towards the granulocytic lineage. Both of these genes 
represent potential candidates to monitor in future y-catenin knock-down studies.
Evidence from this study (Chapter 4) suggested that a correlation exists between the 
levels of y- and /3-catenin protein in primary human AML blasts. Chapter 5 sought to 
investigate whether y-catenin could possibly be causal in influencing the level and 
localisation o f /3-catenin protein in these cells. In normal cells it would appear this is not 
the case; despite the induction of high levels of ectopic y-catenin into CD34+ HPC, the 
protein does not translocate to the nucleus and cannot significantly influence the level or 
localisation o f /3-catenin. This finding supports Chapter 3 data which demonstrated that 
translocation o f catenins are independently regulated during normal haematopoiesis, and 
accumulation o f protein alone does not dictate the level o f nuclear translocation. It was 
also shown that normal human CD34+ HPC transduced with the PINCO-y-catenin 
vector was not a suitable model to investigate y-catenin dysregulation in haematopoietic 
development, given the inability to replicate the degree o f nuclear translocation 
observed in many primary AML blasts. The failure to translocate y-catenin to the 
nucleus may explain the lack o f immunophenotypic or morphological phenotype present 
in the primary haematopoiesis model upon y-catenin overexpression.
In contrast, ectopic y-catenin expression in most myeloid leukaemia cell lines results in
stabilisation o f /3-catenin protein (Figure 5.13). This difference indicates that the
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processes regulating catenin stability are dysfunctional in leukaemic cells. Other studies 
have previously shown this effect within an epithelial context (Salomon et al., 1997; 
Zhurinsky et al., 2000a; Maeda et al., 2004; Li et al., 2007), and have suggested that y- 
catenin overexpression may saturate the catenin degradation machinery thus allowing 
the cytoplasmic accumulation o f signalling competent /3-catenin (Miller and Moon, 
1997; Simcha et al., 1998; Klymkowsky et al., 1999). Another difference observed 
amongst leukaemic cell lines, in contrast to normal cells, is that nuclear translocated y- 
catenin promoted the level o f nuclear localised j3-catenin independently o f overall 
expression level (see Figure 5.13). Again, such an observation has been made 
previously in epithelial settings (Simcha et al., 1998; Maeda et al., 2004; Li et al., 2007) 
yet the mechanism by which it occurs remains unestablished. Indeed it is not even 
known whether such an observation represents an enhanced ability to translocate /3- 
catenin or simply retain it within the nucleus. The many proposed mechanisms which 
regulate catenin nuclear localisation have already been discussed (see 3.5.3), yet none 
suggest an ability of y-catenin to directly nuclear localise /3-catenin. Whichever 
mechanism is responsible, it likely represents a pathological feature of leukaemic cells 
given the strict and independent regulation o f catenins observed in normal blood cells. 
This relationship could also explain the differentiation block observed in y-catenin 
overexpressing THP-1 cells where substantial levels of nuclear /3-catenin are indirectly 
stabilised (5.4.3).
Chapter 5 also examined whether y-catenin expression could be influenced by
exogenous soluble Wnt factors such as Wnt3a (as shown in other contexts (Bradley et
al., 1993; Papkoff et al., 1996)). Although this study represents the first to report y-
catenin induction by a Wnt signal in haematopoietic cells (Wnt3A, see Figure 5.20), it
is unable to confirm its independent ability to transduce this signal in the nucleus given
the interdependence with /3-catenin. It is also unlikely that exogenous Wnt factors are
the mechanism responsible for translocating catenin in some cells (e.g. THP-1) and not
others (e.g. U937), since the localisation o f catenins in U937 cells remains unaffected
despite overnight culture in THP-1 conditioned cell medium. The wealth o f catenin
regulatory molecules that reside inside the cell, probably means a dysregulated internal
mechanism is responsible for the aberrant catenin localisation in leukaemic cells. The
dysregulated component is likely to constitute either part of the machinery responsible
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for catenin degradation (see 1.3.1) or part of the mechanism directly responsible for 
catenin localisation (see 3.5.3).
Finally, Chapter 5 also aimed to investigate one of the potential causes o f the multiple 
y-catenin banding observed in Western blotting throughout this project; 
phosphorylation. Preliminary data from this study would suggest this is not the source 
leaving proteolysis as the next most likely cause. A number of systems have been linked 
with the degradation o f  catenin including the well established ubiquitin/proteasome 
(Aberle et al., 1997; Orford et al., 1997), calpain (Hwang et al., 2002; Li and Iyengar, 
2002; Rios-Doria et al., 2004; Benetti et al., 2005) and caspases (Herren et al., 1998; 
Steinhusen et al., 2000; Ling et al., 2001). Which of these degradation systems is active 
in haematopoietic cells is currently unknown, as is the functional relevance of such 
proteolytic y-catenin fragments to the cell biology.
6.4 Conclusion
In conclusion, this study has demonstrated that y-catenin could be important for normal 
haematopoietic development, where protein level and subcellular localisation is tightly 
regulated independently o f  /3-catenin. Many mechanisms have been proposed to regulate 
y-catenin nuclear localisation, however the exact mechanisms active in haematopoietic 
cells are not known. Data presented here would suggest they must be defective in AML 
leaving two-fold consequences for the cell; firstly, the overexpression of y-catenin 
leading to its nuclear localisation and secondly, the ability of dysregulated y-catenin to 
influence the level and nuclear localisation o f /3-catenin. Clearly, this relationship is not 
the only one by which /3-catenin becomes stabilised in AML since evidence exists in the 
cell line and primary AML blast data, where /3-catenin expression is high independently 
of y-catenin (and vice versa). Rather, the heterogeneity o f AML, and the context- 
dependent nature o f these proteins, make it likely that the pre-existing background of 
molecular defects are highly determinant of y-catenin’s contribution to AML pathology. 
For instance, THP-1 cells seem to provide a sufficiently aberrant molecular background 
whereby dysregulated y-catenin can promote the level and nuclear localisation o f /3- 
catenin. Which catenin is directly responsible for imposing the subsequent
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differentiation block observed in these cells, remains unknown. Previous evidence 
would suggest /3-catenin is the main transcriptional driver, however a co-operative role 
can not be excluded given the proven ability o f y-catenin to bind and activate TCF/LEF 
transcription factors. The evidence for y-catenin having any independent pathological 
role in AML is now questionable however given its interdependence with /3-catenin 
level and localisation. Indeed, previous studies implicating y-catenin in self-renewal o f 
murine/human HPC and induction o f AML-like disease in vivo all failed to co-assess /3- 
catenin expression. Preliminary data of this study would suggest that y-catenin could 
serve important transcriptional roles in normal haematopoiesis by governing lineage fate 
(between monocyte/macrophage and granulocytic development). Therefore, any 
attempts to therapeutically target y-catenin directly in AML must exercise caution. 
However, even taking this into consideration, targeting the y-catenin//3-catenin 
pathological axis could represent a therapeutically viable target since data exists in vivo 
showing normal haematopoiesis can continue in their combined or individual absence.
6.5 Further work
It will be important to firstly substantiate incomplete preliminary data generated from 
this study. O f particular importance, will be an expansion o f the primary AML patient 
cohort for which y-catenin and /3-catenin protein expression has been assessed. Ideally, 
analysis of over 100 AML samples should provide more statistical power for identifying 
any prognostic significance. Further experimental repeats will also be necessary to fully 
characterise the phenotype o f y-catenin knockdown in normal haematopoietic 
development using the in vitro model o f haematopoiesis.
Data from this study led to the hypothesis that a mechanism must exist in normal 
haematopoietic cells governing the translocation o f catenins, which appears to be 
dysfunctional in AML blasts. The full characterisation of this mechanism will be 
essential in any attempts to therapeutically remedy it in AML. The use of a biochemical 
approach such as immuno-precipitation and mass spectrometry could be used to identify 
potential chaperone proteins, or nuclear import/export systems, active in y-catenin 
translocation in healthy and malignant haematopoiesis. A few obvious candidates such
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as LEF-1, TCF-4 or APC may associate with y-catenin, but other novel protein partners 
cannot be excluded (see 3. S. 3).
The discovery o f significant y-catenin nuclear localisation in leukaemic cells has 
highlighted the limitations o f our group’s previous attempts to model y-catenin in AML 
by over-expression in normal human CD34+ HPC. This model is incapable of 
recapitulating the degree of nuclear y-catenin present in many primary AML blasts or 
leukaemic cell lines, and ectopic expression fails to significantly modulate the level or 
localisation o f /3-catenin as it does within a leukaemic setting. Therefore an alternative 
model is required encompassing the aforementioned features. It is possible to artificially 
target y-catenin to the nucleus using an N-terminally fused NLS (Li et al., 2007). 
Should such a strategy be viable in haematopoietic cells, then this model would allow 
the examination o f how nuclear y-catenin translocation affects normal haematopoietic 
development. Further still, this may permit the identification (using microarrays) o f the 
prospective monocytic and granulocytic genes y-catenin could transcriptionally govern 
in late haematopoiesis (see 6.3). However, before such investigations are performed, it 
will be critical to confirm the subcellular localisation o f /3-catenin within this NLS 
model, before any transcriptional independence can be attributed to y-catenin.
The co-localisation o f y- and /3-catenin in the nucleus makes it impossible to
discriminate which protein has primary transcriptional activity in leukaemic cells.
Typically, the TOPFLASH reporter (created by Hans Clevers laboratory) is employed in
experiments aiming to measure the output o f /3-catenin mediated Wnt signalling. The
TOPFLASH reporter is an expression construct that emits a detectable fluorescence
signal when TCF/LEF transcription factors are bound and activated. However, y-catenin
has also been shown to activate this reporter on /3-catenin null backgrounds (Conacci-
Sorrell et al., 2002; Kim et al., 2011) making it unlikely such a system could discern
between y- or /3-catenin mediated transcription in a nucleus where both are abundant.
Resolution o f this issue may only be possible by assessing y-catenin transcriptional
activity on a /3-catenin-null background, however data from this study would suggest
such a haematopoietic setting is unlikely to exist. The TOPFLASH reporter could be
incorporated into the in vitro model o f normal human haematopoiesis in order to
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confirm whether TCF/LEF activity is elevated in the cell types identified to harbour 
high levels o f nuclear y-catenin (e.g. monocyte subsets). This may aid in establishing 
the activity and function of y-catenin in more differentiated haematopoietic subsets.
Finally, many o f  the investigations o f this study have been tailored toward 
understanding y-catenin’s transcriptional potential, however its prospective role as a cell 
adhesion component has been largely neglected. This function is likely to be irrelevant 
for haematopoietic cells in circulation (except maybe for trans-endothelial migration of 
monocytes as described in 3.5.1) but may be more important in the HSC BM niche. 
Indeed, this study has shown y-catenin to be nuclear excluded in CD34+ HSC/HPC 
better suiting a structural role at this level. If y-catenin does mediate a pro-adhesive or 
migratory effect in the BM niche then such a phenotype would be desirable for both 
normal LT-HSCs propagating healthy haematopoiesis, and LICs establishing a 
malignant clone and evading chemotherapy. The interaction with cadherin might also be 
worth investigation, not only for its association with cell adhesion, but also in the 
documented ability o f this molecule to sequester y-catenin from the nucleus (Fukunaga 
et al., 2005). Could this mechanism explain the nuclear exclusion o f y-catenin protein in 
primitive CD34+ cells? Future studies incorporating an inducible model o f E- or N- 
cadherin in human CD34+ HSC will be useful to assess the affect on adhesion, 
migration and catenin re-localisation.
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A ppendix 1
Purification of DNA from gel using a QIAquick™ gel extraction kit
Gel slices were weighed in colourless tubes and 3 volumes o f ‘Buffer QG’ added for 
every 1 volume o f  gel. The gel slices were completely dissolved by incubating at 50°C 
for 10 min and vortexing every 2-3 min to promote solubilisation. Upon full dissolution 
of the gel slices, the colour o f the mixtures was inspected to ensure a yellow colour, 
indicating an optimal pH ( <  7.5) for adsorption o f DNA onto the QIAquick™ 
membrane. To increase the yield o f DNA fragments, one gels volume o f isopropanol 
was added to the samples and mixed. The mixtures were applied to QIAquick™ spin 
columns and centrifuged in a micro centrifuge at 17,900 x g  for 1 minute to bind DNA. 
At the end o f centrifugation, flow through was discarded and 0.5ml of ‘Buffer QG’ 
applied, before centrifugation for another minute. The waste was discarded and the 
columns washed by the addition o f 0.75 ml o f ‘Buffer PE’ and two 1 minute 
centrifugations at 17,900 xg . The QIAquick™ columns were transferred to clean 1.5ml 
micro centrifuge tubes, and the respective DNAs eluted from the membranes by the 
direct addition o f 50^tl Buffer EB (lOmM TrisCl, pH 8.5) and centrifugation as above.
Appendix 2
Purification of Plasmid DNA using a QIAprep® Miniprep kit
Pelleted E.coli cells were resuspended in 250/d ‘Buffer P I’ and mixed with 250/d o f 
‘Buffer P2’ by tube inversion. Then, followed the addition o f 350/d ‘Buffer N3’ and 
centrifugation at 17,900 x g  for 10 minutes. Supernatants were transferred to QIAprep 
spin columns which were centrifuged as above for 1 minute with the resulting eluent 
being discarded. After washing o f the spin columns by sequential addition o f 500/d 
‘Buffer PB’ and 750/d ‘Buffer PE’ each followed by centrifugation as above, the
Appendices
columns were placed in fresh micro centrifuge tubes. Respective DNA was eluted from 
columns by addition o f 50/d ‘Buffer EB’ and a 1 minute RT incubation followed by a 1 
minute centrifugation as above. The eluted DNA from each colony was quantified using 
a Nano Drop® to establish if DNA (and to which concentration) had been successfully 
purified.
A ppendix 3
Purification of Plasmid DNA using a QIAprep® Maxiprep kit
Briefly, pelleted bacteria were resuspended in 10ml ‘Buffer P I’ before mixing with 
10ml of ‘Buffer P2’, and allowing to stand for 5 minutes at RT. Next, 10ml ‘Buffer P3’ 
was added followed by incubation on ice for 15 minutes, and a 30 minute centrifugation 
at 20,000 x g  at 4°C. Supernatant containing plasmid DNA was removed and 
centrifuged again, as above, to remove insoluble material. During this time a ‘QIAGEN- 
tip 500’ was equilibrated with 10ml ‘Buffer QBT’. The supernatant was transferred to 
the ‘QIAGEN-tip’ where plasmid DNA was bound to the column and washed twice 
with 30ml ‘Buffer QC’. DNA was eluted from the column using 15ml ‘Buffer QF’ and 
precipitated by the addition o f  10.5ml RT isopropanol (Fisher) and centrifugation at
15,000 x g  for 30 minutes (4°C). The DNA pellet was finally washed in 5 ml 70% 
ethanol before final centrifugation at 15,000 x g  for 10 min. The supernatant was 
decanted with care, and the pellet air-dried for 10 minutes before resuspending in 1ml 
‘TE Buffer’. Plasmid DNA was then quantified using the Nano Drop® and stored at - 
20°C.
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Appendix 4 A )
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The effect of y-catenin overexpression on FDCP mix cells - The murine 
haematopoietic progenitor cell line FDCP mix was retrovirally transduced with y- 
catenin or control cDNA and placed into standard culture medium containing no 
exogenous growth factors following puromycin selection. A) Control cells maintained a 
normal FDCP mix morphology throughout culture dominated by dark-staining, 
undifferentiated blasts (Bla). B) Conversely, y-catenin overexpressing cells underwent 
spontaneous myeloid differentiation around 14 days post transduction. These cultures 
displayed a heterogeneous mix o f differentiated myeloid cells including 
metamyelocytes (MM), macrophages (Mac), immature neutrophils (IN) and mature 
neutrophils (Neu).
Appendices
A ppendix 5
Calculations for comparing CLSM and Western blotting data. 
• Volume of a sphere = 4/3 Trr3
Where;
r = radius
This equation was adapted into the equation below:
• RVF X Nuclear pixel density
Cytosol pixel density
Where;
RVF = relative volume factor (of nucleus to cytoplasm) derived as below:
Nuclear volume
Cytosolic volume
The volumes and pixel values from 13 cells o f each K562 cell line analysis were 
used to generate average nuclear y-catenin localisation for that cell line:
K562 pBabe-Puro control K562 pBabe-Puro-y-catenin
0.27 X 78.6
325.8
0.30 X 81.1
162.3
Ans x 100 = 6.5% nuclear v-catenin Ans x 100 = 15.0% nuclear y-catenin
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y-Catenin enhances the self-renewal of CD34+ haematopoietic progenitors - Cord- 
blood derived CD34+ haematopoietic progenitors retrovirally transduced with y-catenin 
(and RUNX-1/ETO (aka RUNX-1/RUNX-1T1)) displayed enhanced self-renewal 
capacity, compared with mock-transduced GFP+ cells, as demonstrated by increased 
replating efficiency of myeloid colony-forming cells (Tonks et al. unpublished data).
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